Inside information: Profit warning – Konecranes upgrades its sales guidance for 2024

KONECRANES PLC INSIDE INFORMATION September 12, 2024 at 19:45 EEST Inside information: Profit warning – Konecranes upgrades its sales guidance for 2024 Konecranes upgrades its sales guidance for 2024. Konecranes’ delivery execution has continued strong, and as a result, Konecranes now expects its full-year 2024 sales to increase from the previous year. Konecranes updated financial guidance for 2024: Konecranes expects net sales to increase in 2024 compared to 2023. Konecranes expects the full-year 2024 comparable EBITA margin to improve from 2023. In 2023, Konecranes’ net sales totalled EUR 3,966.3 million, and the comparable EBITA margin was 11.4%. Konecranes’ previous financial guidance for 2024 (issued on June 12, 2024, reiterated on July 26, 2024): Konecranes expects net sales to remain approximately on the same level or to increase in 2024 compared to 2023. Konecranes expects the full-year 2024 comparable EBITA margin to improve from 2023. KONECRANES PLC Kiira Fröberg Vice President, Investor Relations FURTHER INFORMATION For investors and analysts, please contact Kiira Fröberg, Vice President, Investor Relations, tel. +358 (0) 20 427 2050 Konecranes is a global leader in material handling solutions, serving a broad range of customers across multiple industries. We consistently set the industry benchmark, from everyday improvements to the breakthroughs at moments that matter most, because we know we can always find a safer, more productive and sustainable way. That's why, with around 16,600 professionals in over 50 countries, Konecranes is trusted every day to lift, handle and move what the world needs. In 2023, Group sales totalled EUR 4.0 billion. Konecranes shares are listed on Nasdaq Helsinki (symbol: KCR). DISTRIBUTION Nasdaq Helsinki Major media www.konecranes.com

Gaming Innovation Group: Key dates for the Split of GiG

Reference is made to the announcement from Gaming Innovation Group Inc. ("GiG" or the "Company") on 4 September 2024 with the notice to a special meeting of shareholders to be held on 23 September 2024 with a proposal to, among other things, complete the restructuring process in which GiG will be divided in two, GiG Media and GiG Platform, whereby GiG Platform will be spun off to operate as an independent public company (the "Spinoff"). Subject to the proposal being approved by the general meeting, the Spinoff will be completed in the form of a distribution in kind in Euronext Securities Oslo (VPS) of one Norwegian Depositary Receipt (NDR) per share held in GiG. Each NDR will represent the beneficial interest in one share in GiG Software P.L.C., a Maltese company which will operate the GiG Platform business. Key information for the Spinoff: Last day of trading in the GiG share inclusive the right to receive NDRs: 23 September 2024 Ex-date: 24 September 2024Record date: 25 September 2024Distribution date: on or about 30 September 2024Date of resolution: 23 September 2024Ratio: one NDR per GiG shareISIN no. for the NDRs: NO 0013326033 Investors holding GiG shares in Euroclear Sweden trading on NASDAQ Stockholm will receive one Swedish Depository Receipt (SDR) per share held in GiG. The ISIN no. for the SDRs is SE 0022760229. Third-party analyses of GiG Media and GiG Platform indicate, on average, that GiG Platform may be valued at 14 percent of the total value of GiG before the Spinoff. Please note that these analyses were prepared for general distribution and not intended to be advisory and that they may not be indicative of the market capitalisation of GiG Platform once trading in the GiG Platform depository receipts commences at the NASDAQ First North Premier Growth Market in Stockholm.  This information is given pursuant to Euronext Oslo Børs' Rule Book II section 4.8.4.3, cf. section 4.2.5.2, and is subject to the disclosure requirements under section 5-12 of the Norwegian Securities Trading Act.  For more information, please contact: Tore Formo, Group CFO of GiG, tore@gig.com, +47 916 68 678 About Gaming Innovation Group (GiG) Gaming Innovation Group is a leading iGaming technology company that provides solutions, products, and services to iGaming Operators. Founded in 2012, Gaming Innovation Group's vision is 'To be the industry-leading platform, sportsbook and media provider delivering world-class solutions to our iGaming partners and their customers.  GiG's mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under GIGSEK. www.gig.com

Securitas sets provision related to U.S. Government investigation in Paragon Systems, Inc.

As previously communicated, the U.S. Government is conducting an investigation into Paragon Systems, Inc, a U.S.- based subsidiary operating under a proxy agreement as required by the U.S. authorities to be eligible for U.S. government business. The investigation relates to alleged misconduct by certain former employees and to Paragon’s relationship with various small business entities which were a direct or indirect party to contracts with the U.S. Government starting around 2012. Paragon is cooperating fully with the investigation.  As the result of an ongoing constructive dialog with the authorities and in line with applicable accounting standards, Securitas has now set a provision of approximately MUSD 53 (MSEK 551), which is the current estimated cost related to this matter. The amount is expected to be partly tax deductible.  The provision will be accounted for in the third quarter 2024 as an item affecting comparability under the heading Other in the segment reporting where the business unit Securitas Critical Infrastructure Services is reported.   This press release is available at www.securitas.com   Contact: Investors: Micaela Sjökvist, VP Group Investor Relations; +46 76 116 7443, micaela.sjokvist@securitas.com  Media: Carin Andersson, VP Group Communications; +46 10 470 3020, press@securitas.com  This is information that Securitas AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 a.m. (CEST) on Friday, September 13, 2024. 

Executive Vice President & General Counsel leaves Skanska

"I want to thank Caroline for her commitment, strategic insight and development of the Legal function across the Group.  Her expert legal guidance has been vital in our continued success in navigating complex market conditions and strongly contributed to driving value to the company. I wish her all the best in her future endeavors”, says Anders Danielsson, President and CEO of Skanska Group.  “I am thankful and proud of what we have achieved over the last eight years at Skanska. Together with the Group Leadership Team we have developed the company across our markets with clear governance to the stable and profitable situation we are in today”, says Caroline Fellenius Omnell, Executive Vice President & General Counsel, Skanska Group.  Ulrika Wester will as of today, September 13, step in as acting Executive Vice President & General Counsel until a successor has been appointed. 

Nomination Committee for HANZA AB's 2025 Annual General Meeting appointed

According to a decision at HANZA AB's most recent Annual General Meeting, a Nomination Committee of four members, including the Chairman of the Board, shall be appointed by the three largest shareholders or groups of shareholders in terms of voting rights. Since one of the main shareholders is also the Chairman of the Board, and thus already has a seat on the Nomination Committee, he has waived his right to nominate a member in favor of the fourth largest shareholder. The Nomination Committee for the 2025 AGM has now been appointed and consists of the following members: · Gerald Engström, Chairman of the Nomination Committee, own holding · Håkan Halén, own holding · Massimo Franzé, appointed by Ritter Beteiligungs GmbH · Francesco Franzé, Chairman of the Board of Directors The members of the Nomination Committee are appointed by shareholders in HANZA AB who in total, excluding the Chairman of the Board's ownership, represent approximately 35 percent of the number of shares and votes in HANZA AB as of August 31, 2024. The Nomination Committee shall submit proposals to the 2025 AGM for resolutions on the following issues: Election of Chairman of the AGM, Chairman and members of the Board, auditors, remuneration to the Board and auditors, and principles for the composition and work of the Nomination Committee for the 2026 AGM. The date of HANZA AB's 2025 Annual General Meeting has not yet been decided and will be announced in connection with the company's interim report for the third quarter. Shareholders are welcome to submit proposals and comments to the Nomination Committee by e-mail to info@hanza.com, no later than March 1, 2025. The Nomination Committee's proposals will be presented in the notice of the 2025 AGM and on the company's website

Careium revises full-year outlook due to infrastructure transition delays in the UK and Sweden

Careium, the European champion in technology enabled care, has revised its full-year growth outlook downward due to infrastructure transition delays affecting its business more than expected, and it has clarified its profit outlook, reaffirming an increase in EBIT for 2024. The delays stem from the UK’s announcement of a two-year extension in March 2024 for its transition from analogue to digital landlines. Similarly, Sweden extended its 2G and 3G infrastructure by an additional year, as announced in May 2024.New outlook:For the full year 2024, Careium expects an organic sales growth of 5 to 10 percent. Alongside the growth in sales, we expect EBIT to increase, leading to an EBIT margin of 7.5 to 10 percent in 2024.Previous outlook, issued on 15 February, 2024:For the full year 2024, Careium expects an organic sales growth of 12 to 15 percent. Alongside the robust growth in sales, we expect EBIT to increase in 2024. “Careium achieved 7.9% organic growth during the first half of 2024. However, due to current delays in customer orders and a particularly strong comparable period, we anticipate a slightly negative growth for the third quarter, followed by returning to clearly positive growth in the fourth quarter. Our outlook for increased EBIT in 2024 remains strong”, said President and CEO Christian Walén.  Careium will publish its third quarter results on October 24, 2024, and its fourth quarter results on February 13, 2025.

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage – 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions. "Our main priority is to protect the data integrity of the study. Together with our CRO, we will do our utmost to minimize the time from the last patient's last visit to top-line data, and our expectation is that these may be brought forward compared to the timelines previously communicated, before year-end” says Anna Ljung, CEO of Moberg Pharma. On September 13[th], 2024, at 15:00 (CET), Moberg Pharma's CEO Anna Ljung, CMO Anders Bröijersén, and CSO Amir Tavakkol will answer questions during a telephone conference. The Q&A session will be held in English. To participate in the conference, please dial in on one of the numbers below before the conference starts: SE: +46 8 10 884 80 16. Access Code: 961943US: +1 855 979 6654. Access Code: 961943 For additional information, please contact:Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.seAnders Bröijersén, Chief Medical Officer, telephone: + 46 76 001 15 76, e- mail: anders.broijersen@mobergpharma.seAmir Tavakkol, Chief Scientific Officer, telephone: +1 973 307 4856, e- mail: amir.tavakkol@mobergpharma.se About this informationThis information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8.00 am CEST on September 13[th], 2024, through the contact persons above. About MOB-015 and OnychomycosisApproximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. MOB-015 is an in-house developed topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. MOB-015 has been granted marketing authorization in 13 countries.[ ]The approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. A North American Phase 3 study is ongoing at 33 study centers in the USA and Canada, with a total of 384 patients. The patients are being evaluated over 52 weeks and the primary endpoint will be the proportion of subjects achieving complete cure of their target nail. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s drug MOB-015, is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden under the brand name Terclara[®] and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

Kesko signs a sustainability-linked loan with the Nordic Investment Bank

The new loan will support Kesko’s ambition to minimise impact on the climate and nature through its own operations and its value chain. The loan’s interest rate margin is tied to three key performance indicators (KPIs) aligned with sustainability targets that are part of Kesko’s wider sustainability strategy.The agreed KPIs are: · KPI1:The reduction of absolute greenhouse gas emissions (GHG) from Kesko’s own operations (Scope 1) and from energy purchased and used by Kesko (Scope 2). The KPI is aligned with Kesko’s science-based targets to decrease absolute Scope 1 and 2 GHG emissions by 90% by the end of 2030 from a 2020 baseline. · KPI2: The increase in the share of Kesko’s suppliers of goods and services that have publicly set GHG emission reduction targets approved by the Science Based Targets initiative. The KPI is aligned with Kesko’s science-based target that 67% of suppliers and service providers by spend will have set science-based targets by the end of 2026. · KPI 3: The reduction of food waste generated in Kesko’s food retail operations (including K-retailer grocery stores and Kesko’s own warehouses and logistics) in relation to total food sold. The KPI is aligned with Kesko’s target to reduce food waste by 50% by 2030 from a 2019 baseline. Kesko and NIB have also agreed that the climate-related KPIs (KPI 1 and 2) for the loan shall be updated once Kesko has finalised the ongoing process of updating its science-based targets and the new targets have been approved by the Science Based Targets initiative (SBTi). ”Sustainability is at the heart of Kesko’s strategy. Our objective is to enable sustainable choices for our customers and drive change throughout our value chain from production to consumption.We are very pleased to have signed a sustainability linked 7-year loan with NIB, which supports and promotes our sustainability efforts, especially when it comes to reducing our own and value chain’s greenhouse gas emissions as well as reducing food waste in our grocery tradeoperations,” says Anu Hämäläinen, Kesko’s Chief Financial Officer. Further information:Jarkko Karjalainen, Vice President, Group Treasury and M&A, tel. +358105322 694Hanna Jaakkola, Vice President, Investor Relations, tel. +358105323 540 Kesko CorporationDISTRIBUTION:Main news mediawww.kesko.fi

Altti Väisänen appointed as Kamux’s Director, Business Development

Kamux Corporation, Stock Exchange Release, 13.9.2024 at 9:30 Altti Väisänen appointed as Kamux’s Director, Business Development Altti Väisänen (40, M.Sc.Econ.) has been appointed Director, Business Development, Car Flow & Data, at Kamux Corporation and a member of the Group Management Team as of October 10, 2024. In his role, Väisänen is responsible for Kamux Group’s car-related presales processes as well as the company's strategy implementation and data activities. He will be based in Espoo, Finland, and report to CEO Tapio Pajuharju. Most recently Väisänen worked at the U.S.-based Massachusetts Bay Transportation Authority, where he held the position of Senior Director, Strategy and Special Projects. Prior to that, he worked as Director, Supply Operations & Logistics at Swappie, and at VR Group for example as VP of Strategy & Corporate Development. In addition, he has worked at Assistor Oy and Avelon Autologistics Oy, which are closely linked to the automotive industry, as well as at Bain & Company. CEO Tapio Pajuharju: “I am extremely happy to welcome Altti Väisänen to Kamux. Acceleration of strategy implementation, developing car related processes, and data driven decision making are crucial for customer satisfaction and our success. Altti has extensive experience and an impressive track record of building efficient company-wide processes with a customer-centric approach, as well as successful implementation of strategic initiatives. In addition, Altti brings to our management team valuable process know-how and significant experience in the presales process of cars.” Altti Väisänen: ”I am very excited for the opportunity to join Kamux on its path to profitable growth and to continue the strategy implementation as well as building scale and standardization in Kamux’s car flow together with Kamux employees and customers. I was impressed with the customer-focused entrepreneurial mindset and the can-do attitude of the organization.” The members of the Group Management Team are:Tapio Pajuharju, CEO;Jukka Havia, CFO;Jani Koivu, Managing Director, Kamux Finland;Martin Verrelli, Managing Director, Kamux Germany;Aino Hökeberg, Chief Marketing and Concept Officer, interim Managing Director, Kamux Sweden;Jarkko Lehtismäki, Chief Digital Officer;Marjo Nurmi, Chief People and Sustainability Officer (until Sept 30, 2024); andAltti Väisänen, Director, Business Development, Car Flow & Data (as of Oct 10, 2024) For more information, please contact:Tapio Pajuharju. CEO, tel. +358 50 577 4200Marjo Nurmi, Chief People and Sustainability Officer, tel. +358 50 632 16 Kamux CorporationCommunications Kamux is a retail chain specialized in preowned cars and related integrated services that has grown rapidly. Kamux combines online shopping with an extensive showroom network to provide its customers with a great service experience anytime, anywhere. In addition to digital channels, the company has a total of 73 car showrooms in Finland, Sweden and Germany. Since its founding in Hämeenlinna, Finland, in 2003 the company has sold over 500,000 used cars, 68,257 of which were sold in 2023. Kamux’s revenue in 2023 was EUR 1,002 million and its average number of employees was 885 in terms of full-time equivalent employees. Kamux Corporation is listed on Nasdaq Helsinki Ltd. For more information, please visit www.kamux.com 

Roc Oil Company Pty Limited announces a recommended cash offer to the shareholders of Tethys Oil AB

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS ANNOUNCEMENT AND IN THE OFFER DOCUMENT WHICH WILL BE PUBLISHED SHORTLY BEFORE THE BEGINNING OF THE ACCEPTANCE PERIOD FOR THE OFFER. SHAREHOLDERS IN THE UNITED STATES SHOULD ALSO REFER TO THE SECTION TITLED "SPECIAL NOTICE TO SHAREHOLDERS IN THE UNITED STATES OF AMERICA” AT THE END OF THIS ANNOUNCEMENT AND IN THE OFFER DOCUMENT. Press release, 13 September 2024 Roc Oil Company Pty Limited [1](“ROC” or the “Offeror”), one of Australia’s leading independent oil and gas companies, hereby announces a recommended public cash offer to the shareholders of Tethys Oil AB (“Tethys”) to tender all their shares in Tethys to the Offeror at a price of SEK 58.70 [2]in cash per share (the “Offer”). The shares in Tethys are admitted to trading on Nasdaq Stockholm. The Offer in brief · The shareholders of Tethys are offered SEK 58.70 in cash per share in Tethys. · The total value of the Offer, based on all outstanding shares in Tethys, amounts to approximately SEK 1.894 billion.[3] · The price of the Offer represents a premium of approximately: · 89.05 percent compared to the closing price of SEK 31.05 of Tethys’ shares on Nasdaq Stockholm on 12 September 2024, being the last day of trading before the announcement of the Offer; · 88.95 percent compared to the volume-weighted average trading price of SEK 31.07 of Tethys’ shares on Nasdaq Stockholm during the last 30 trading days before the announcement of the Offer; · 76.73 percent compared to the volume-weighted average trading price of SEK 33.21 of Tethys’ shares on Nasdaq Stockholm during the last 90 trading days prior to the announcement of the Offer; and · 65.94 percent compared to the volume-weighted average trading price of SEK 35.38 of Tethys’ shares on Nasdaq Stockholm during the last 180 trading days before the announcement of the Offer. · The recommended Offer is the result of a strategic review carried out by the board of directors of Tethys (the “Tethys Board”) as announced by Tethys on 5 February 2024. Following the conclusion of the strategic review, the independent bid committee of the Tethys Board (the “Tethys Bid Committee”) has decided to recommend the Offer as the best alternative to maximize value for its shareholders. · The Tethys Bid Committee unanimously recommends that shareholders of Tethys accept the Offer. The recommendation is supported by a fairness opinion provided by PwC, according to which the Offer is fair to Tethys’ shareholders from a financial point of view. · Lansdowne Partners Austria GmbH, Magnus Nordin [4] (CEO of Tethys) and Göran Källebo, holding in total approximately 16.86 percent of the outstanding shares and votes in Tethys, have irrevocably undertaken to accept the Offer, subject to certain conditions set out under “Undertakings from shareholders in Tethys” below. · Completion of the Offer is conditional upon the Offer being accepted to such extent that the Offeror becomes the owner of shares in Tethys representing more than 90 percent of the total number of shares in Tethys. Further, the completion of the Offer is subject to the conditions (ii) – (vii) set out under “Conditions for completion of the Offer” below. · An offer document regarding the Offer is expected to be published on or around 25 October 2024. The acceptance period for the Offer is expected to commence on or around 28 October 2024 and expire on or around 2 December 2024. Lei (David) Teng, Chairman of ROC, comments: “We believe the all-cash Offer is a compelling outcome of Tethys’ strategic review and presents Tethys’ shareholders with an opportunity to realise value at a very attractive premium. Tethys is a unique independent company with quality assets that are an excellent fit with ROC’s existing portfolio. Transitioning to a larger operator would enable Tethys’ business to realise its full potential as we see opportunities for new investments into prospects and development of discoveries. The proposed acquisition also aligns with our long-term strategy, to grow profitably in core upstream areas, expand our footprint in strategically important energy regions and commercialise large undeveloped oil and gas resource bases.” Per Seime, Chairman of Tethys, comments: “The Board of Tethys now concludes the strategic review initiated in February. Following the careful consideration of several attractive proposals, the Tethys independent bid committee of the board is very pleased to today announce its unanimous recommendation of ROC’s all-cash offer.” Background and reasons for the Offer Tethys is an oil exploration and production company with a focus on onshore areas with known oil discoveries. Tethys’ core area is the Sultanate of Oman, where it holds interests in Blocks 3&4, Block 49, Block 56 and Block 58. On 5 February 2024, the Tethys Board announced a strategic review to explore the possibility of rebalancing the Tethys portfolio’s mix of assets in different stages of the lifecycle and increasing the visibility of the assets’ fair market value. ROC has reviewed Tethys’ business before deciding to announce the Offer. Given the Offer’s significant premium to Tethys’ share price, ROC was successful in obtaining the Tethys Bid Committee’s recommendation to proceed with a public cash offer. ROC is one of Australia’s leading independent upstream oil and gas companies with a presence in China, South-East Asia and Australia. ROC operates across the full range of upstream business activities from exploration and appraisal to development and production delivery. As an operator with strong industry relationships, including national oil companies, ROC has a unique set of competitive advantages and a distinct industry position for a company of its size. In this context Tethys’ portfolio of assets fits well into ROC. ROC believes there are optimisation opportunities and synergies leveraging ROC’s existing operational excellence and high-performing team and expanding its focus areas. ROC sees opportunities for new investments into prospects and development of discoveries, which may be better served by being part of ROC and therefore transitioning to a larger operator would enable Tethys’ business to realize the portfolio’s full potential. ROC highly values the talented team at Tethys and ROC’s intentions do not currently entail any material changes to Tethys’ business, the locations where Tethys conducts its operations or Tethys’ management and employees, including their terms of employment. The Offer Consideration The shareholders of Tethys are offered SEK 58.70 in cash per share in Tethys. Should Tethys, prior to the settlement of the Offer, distribute dividends or in any other way distribute or transfer value to its shareholders, the consideration in the Offer will be adjusted accordingly. The Offeror reserves the right to determine whether this price adjustment mechanism or if condition (vii) to the completion of the Offer (see below under “Conditions for completion of the Offer”) shall be invoked. No commission will be charged in respect of the settlement of the Tethys shares tendered to the Offeror under the Offer. Premium The price of the Offer represents a premium of approximately: [5] · 89.05 percent compared to the closing price of SEK 31.05 for Tethys’ share on Nasdaq Stockholm on 12 September 2024, being the last day of trading day before the announcement of the Offer; · 88.95 percent compared to the volume-weighted average trading price of SEK 31.07 for Tethys’ share on Nasdaq Stockholm during the last 30 trading days before the announcement of the Offer; · 76.73 percent compared to the volume-weighted average trading price of SEK 33.21 for Tethys’ share on Nasdaq Stockholm during the last 90 trading days before the announcement of the Offer; and · 65.94 percent compared to the volume-weighted average trading price of SEK 35.38 for Tethys’ share on Nasdaq Stockholm during the last 180 trading days before the announcement of the Offer. The total value of the Offer The total value of the Offer, based on all outstanding shares in Tethys, amounts to approximately SEK 1.894 billion. [6] Recommendation from the Tethys Bid Committee and fairness opinion The Tethys Bid Committee has assessed the Offer and informed ROC that the Tethys Bid Committee has unanimously resolved to recommend the shareholders of Tethys to accept the Offer. The recommendation is supported by a fairness opinion from PwC, according to which the Offer is fair for Tethys’ shareholders from a financial point of view. The Tethys Bid Committee’s recommendation of the Offer is the result of a strategic review initiated by the Tethys Board, as announced by Tethys on 5 February 2024, where Tethys has considered a number of different proposals including other proposals for the whole of Tethys and proposals for some of Tethys’ assets. Following the conclusion of the strategic review, the Tethys Bid Committee has decided to recommend the Offer as the best alternative to maximize value for Tethys shareholders. Magnus Nordin, who is the CEO of Tethys and a member of the Tethys Board, has in his capacity as shareholder undertaken towards the Offeror to accept the Offer, see “Undertakings from shareholders in Tethys” below. Accordingly, he has not participated in the issuance of Tethys Bid Committee’s recommendation of the Offer and will not participate in Tethys’ handling or decisions regarding the Offer as he is deemed to have a conflict of interest pursuant to Rule II.18 of the Takeover Rules for Nasdaq Stockholm and Nordic Growth Market NGM issued by the Swedish Stock Market Self-Regulation Committee (Sw. Aktiemarknadens självregleringskommitté) (the “Takeover Rules”). Undertakings from shareholders in Tethys [7] The Offeror has obtained irrevocable undertakings to accept the Offer from the shareholders Lansdowne Partners Austria GmbH, in respect of 3,633,699 shares corresponding to approximately 11.26 percent of the outstanding shares in Tethys, Magnus Nordin [8], in respect of 1,555,427 shares corresponding to approximately 4.82 percent of the outstanding shares in Tethys, and Göran Källebo, in respect of 252,000 shares corresponding to approximately 0.78 percent of the outstanding shares in Tethys. Accordingly, irrevocable undertakings to accept the Offer from shareholders representing in total 5,441,126 shares in Tethys have been obtained, which corresponds to approximately 16.86 percent of the total number of outstanding shares and votes in Tethys. If, prior to the expiry of the initial acceptance period of the Offer, a third party announces a public offer in cash to acquire all outstanding shares in Tethys and (i) the offer value per share exceeds the value per share of the Offer by more than 12.5 percent (the "Superior Competing Offer"), and (ii) the Offeror does not within 10 business days after the public announcement of the Superior Competing Offer publicly announce an increase of the Offer (the "Revised Offer") so that the price per share in the Revised Offer at least corresponds to the price per share in the Superior Competing Offer at the time the Revised Offer is formally announced, the shareholders who have undertaken to accept the Offer are entitled to withdraw their acceptance of the Offer and accept the Superior Competing Offer. In the event of one or more Revised Offers, and one or more subsequent Superior Competing Offers prior to the expiry of the initial acceptance period of the Offer, the foregoing shall be applied accordingly in each case. The irrevocable undertakings to accept the Offer obtained from shareholders in Tethys expire at the earlier of (i) the time of an announcement of a withdrawal of the Offer, and (ii) 31 December 2024, if no completion or withdrawal of the Offer has occurred by such time. If any necessary regulatory, governmental or similar clearances, approvals, decisions and other actions from authorities or similar have not been obtained at the latest on 31 December 2024 but can be anticipated to be obtained not later than on 31 March 2025, and provided that the Offeror has complied with the Takeover Rules, the Offeror is entitled to unilaterally postpone the date set out in (ii) above to a later date, however in no event later than 31 March 2025. The shareholders who have undertaken to accept the Offer have the right to terminate the irrevocable undertakings to accept the Offer, and withdraw their acceptance of the Offer, in the event that (i) the Offeror publicly announces a waiver of the acceptance level condition in the Offer and either (A) declares the Offer unconditional without the Offeror having acquired at least 80 percent of the outstanding shares in Tethys or (B) such waiver entails that the acceptance level condition in the Offer remains and is less than 80 percent of the outstanding shares in Tethys, or (ii) the Offeror has breached the Takeover Rules. The Offeror’s shareholding in Tethys As of the announcement of the Offer, neither the Offeror, nor any of its closely related companies or other closely related parties, owns or controls any shares or other financial instruments in Tethys that give a financial exposure to Tethys’ shares, nor has the Offeror, or any closely related companies or other closely related parties, acquired, agreed to acquire, or taken measures to acquire any shares in Tethys or any financial instruments that give a financial exposure to Tethys’ shares during the six months preceding the announcement of the Offer. To the extent permissible under applicable law or regulations, the Offeror and its affiliates may acquire, or take measures to acquire, shares in Tethys in other ways than through the Offer. Information about such acquisitions of shares, or measures to acquire shares, will be disclosed in accordance with applicable laws and regulations. Conditions for completion of the Offer Completion of the Offer is conditional upon: i. the Offer being accepted to such extent that the Offeror becomes the owner of shares in Tethys representing more than 90 percent of the total number of shares in Tethys;ii. no other party announcing an offer to acquire shares in Tethys on terms more favorable to the shareholders of Tethys than the terms of the Offer;iii. with respect to the Offer and completion of the acquisition of Tethys, receipt of all necessary regulatory, governmental or similar clearances, approvals, decisions and other actions from authorities or similar, including from authorities screening foreign direct investments, being obtained, in each case on terms which, in the Offeror’s opinion, are acceptable;iv. neither the Offer nor the acquisition of Tethys being rendered wholly or partially impossible or significantly impeded as a result of legislation or other regulation, any decision of a court or public authority, or any similar circumstance; v. no circumstances having occurred which could have a material adverse effect or could reasonably be expected to have a material adverse effect on Tethys’ financial position, prospects or operations, including Tethys’ sales, results, liquidity, solidity, solvency, equity ratio, equity or assets;vi. no information made public by Tethys or otherwise made available by Tethys to the Offeror or its advisors being inaccurate, incomplete or misleading, and Tethys having made public all information which should have been made public by Tethys; andvii. Tethys not taking any action that is likely to impair the prerequisites for making or completing the Offer. The Offeror reserves the right to withdraw the Offer in the event that it becomes clear that any of the above conditions are not satisfied or cannot be satisfied. However, with regard to conditions (ii) – (vii) above, the Offer may only be withdrawn where the non-satisfaction of such condition is of material importance to the Offeror’s acquisition of Tethys or if otherwise approved by the Swedish Securities Council (Sw. Aktiemarknadsnämnden). The Offeror reserves the right to waive, in whole or in part, one, several or all of the conditions set out above, including, with respect to condition (i) above, to complete the Offer at a lower level of acceptance. Approvals from authorities The completion of the Offer is conditional upon, inter alia, all necessary clearances, approvals, decisions and other actions from authorities or similar, being obtained, in each case on terms which, in the Offeror’s opinion, are acceptable. According to the Offeror’s assessment, the completion of the Offer requires approvals from the Oman Ministry of Energy and Minerals pursuant to regulatory concession agreements and joint operating agreements to which Tethys is a party, as well as approvals from authorities screening foreign direct investments in Sweden, Denmark and Lithuania. The Offeror will promote that Tethys submits notifications to the Oman Ministry of Energy and Minerals as soon as possible after the announcement of the Offer. The Offeror will, as soon as possible after the announcement of the Offer, submit all notifications and applications (including to the relevant authorities screening foreign direct investments) required for the approvals etc. referred to in condition (iii) to the completion of the Offer (see above under “Conditions for completion of the Offer“), including proceeding with so-called Phase 2 or equivalent in-depth investigations, and supplementing any notification and application required, by any relevant authority. In case the approvals are not granted within the initial acceptance period of the Offer, the acceptance period of the Offer may be extended (see “Preliminary timetable” below). About ROC Roc Oil Company Pty Limited (“ROC” or the “Offeror”) is a limited liability company incorporated in New South Wales, Australia, with corporate registration number ACN 075 965 856 and registered address at Level 11, 20 Hunter Street, Sydney, New South Wales 2000, Australia. ROC is one of Australia’s leading independent upstream oil and gas companies with a presence in China, South-East Asia and Australia. ROC operates across the full range of upstream business activities from exploration and appraisal to development and production delivery. As an operator with strong industry relationships, including National Oil Companies, ROC has a unique set of competitive advantages – a distinct industry position for a company of its size. There are few other Australian upstream companies of a similar size capable of delivering this full suite of services. ROC has a workforce of approximately 127, located in offices in China, Australia and Malaysia. ROC has a strong balance sheet with no debt as of 30 June 2024. ROC's sales revenue and cash flow from operations for the year ended 31 December 2023 were USD 249 million and USD 127 million, respectively, supported by strong production from its core assets, which averaged 17,155 barrels of oil equivalent per day for 2023. During the first half of 2024, ROC's strong operating performance continued with production averaging 22,059 barrels of oil equivalent per day and sales revenue of USD 110 million. ROC's strategy is to create shareholder value by acquiring meaningful interests, generally as operator, in regions containing, or adjacent to, proven hydrocarbons with considerable exploration upside. ROC’s core focus areas are China, Australia and South-East Asia, preferably in countries with attractive fiscal regimes. From its inception, ROC’s portfolio growth has been achieved through a combination of acquiring producing and developed assets and through organic growth from exploration, appraisal and development success. Incorporated in Australia, ROC was listed on the Australian Securities Exchange (ASX) in 1999. Following a takeover by Transcendent Resources Limited, a wholly owned subsidiary of Fosun International Limited, in 2014, ROC delisted from the ASX in 2015 and continues to operate as an upstream oil and gas company with Fosun International Limited as its ultimate parent company. The Fosun International Limited group is a large investment group and has substantial operations and business interests in China and internationally. In 2019, Hainan Mining Co. Ltd acquired 51 percent of ROC from Fosun International Limited and in 2023, Hainan Mining Co. Ltd acquired the remaining 49 percent of ROC from Fosun International Limited. Fosun International Limited has a controlling stake in Hainan Mining Co. Ltd and continues to be ROC’s ultimate parent company. Hainan Mining Co. Ltd (ticker: 601989) is listed on the Shanghai Stock Exchange and Fosun International Limited (ticker: 00656) is listed on the Hong Kong Stock Exchange. For further information on ROC, Hainan Mining Co. Ltd and Fosun International Limited, see their respective websites, https://www.rocoil.com.au/, www.hnmining.com and https://en.fosun.com/. About Tethys Tethys is an oil exploration and production company with a focus on onshore areas with known oil discoveries. Tethys’ core area is the Sultanate of Oman, where it holds interests in Blocks 3&4, Block 49, Block 56 and Block 58. Tethys had audited net working interest 2P reserves of approximately 21.7 million barrels of oil and net working interest 2C contingent resources of approximately 15.5 million barrels of oil as of year-end 2023 and had an average oil production of 7,860 barrels per day during the first six months of 2024 (net to Tethys before government take). Tethys’ shares are admitted to trading on Nasdaq Stockholm with ticker TETY. For further information on Tethys, see Tethys’ website . Financing of the Offer The consideration payable to Tethys’ shareholders that accept the Offer is financed in full by cash funds available to ROC. The above-mentioned financing provides the Offeror with sufficient cash resources to make payment in full in accordance with the Offer and, accordingly, completion of the Offer is not subject to any financing condition. Due Diligence review The Offeror has been permitted by the Tethys Board to carry out a confirmatory due diligence review of Tethys in connection with the preparation of the Offer. Tethys has confirmed that no inside information has been disclosed to the Offeror during such review and preparations. Warrants issued by Tethys within Tethys’ incentive programs The Offer does not comprise the warrants that have been issued by Tethys to participants in Tethys’ warrants incentive programs. The Offeror will offer the participants in such warrant incentive programs a fair treatment in connection with the Offer. Preliminary timetable Publication of the offer document: 25 October 2024 Acceptance period: 28 October 2024 – 2 December 2024 Commencement of settlement: around 9 December 2024 All dates are preliminary and may be subject to change. The Offeror reserves the right to, on one or several occasions, amend the acceptance period for the Offer, as well as to amend the settlement date. Notice of any such amendment will be announced by the Offeror by means of a press release in accordance with applicable rules and regulations. Compulsory redemption proceedings and delisting If the Offeror, whether in connection with the Offer or otherwise, acquires shares representing more than 90 percent of the total number of shares in Tethys, the Offeror intends to commence a compulsory redemption of the remaining shares in Tethys under the Swedish Companies Act (2005:551) (Sw. aktiebolagslagen (2005:551)). In connection therewith, the Offeror intends to promote a delisting of the shares in Tethys from Nasdaq Stockholm. Governing law and disputes The Offer and the agreements entered into between the Offeror and Tethys’ shareholders as a result of the Offer, shall be governed by and construed in accordance with substantive Swedish law. Any disputes concerning the Offer, or which arises in connection therewith, shall be settled exclusively by Swedish courts, with Stockholm District Court (Sw. Stockholms tingsrätt) as first instance. The Takeover Rules for Nasdaq Stockholm and Nordic Growth Market NGM issued by the Swedish Stock Market Self-Regulation Committee (Sw. Aktiemarknadens självregleringskommitté) (the “Takeover Rules”) and the Swedish Securities Council’s (Sw. Aktiemarknadsnämnden) statements and rulings regarding interpretation and application of the Takeover Rules, and, where applicable, the Swedish Securities Council’s interpretation and application of the formerly applicable Rules on Public Offers for the Acquisition of Shares issued by the Swedish Industry and Commerce Stock Exchange Committee (Sw. Näringslivets Börskommitté) are applicable to the Offer. Furthermore, the Offeror has, in accordance with the Swedish Stock Market (Takeover Bids) Act (Sw. lag om offentliga uppköpserbjudanden på aktiemarknaden (2006:451)), on 12 September 2024 undertaken, in writing, towards Nasdaq Stockholm to comply with said rules, rulings and statements, and to submit to any sanctions that can be imposed by Nasdaq Stockholm in event of a breach of the Takeover Rules. The Offeror has, on 13 September 2024, informed the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) about the Offer and about the above-mentioned undertakings towards Nasdaq Stockholm. Advisors The Offeror has engaged Pareto Securities AB/AS as financial advisor and Snellman Attorneys Ltd and Pillsbury Winthrop Shaw Pittman LLP as legal advisors in connection with the Offer. Roc Oil Company Pty Limited Contacts and further information about the Offer Bruce Zhang, Managing Director of Hainan Mining+861056117616strata@rocoil.com.au Brunswick Grouprocoil@brunswickgroup.com Information about the Offer is made available at: www.project-strata.com For administrative questions regarding the Offer, please contact your bank or nominee where you have your shares registered. The Offeror discloses the information provided herein pursuant to the Swedish Stock Market (Takeover Bids) Act and the Takeover Rules. The information was submitted for announcement at 09:01 (CEST) on 13 September 2024. Important information This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. The Offer is not being made, directly or indirectly, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa and/or Switzerland (the “Restricted Jurisdictions”) or in any other jurisdiction where the Offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by law. The distribution of the information in this press release and any related Offer documentation in certain jurisdictions may be restricted or affected by the laws of such jurisdiction. Accordingly, the information in this press release may not be forwarded, distributed, reproduced or otherwise made available in or into or accessed from any country in which the Offer would require that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law or where it would be in conflict with any law or regulation in such country, including the Restricted Jurisdictions, and does not constitute an offer or solicitation to acquire, sell, subscribe or exchange securities, to persons in the Restricted Jurisdictions or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of any of the Restricted Jurisdictions. The Offer cannot be accepted by any such use or by such means, instrumentality or facility of, in or from, any of the Restricted Jurisdictions. Accordingly, this press release or any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into or accessed from any of the Restricted Jurisdictions. This press release is not being, and must not be, sent to shareholders with registered addresses in any of the Restricted Jurisdictions. Banks, brokers, dealers and other nominees holding shares for persons in any of the Restricted Jurisdictions must not forward this press release or any other document received in connection with the Offer to such persons. Any failure by such persons to inform themselves and observe applicable restrictions or requirements may constitute a violation of the securities laws of the Restricted Jurisdictions. To the fullest extent permitted by applicable law, the Offeror disclaims any responsibility or liability for the violations of any such restrictions by any person. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. No consideration under the Offer will be delivered in or into any of the Restricted Jurisdictions. The Offer shall be governed by and construed in accordance with Swedish substantive law. The courts of Sweden shall have exclusive jurisdiction over any dispute arising out of or in connection with the Offer and the Stockholm District Court shall be the court of first instance. The Offer and the information and documents contained in this press release are not being made and have not been approved by an authorized person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the “FSMA”). Accordingly, the information and documents contained in this press release are not being distributed to, and must not be passed on to, the general public in the United Kingdom unless an exemption applies. The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire day to day control of the affairs of a body corporate; or to acquire 50 percent or more of the voting shares in a body corporate, within article 62 of the FSMA (Financial Promotion) Order 2005. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and/or effects of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that could occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to several factors, many of which are outside the control of the Offeror. Any such forward-looking statements speak only as of the date on which they are made and the Offeror has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Information about Tethys in this press release has been derived from information published by Tethys. The Offeror disclaims any and all responsibility or liability for any information about Tethys derived from Tethys' website and/or from other information published by Tethys that is proved to be factually incorrect or misleading. Special notice to shareholders in the United States of America The Offer described in this press release is made for the issued and outstanding shares of Tethys, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which may be different from those of the United States of America (“United States” or “U.S.”). The Offer is made in the United States pursuant to Section 14(e) of the U.S. Securities Exchange Act of 1934, as amended (the “U.S. Exchange Act”) and Regulation 14E thereunder, in each case to the extent applicable, subject to the exemptions provided under Rule 14d-1(d) under the U.S. Exchange Act (the “Tier II Exemption”) and otherwise in compliance with the disclosure and procedural requirements of Swedish law, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered) and waivers of conditions, which may be different from requirements or customary practices in relation to U.S. domestic tender offers. As permitted under the Tier II Exemption, the settlement of the Offer is based on the applicable Swedish law provisions which differ from the settlement procedures customary in the United States, particularly as regards the time when payment of the consideration is rendered. Holders of the shares of Tethys domiciled in the United States (the “U.S. Holders”) are encouraged to consult with their own advisors regarding the Offer. U.S. Holders are advised that shares of Tethys are not listed on a U.S. securities exchange and that Tethys is not subject to the periodic reporting requirements of the U.S. Exchange Act, and is not required to, and does not, file any reports with the U.S. Securities and Exchange Commission (“SEC”) thereunder. The Offer is being made in the United States by Roc Oil Company Pty Limited and no one else. Tethys’ financial statements and all financial information included herein, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to the financial statements or financial information of companies in the United States or other companies whose financial statements are prepared in accordance with U.S. generally accepted accounting principles. The Offer is made to the U.S. Holders on the same terms and conditions as those made to all other shareholders of Tethys to whom an offer is made. Any information documents, including the offer document, are being disseminated to U.S. Holders on a basis comparable to the method pursuant to which such documents are provided to Tethys’ other shareholders. The Offer, which is subject to Swedish law, is being made to the U.S. Holders in accordance with the applicable U.S. securities laws, and applicable exemptions thereunder, including the Tier II Exemption. To the extent the Offer is subject to U.S. securities laws, those laws only apply to U.S. Holders and thus will not give rise to claims on the part of any other person. The U.S. Holders should consider that the price for the Offer is being paid in SEK and that no adjustment will be made based on any changes in the exchange rate. It may be difficult for Tethys’ shareholders to enforce their rights and any claims they may have arising under the U.S. federal or state securities laws in connection with the Offer, since Tethys and the Offeror are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. Tethys’ shareholders may not be able to sue Tethys or the Offeror or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel Tethys or the Offeror and/or their respective affiliates to subject themselves to the jurisdiction or judgment of a U.S. court. To the extent permissible under applicable law or regulations and pursuant to Rule 14e-5(b), the Offeror and its affiliates or its brokers and its brokers’ affiliates (acting as agents for the Offeror or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly purchase or arrange to purchase shares of Tethys outside the United States, or any securities that are convertible into, exchangeable for or exercisable for such shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices, and, to the extent required under applicable law, information about such purchases will be disclosed by means of a press release or other means reasonably calculated to inform U.S. Holders of such information to the extent that such information is made public in Tethys’s home jurisdiction. In addition, the financial advisors to the Offeror may also engage in ordinary course trading activities in securities of Tethys, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with the applicable law. Any information about such purchases will be announced in Swedish and in a non-binding English translation available to the U.S. Holders through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish or U.S. law, rules or regulations. The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult an independent professional adviser regarding the tax consequences of accepting the Offer. Neither the Offeror nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be responsible for any tax effects or liabilities resulting from acceptance of this Offer. NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, PASSED ANY COMMENTS UPON THE MERITS OR FAIRNESS OF THE OFFER, PASSED ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS PRESS RELEASE OR PASSED ANY COMMENT ON WHETHER THE CONTENT IN THIS PRESS RELEASE IS CORRECT OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. [1] Roc Oil Company Pty Limited (“ROC” or the “Offeror”) is a limited liability company incorporated in New South Wales, Australia, with corporate registration number ACN 075 965 856. [2] Should Tethys, prior to the settlement of the Offer, distribute dividends or in any other way distribute or transfer value to the shareholders, the consideration in the Offer will be adjusted accordingly. The Offeror reserves the right to determine whether this price adjustment mechanism or if condition (vii) to the completion of the Offer (see below under “Conditions for completion of the Offer”) shall be invoked. [3] All references in this announcement to outstanding shares or votes in Tethys are based on 32,268,927 outstanding shares in Tethys, which corresponds to all 33,458,828 issued shares in Tethys less the 1,189,901 issued shares in Tethys which are held in treasury by Tethys. [4] Privately and through the companies Minotaurus AB and Minotaurus Energi AS. [5] Source for Tethys’ share prices: Bloomberg. [6] All references in this announcement to outstanding shares or votes in Tethys are based on 32,268,927 outstanding shares in Tethys, which corresponds to all 33,458,828 issued shares in Tethys less the 1,189,901 issued shares in Tethys which are held in treasury by Tethys. [7] All references in this announcement to outstanding shares or votes in Tethys are based on 32,268,927 outstanding shares in Tethys, which corresponds to all 33,458,828 issued shares in Tethys less the 1,189,901 issued shares in Tethys which are held in treasury by Tethys. [8] Privately and through the companies Minotaurus AB and Minotaurus Energi AS.

Brain+ A/S announces the exercise price for its warrants of series TO 4

Holders of Brain+ warrants of series TO 4, who which to exercise the rights attached to the warrants to subscribe for new shares in the Company at the subscription price of DKK 0.08, must inform their custodian bank no later than 27 September 2024. Please note that some custodian banks might have earlier deadlines for exercise than the official exercise period. Holders of warrants of series TO 4, who do not wish to exercise their warrants to subscribe for new shares, should sell the warrants over the market no later than 25 September 2024. Please note that warrants of series TO 4 that are not exercised no later than 27 September 2024, or not sold no later than 25 September 2024, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. The complete terms and conditions for the warrants of series TO 4 can be found in the company announcement issued by Brain+ on 7 May 2024. The company announcement, as well as additional informative documents are available at the Company’s website: https://www.brain-plus.com/2024-unit-rights-issue/.  Summarized terms for Brain+’ warrants of series TO 4: Exercise 16 - 27 September 2024period:Exercise DKK 0.08price:Last day 25 September 2024oftrading:Issue 65,496,978 warrants, which entitle to a maximum subscription ofvolume: 65,496,978 new Brain+ shares. If all warrants are exercised, the Company will receive approximately DKK 5.2 million in proceeds before issuing costs.Dilution: Upon full exercise of warrants of series TO 4, the number of shares of nominal value DKK 0.08 each in Brain+ will increase by 65,496,978 from 171,501,141 shares to 236,998,119 shares, and the share capital will increase by DKK 5,239,758.24 from DKK 13,720,091.28 to DKK 18,959,849.52. If all warrants of series TO 4 are exercised, the dilution of the number of shares and votes in Brain+ will be approximately 27.6 percent. How warrants are exercised (Nominee-registered warrants)Subscription and payment for new shares by exercise of warrants shall be made in accordance with instructions from each nominee/custodian bank. Please contact your nominee/custodian bank directly for additional information and instructions. OutcomeThe outcome of the exercise of warrants of Series TO 4 will be published in a company announcement on or around 1 October 2024. Shares that have been subscribed and paid for will be delivered to the subscriber when registration of the capital increase has been completed with the Danish Business Authority. AdvisorsIn connection with the rights issue, Sedermera Corporate Finance AB act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent. For more information about the warrant exercise, please contact: Sedermera Corporate Finance ABPhone: +46 (0) 40 615 14 10E-mail: cf@sedermera.sewww.sedermera.se For more information about Brain+ and the warrant exercise, please contact: Kim Baden-Kristensen, CEO                            Hanne Vissing Leth, CFOPhone: +45 31 39 33 17                                  Phone: +45 53 88 99 02E-mail: kim@brain-plus.com                            E-mail: Hanne@brain-plus.com www.brain-plus.com Certified Adviser Keswick Global AGPhone: +43 1 740 408 045E-mail: info@keswickglobal.com (cf@sedermera.se) Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia by 2030.

Composition of Sitowise's Shareholders' Nomination Board

Sitowise Group Plc, Stock Exchange Release, 13 September 2024 at 10.15 a.m. (EEST) The following members have been appointed to Sitowise Group Plc's Shareholders' Nomination Board: · Jan Hummel, Paradigm Capital Value Fund SICAV, · Juhana Kallio, Intera Partners Oy, · Stian Runde, Protector Forsikring ASA, and · Eero Heliövaara, Chair of Sitowise Board of Directors. Representatives of the three largest shareholders are elected annually to Sitowise's shareholders' nomination committee. The company's three largest shareholders, according to the situation on the first business day of September, are each entitled to nominate one member. The committee also includes the chairman of the company's board as an expert member. The shareholders' nomination committee elects a chairman from among its members. Annual General Meeting 2023 established the Shareholders’ Nomination Board. The Nomination Board is established for the time being and prepares proposals for the election and remuneration of the chairperson and members of the Board of Directors to the Annual General Meeting. The now appointed Nomination Board will forward its proposals for the 2025 Annual General Meeting to the company’s Board of Directors by 1 February 2025. The charter of the Nomination Board is available on the company’s website. Sitowise Group Plc Additional information: Hanna Masala, CFO, hanna.masala@sitowise.com, tel. +358 40 558 1323  Distribution: Nasdaq Helsinki LtdMajor mediawww.sitowise.com About Sitowise Sitowise is a Nordic expert in the built environment and forestry with strong focus on digitality. We provide design and consulting knowhow to enable more sustainable environment and smarter urban development as well as smooth transportation. Sitowise offers services related to real estate and buildings, infrastructure, and digital solutions both in Finland and in Sweden. Global megatrends drive huge changes that require a re-evaluation of the smartness in the built environment – therefore we have set our vision to be Redefining Smartness in Cities. The Group's net sales were EUR  211 million in 2023 and the company employs more than 2,100 experts. Sitowise Group Plc is listed on Nasdaq Helsinki under the trading symbol SITOWS.

New AI-powered PoC, built on AiQu, revolutionizes technical quality assessment

Mölndal                                                                                      2024-09-13 A major player in the Tech sector has invested in a Proof of Concept (PoC) that utilizes advanced AI technology for quality assessment. With the help of Aixia's proprietary AI platform AiQu, the company will automate and streamline processes for its production environment. which will generate a big step forward for technological innovation for the company. AiQu – the AI platform behind Aixia's successful concept around AI for Industry. The PoC is built on top of AiQu, an AI platform designed to manage and optimize AI workloads in a scalable and efficient manner. "We are proud that we have now been trusted to carry out this Proof of Concept with our proprietary platform AiQu," says Mattias Bergkvist, CEO of Aixia." // For more information:Get in touch with the company at:CEO Mattias Bergkvist Phone: 031-762 02 40info@aixia.sewww.aixia.se

Elkem ASA - Notice of an extraordinary general meeting 2024

Oslo, 13 September 2024 An extraordinary general meeting of Elkem ASA will be held on 8 October at 09:00 (Norwegian time) for the election of new board members and a new member to the nomination committee. The meeting will be conducted as a digital meeting on the Lumi AGM, and with utilisation of electronic voting for all attending shareholders. The full notice is attached, and all relevant documents can be found on www.elkem.com/investor/debt-and-share-information/annual-general-meeting/ This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Odd-Geir LyngstadVP Finance & Investor RelationsTel: +47 976 72 806Email: odd-geir.lyngstad@elkem.com About Elkem:Elkem is one of the world’s leading providers of advanced silicon-based materials shaping a better and more sustainable future. The company develops silicones, silicon products and carbon solutions by combining natural raw materials, renewable energy and human ingenuity. Elkem helps its customers create and improve essential innovations like electric mobility, digital communications, health and personal care as well as smarter and more sustainable cities. With a strong track record since 1904, its global team of more than 7,300 people has a joint commitment to stakeholders: Delivering your potential. In 2023, Elkem achieved an operating income of NOK 35.5 billion and CDP ratings of A on Forest, and A- on Climate Change and Water Security. Elkem is listed on the Oslo Stock Exchange (ticker: ELK), where the company is also included in the ESG Index. www.elkem.com

Allurity completes strategic acquisition of Lyvoc, continuing its European growth journey

Allurity proudly announces the strategic acquisition of Lyvoc, a premier cybersecurity integration partner renowned for its expertise in supporting its clients to accelerate and secure their digital transformation. This acquisition marks a significant milestone for Allurity, enhancing its market position and expanding its comprehensive cybersecurity offering. Lyvoc, based in France, brings a wealth of knowledge and experience in Identity and Access Management (IAM), Cloud Security and Security Compliance Automation. With a dedicated team of more than 50 passionate cybersecurity professionals, Lyvoc has built focused partnerships with Okta (for IAM), Drata (for Security Compliance Automation) and Wiz (for Cloud Security) and has trusted relationships with more than 150 customers. The strong technical expertise, combined with organizational change management and project management skills, ensures a seamless integration and superior service delivery. “By joining forces with Lyvoc, Allurity enhances its capabilities with advanced cybersecurity integration services and deep technical expertise,” stated Frida Westerberg, CEO of Allurity. “This strategic acquisition aligns perfectly with our vision to become the preferred partner for tech-enabled cybersecurity services in Europe. It not only expands our global impact but also strengthens our mission to create a safe digital world. Lyvoc brings a highly skilled team of passionate cybersecurity specialists and establishes our presence in France, a key market for cybersecurity in Europe.” “Lyvoc has always been at the forefront of delivering innovative cybersecurity solutions to protect against evolving cyber threats. We have been awarded #1 Okta partner in EMEA 2 years in a row,” said Roland Kamara, Founder/CEO of Lyvoc. “Joining forces with Allurity allows us to expand our core partnerships (Okta, Wiz, Drata) to more countries and combine our strengths to offer holistic cybersecurity services. Together, we are poised to set new standards in cybersecurity, ensuring that our clients receive the best protection and insights.” The Allurity group now includes nine premier brands across Europe, including Spanish Aiuken, Swedish Arctic Group and ID North, Portuguese CloudComputing, Danish CSIS, British SecAlliance, Swiss SECURIX, German SRLabs and now French Lyvoc. This acquisition accelerates Allurity’s strategy to become the leading cybersecurity powerhouse in Europe. Currently, the group generates approximately EUR 120 million in revenue, serving customers globally. About Allurity: Allurity is a group of tech-enabled cybersecurity service providers with a common mission of enabling a safe digital world. Allurity comprises nine best-in-class cybersecurity brands across Europe, serving clients globally and leveraging the combined expertise of its members. The group offers a comprehensive range of services, from proactive to reactive solutions, to enhance data protection and mitigate the impact of cybercrime. Supported by Trill Impact, a pioneering Swedish impact investor, Allurity is dedicated to driving positive societal change while achieving competitive financial returns. Read more atallurity.com About Lyvoc: Lyvoc is a team of passionate cybersecurity professionals dedicated to accelerating and securing all customers’ digital transformation. By partnering with industry-leading SaaS solutions such as Okta, Wiz, and Drata, Lyvoc delivers a comprehensive approach to protecting identities, securing cloud environments, and ensuring compliance with various standards. The team brings together deep technical expertise in cybersecurity and development, paired with strong organizational change management and project management capabilities. Read more atlyvoc.com For media enquiries, please contact: Maria Lörne, CMO Allurity, mediarelations@allurity.com

Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Cognitive Stimulation Therapy (CST): The best kept secret for better dementia treatment In August this year, The UK National Health Services (NHS) released its new Right Care guidance, directing the country’s health care system on how to best organize and spend resources. The guidance emphasizes the need for improved care pathways and specifically mentions the importance of evidence-based interventions like Cognitive Stimulation Therapy (CST) for dementia. Dementia affects approximately 1 million people in the UK and represents a severe and growing burden on the healthcare system and on society as a whole. CST is an intervention therapy, which has demonstrated clinical benefits for people with dementia corresponding to a 6-month delay in cognitive decline and better quality-of-life. However, despite growing recognition of its strong potential, adoption of the therapy remains relatively low due to several barriers, including lack of healthcare personnel resources and logistic barriers. Brain+ A/S (“Brain” or the “Company”) is on track to release the CST-Assistant as a Medical Device Software on the UK market by end September 2024 to offer CST at scale. The product-market fit of the product was earlier in 2024 validated in a clinical trial conducted at two AgeUK sites and its relevance endorsed by Professor Amy Spector, the founder of CST. Devika Wood, new UK-based Chief Commercial Officer at Brain+, stated:   “Based on our initial commercial outreach on the UK dementia care market, I believe CST to be the best kept secret for better dementia treatment. Even if CST has the highest adoption rate in the UK of any country in the world, still the documented benefits and enormous potential of this therapy are unknown to many in the healthcare system. The ability of our CST-Assistant to standardize high-quality and scalable CST delivery aligns perfectly with the new Right Care principles of providing appropriate, timely, and effective care for people with dementia.  We have set a commercial plan which targets 104 NHS Services primed for CST adoption and our sales targets are backed by concrete market demand.” UK commercial plan targeting selected NHS institutions to be executed by UK team with strong healthtech sales track-record Together with the leading UK based healthtech commercial advisor, Quiddity Health, Brain+ has developed a vetted commercialization strategy for the CST-Assistant in the UK market. To execute the strategy, an in-house UK-based Brain+ commercial leadership team is now in place, led by Devika Wood, new Chief Commercial Officer. Devika brings a strong track record of successfully scaling healthtech solutions in the UK and beyond, having delivered multi-million pounds contracts and exponential revenue growth in her previous ventures. Complementing Devika is Fiona Costello, new SVP of Partnerships. Fiona has extensive experience in forging strategic business partnerships with UK national healthcare providers and penetrating complex healthcare markets, and she has driven the adoption of innovative health technologies across international health systems. The commercial team has developed a targeted UK commercial plan, focused initially on selling the CST-Assistant as a Software-as-a-Service (SaaS) product to NHS Trusts as the primary target market. The plan focuses on 104 NHS institutions primed for scaling their delivery of CST to people with dementia. The selection criteria for the first wave of sales targets are threefold, so focus will initially be on dementia care institutions, which have 1) existing CST offering and therapeutic knowhow, 2) a strong digital health adoption track record, and 3) a dedicated dementia care strategy. Sales conversations with NHS trusts are conducted primarily by the SVP of Partnerships, while other target segments, like public and private Care Homes and Insurance companies, are handled by the CCO. In-depth specialist conversations will be supported by the full Brain+ team. Key 2024 milestones in UK commercial plan:  · September – Launch new Brain+ branding and awareness campaign to increase and accelerate awareness of our unique approach and CST offering in our target market · September – Introduce the CST-Assistant as a new Medical Device Software to offer scalable CST. Following commercial release of the CST-Assistant, targeted outreach to identified key CST stakeholders and decision makers in selected NHS trusts will begin.  · October - Publish White Paper on the CST-Assistant, highlighting the benefits of our product as a new and innovative approach to high-quality and scalable CST delivery that actively addresses the current barriers to adoption in the UK  · October - Launch webinar with key partners and CST advocates for an introduction to CST and the CST-Assistant, bringing the white paper and its core messaging to life.  · November/December – Build pipeline of active customer leads among NHS Trusts · November/December – Close the first UK sale in the form of ‘evaluation track’ type of contract with NHS trust, in range of 10.000-30.000 pounds. Such early contracts are expected to set the basis for transition into larger, recurring SaaS contracts from 2025 Projected strong UK sales trajectory for 2025-2027 Brain+ has progressed according to plan following the launch of its UK focused commercial strategy in Q1 2024 and is now on the brink of commercialization in the UK. With a UK dementia market ripe for scalable CST adoption, the CST-Assistant validated and ready for launch as a Medical Device Software, and a targeted commercial plan in place to be executed by an experienced commercial team, scalable sales and proof-of-business are within reach. Concretely, Brain+ has the following sales projections for the coming years: · 2024: Close early NHS ‘evaluation track’ contract(s) with a combined UK sales value of DKK 0.15-0.2 million · 2025: Close additional sales contract to reach DKK 7-8 million in recurring revenue by end year. · 2026: Scale sales to a level of DKK 11-12 million in recurring revenue · 2027: Reach a level of DKK 25-27 million in recurring revenue The sales projections are supported by a plan of releasing additional Brain+ CST products in 2025 and 2026 to further scale the company’s healthtech offerings through remote delivery of the therapy and interacting with people at home.  The ability of Brain+ to execute on its UK commercial plan and meet the sales targets will also depend on the level of funding available for the Company until expected operational break even by late 2026. Contact Information CEO and Co-founder: Kim Baden-Kristensen, + 45 31 39 33 17 (SMS), kim@brain-plus.com

These are the world’s best airline rewards programs!

Winner North America:Air Canada AeroplanWinner Middle East and Africa:Qatar Airways Privilege ClubWinner Asia Pacific:Cathay Pacific Asia Miles "This is just an incredibly proud day for all of us at Loyal Solutions. To witness 3 of our close partners being named the best program in their region is so gratifying and such a motivation for all of us. We understand that Loyal Solutions is only one part of the equation, but we are proud to have contributed in some way to our clients success. For us, it is yet another confirmation of the value our market leading SaaS platform, LoyalTfacts, is creating for our partners. A big thank you to everyone at Loyal Solutions for  your hard work and commitment every day, enabling us to deliver solutions and technology which in turn enables our clients to offer Award winning solutions. A huge congratulation to Air Canada, Qatar Airways and Cathay Pacific on this achievement, we will do our very best to assist in you repeating next year, and the following, and the following.... " Says Peter Kisbye, CEO at Loyal Solutions.  Read the full article on CNN Travel  here  .

Statement from the Board of Directors of Jetpak Top Holding AB (publ) regarding the increased voluntary cash offer from Notalp Logistik AB

The Board of Directors of Jetpak Top Holding AB (publ) (”Jetpak” or the ”Company”) recommends the shareholders of Jetpak to accept the offer. This statement is made by the Board of Directors of Jetpak pursuant to section II.19 of the Takeover rules for certain trading platforms adopted by the Stock Market Self-Regulation Committee issued on 1 January 2024 (the “Takeover Rules”). Background On 19 June 2024, Notalp Logistik AB (name changed from Goldcup 35626 AB) (”Notalp Logistik” or ”BidCo”)[1] announced a voluntary cash offer to the shareholders of Jetpak to tender all their shares in Jetpak at an offer price in cash of SEK 98.00 per share (the ”Offer”). On 6 September 2024, BidCo announced an increase of the price in the Offer to SEK 104.50 (the “Increased Offer Price”). In connection with BidCo’s announcement of the Increased Offer Price, the acceptance period for the Offer was extended up to and including 19.00 (CEST) on 20 September 2024. BidCo also announced that BidCo will neither increase the price in the Offer nor extend the acceptance period further. In the same press release, it was also announced that (i) BidCo had entered into an irrevocable and unilateral option agreement with Cidro Förvaltning AB to acquire approximately 12.09 percent of the total number of shares and votes in Jetpak (the “Option”), and (ii) BidCo, directly or indirectly, controls 89.67 percent of the total number of shares and votes in Jetpak, including the shares under the Option and the shares acquired in the mandatory offer (see below for further information on the mandatory offer). The Increased Offer Price values all 12,187,675 outstanding shares in Jetpak to approximately SEK 1,274 million. The Increased Offer Price represents a premium of: · approximately 11.17 percent compared to the closing price of SEK 94.00 of the Jetpak share on Nasdaq First North Premier Growth Market on 19 June 2024, which was the last day of trading prior to the announcement of the Offer. · approximately 13.01 percent compared to the volume-weighted average share price of SEK92.47 of the Jetpak share on Nasdaq First North Premier Growth Market during the last 20 trading days up to and including 19 June 2024, which was the last day of trading prior to the announcement of the Offer, · approximately 12.03 percent compared to the volume-weighted average share price of SEK93.28 for the Jetpak share on Nasdaq First North Premier Growth Market during the last 30 trading days up to and including 19 June 2024, which was the last day of trading prior to the announcement of the Offer, and · approximately 11.98 percent compared to the price of SEK 93.32 in the mandatory offer announced by PakLogistik Intressenter on 7 June 2024 (see below for further information on the mandatory offer). Shareholders who have already tendered their shares in Jetpak at SEK 98 in cash per share will automatically benefit from the Increased Offer Price of SEK 104.50 in cash per share, provided that the Offer is declared unconditional and completed, and thus do not need to accept the Offer again. Completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that Notalp Logistik, together with the other members of the Consortium, becomes the owner of shares representing more than 90 percent of the total number of shares in Jetpak. Notalp Logistik has reserved the right to waive these and other fulfilment conditions in whole or in part. On 7 June 2024, Pak Logistik Intressenter, a member of the Consortium and a company wholly owned by Paradeigma, also being a member of the Consortium, announced a mandatory offer to the shareholders of Jetpak to tender all their shares in Jetpak to Pak Logistik Intressenter at a price of SEK 93.32 in cash per share (the ”Mandatory Offer”). For further information on the Mandatory Offer, including how the Mandatory Offer relates to the Offer, see www.logistics-offer.com. On 19 June 2024, Notalp Logistik AB published an offer document regarding the Offer. By reason of, inter alia, the Increased Offer Price, Notalp Logistik published a supplement to the offer document on 9 September 2024. Notalp Logistik has previously published supplements to the offer document on 9 July 2024 and 28 August 2024. For further information on the Offer, see the offer document and the supplements, as well as www.notalp-transportation-offer.com. By reason of the Increased Offer Price, the Board of Directors has obtained a new independent fairness opinion from Deloitte AB (“Deloitte”) in accordance with section IV.3 of the Takeover Rules. Deloitte receives a fixed fee, irrespective of the outcome of the Offer. The fairness opinion is attached to this statement. Further, the Board of Directors has engaged the law firm TM & Partners as legal advisor in connection with the Offer. Statement from the Board of Directors regarding the Offer Isabel Hummel is the Chair of the Board of Directors of Tuna Holding, a member of the Consortium, and is a member of the Board of Directors of Jetpak since the annual general meeting held on 11 June 2024. Consequently, Isabel Hummel has a conflict of interest pursuant to section II.18 of the Takeover Rules. In accordance with the Takeover Rules, Isabel Hummel has therefore not participated, and will not participate, in Jetpak’s handling of or decisions regarding the Offer. In the evaluation of the Offer, the Board of Directors has taken a number of factors into account, including the Company’s strategy and business plan, the Company’s current financial position, prevailing market conditions and challenges in the markets in which the Company operates, the Company’s expected future development and thereto related opportunities and risks, valuation methods normally used in evaluating public offers for listed companies, including the Increased Offer Price’s valuation of the Company in relation to comparable listed companies and comparable transactions and the stock market’s expectations of the Company. In its evaluation of the Offer, the Board of Directors also has considered the new independent fairness opinion provided by Deloitte by reason of the Increased Offer Price. According to the independent fairness opinion provided by Deloitte, the Increased Offer Price is, subject to the assumptions stated in the opinion, considered fair to the shareholders of Jetpak from a financial point of view. Furthermore, the Board of Directors notes the statement from Notalp Logistik AB that, if they acquire shares corresponding to more than 90 percent of the total number of shares in Jetpak, they intend to initiate a compulsory redemption proceeding to acquire all remaining shares in the Company and to promote a delisting of Jetpak’s shares from Nasdaq First North Premier Growth Market. The Board of Directors also notes that BidCo, in accordance with the above mentioned, is able to control 89.67 percent of the total number of shares and votes in Jetpak. The Board of Directors therefore wants to highlight that the liquidity in the Company’s share may become limited, and it may become difficult for shareholders to sell their shares in Jetpak. If the shares become subject to a compulsory redemption proceeding, it may take a long time to receive consideration for their shares. Furthermore, BidCo will not increase the price in the Offer, which will limit the shareholder's chances to receive an increased price for their shares. In light of above-mentioned factors, the Board of Directors recommends the Company’s shareholders to accept the increased Offer. Effects on Jetpak and its employees The Board of Director’s view regarding the Offer’s impact on the employees and employment in the Company in accordance with what was stated on 5 July 2024 regarding the Offer on 5 July 2024 has not changed as a result of the Increased Offer Price. _____ This statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Disputes arising from this statement shall be settled exclusively by Swedish courts. For more information, please contact: Håkan Mattisson, CFO Phone: +46 8 5558 52 20 e-mail: ir@jetpak.se About Jetpak Jetpak is a logistic group represented in more than 170 locations around the Nordic region and in Europe. Jetpak has a unique and flexible customer offering based on having access to normally approximately 4,000 daily flight departures, in combination with a comprehensive distribution network with more than 950 delivery vehicles. This is something that makes it possible for Jetpak to deliver the fastest and most comprehensive 24/7/365 same-day logistic service to the market. This can be further supplemented by a unique customized next-day service for systemized transports. Segment wise, Jetpak has its business divided into one Express Air segment, where the customers' fast logistic needs have been solved by an air-based solution, and into one Express Road segment, where the customers' logistic needs have been solved by a land-based courier transport solution. The group's parent company, Jetpak Top Holding AB (publ), is listed on Nasdaq First North Premier Growth Market in Stockholm, Sweden. The Company’s certified adviser is FNCA Sweden AB. [1] Notalp Logistik is currently wholly owned by Paradeigma Partners AB (”Paradeigma”), and will, upon completion of the Offer, be owned by a consortium led by Paradeigma, which in turn is wholly owned by Paradigm Capital Value Fund (Sicav), and which further includes PakLogistikIntressenter AB (”Pak Logistik Intressenter”) and Aktiebolaget Tuna Holding (”TunaHolding”) (together the ”Consortium”).

Prisma Properties Expands with KFC – Signs Long-Term Lease in Häggvik, Stockholm

This is the sixth restaurant in the Nordics where Nordic Service Partners and KFC have chosen Prisma Properties as their development partner. "Häggvik is a fast-growing part of Sollentuna, and this project will further enhance the dining options for the local community. The fact that KFC has once again chosen Prisma as a partner is a clear sign of our ability to deliver quality," says Carsten Krebs, CDO of Prisma Properties. "This will be our seventh KFC location in Stockholm, and we’re looking to hire about 50 new employees. We’re excited to bring our tasty offerings to even more chicken lovers," says Johan Persson, CEO of Nordic Service Partners. The new restaurant is set to open in Q4 2024. For further information, please contact: Carsten Krebs, CDO Prisma Properties carsten.krebs@prismaproperties.se+46 73-311 89 62

Lagercrantz acquires Mastsystem

Mastsystem is known for its technical excellence and high-performance product portfolio including telescopic field masts, vehicular masts, lifting pole and accessories. The products serve both prime contractors and defence end users. The company is headquartered in Joensuu, Finland since its founding in 1996. For more information, please visit https://www.mastsystem.com/. Mastsystem is generating an annual revenue of around MEUR 15 with EBITA of around MEUR 6. The acquisition will be done at an EV/EBITA multiple of approximately 7x. ”We are very happy to welcome Mastsystem to Lagercrantz. We see great potential in Mastsystem's offering, and the organisation’s high level of competence provides a strong platform for continued growth in many years to come.”, says Peter Baaske, head of division Electrify. ”I see Lagercrantz as a strategic, long-term owner with whom we can further develop Mastsystem by building on our established position and extensive experience.”, says Heikki Miettinen, MD Mastsystem. The acquisition is subject to approval by the Finnish authorities, which is now taking place. Mastsystem will be part of the division Electrify. The acquisition is expected to generate a small positive addition to Lagercrantz’ earnings per share. Stockholm, 13 September 2024 Lagercrantz Group AB (publ)

Amendments to the terms and conditions of Solteq Plc notes approved in written procedure

Stock exchange bulletin Other information disclosed according to the Rules of the Exchange 13 September 2024 at 3.10 p.m. EEST Solteq Plc (“Solteq” or the “Company”) has successfully completed its consent solicitation by way of a written procedure (the “Written Procedure”) in order to amend the terms and conditions (the “Terms and Conditions”) of its EUR 23 million senior unsecured fixed rate notes (ISIN: FI4000442264) (the “Notes”) so as to: · extend the Final Maturity Date under the Terms and Conditions by 24 months, with the new Final Maturity Date being 1 October 2026; · increase the coupon rate on the Notes from 6.0 percent to 10.0 percent; · amend the redemption price applicable to Voluntary Total Redemptions under the Terms and Conditions by gradually increasing the redemption price of the Notes from 100.0 percent to 104.0 percent during the extended maturity period of the Notes; and · decrease the permitted size of the Working Capital Facility included in the Terms and Conditions of the Notes to either EUR 7 million or 90 percent of EBITDA, whichever is greater. In accordance with the request (the “Request”) dated 21 August 2024 and addressed to the Noteholders, Solteq sought for the approval of the Noteholders in a Written Procedure to execute the changes to the Terms and Conditions. The Written Procedure commenced on 21 August 2024 and expired on 13 September 2024 at 3:00 p.m. (Finnish time). Pursuant to the Terms and Conditions, quorum in respect of a Written Procedure in relation to the Request existed if Noteholders representing at least 50 per cent of the Adjusted Nominal Amount reply to the Request in the Written Procedure. The approval of the Request was further subject to that at least two thirds (2/3) of the votes cast in the Written Procedure consent to the Request. Quorum in respect of a Written Procedure in relation to the Request existed and the Request was approved by required majority of the Noteholders participating in the Written Procedure. Thus, the requested amendments to the Terms and Conditions will become effective as of 13 September 2024. The amendments to the Terms and Conditions as approved in the Written Procedure are attached to this stock exchange release. The Company will pay to those Noteholders who have voted in favour of the Request a fee of 1.75 per cent (the “Fee”) for the Nominal Amount of the Notes held by each Noteholder for which such Noteholder has voted in favour of the Request. The Fee will be paid to those Noteholders from whom a valid Voting Form in favour of the Request was received by Nordic Trustee Oy before the Final Response Time, and who remain to be Noteholders on 17 September 2024. The Fee will be paid no later than 1 October 2024 to the Noteholders eligible to receive it, as described in more detail in the Request. Further information CEO Aarne AktanTel: +358 40 342 4440E-mail: aarne.aktan@solteq.com CFO, General Counsel Mikko Sairanen Tel: +358 50 567 3421 E-mail: mikko.sairanen@solteq.com Attachment: The amendments to the Terms and Conditions as approved in the Written Procedure Distribution Nasdaq HelsinkiKey mediawww.solteq.com About Solteq Solteq is a Nordic software solution and expert service provider specializing in retail and energy sectors and needs related to e-commerce. The company employs over 400 professionals and has offices in Finland, Sweden, Norway, Denmark, Poland, and the UK.

Sinch issues bonds of 500 MSEK

Stockholm, Sweden – 13 September 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, has as of 12 September successfully issued senior unsecured bonds of SEK 500 million within the framework of the company’s MTN program. The bond has a tenor of 3 years and a floating interest rate of 3-month STIBOR plus 175 bps. The transaction generated significant interest among investors and was heavily oversubscribed with final orders amounting to double the issue size. The proceeds from the issuance will be used to refinance part of the company's outstanding bond debt and settlement is expected on September 24th, 2024. Danske Bank, Handelsbanken, and SEB acted as Joint Bookrunners for the issuance. For further information, please contact Ola ElmelandInvestor Relations DirectorMobile: +46 721 43 34 59E-mail: investors@sinch.com About Sinch Sinch is pioneering the way the world communicates. More than 150,000 businesses – including many of the world's largest tech companies – rely on Sinch’s Customer Communications Cloud to improve customer experience through mobile messaging, voice and email. Sinch has been profitable and fast-growing since it was founded in 2008. It is headquartered in Stockholm, Sweden, with shares traded at NASDAQ Stockholm: XSTO:SINCH. Learn more at sinch.com .

Sinch calls for early redemption of outstanding bonds 2019/2024

Stockholm, Sweden – 13 September 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, today announces the conditional early redemption of its outstanding bond (nominal outstanding amount of 750 MSEK) with ISIN SE0013382140 (the "Bonds" and the "Early Redemption"). The Bonds will be repurchased on 9 October 2024 (the "Redemption Date") at a price equivalent to 100.00 percent of the nominal amount plus accrued but unpaid interest up to and including the Redemption Date (the "Redemption Amount"), upon the Company having received the settlement of issued senior, unsecured bonds of 500 million SEK under the Company’s MTN-program prior to the record date for the Early Redemption. The fulfilment of the condition will be confirmed by the Company through a press release. If the condition is fulfilled or waived by the Company, the Redemption Amount will be paid to each person registered as a holder of Bonds in the debt register maintained by Euroclear Sweden at the close of business on 2 October 2024. In connection with the Early Redemption, the Bonds will be delisted from Nasdaq Stockholm. A notice of Early Redemption will be sent to the direct registered owners of Bonds in the debt register as of 12 September 2024. The notice of Early Redemption will also be available on the Company's website www.sinch.com. For further information, please contact Ola ElmelandInvestor Relations DirectorMobile: +46 721 43 34 59E-mail: investors@sinch.com About Sinch Sinch is pioneering the way the world communicates. More than 150,000 businesses – including many of the world's largest tech companies – rely on Sinch’s Customer Communications Cloud to improve customer experience through mobile messaging, voice and email. Sinch has been profitable and fast-growing since it was founded in 2008. It is headquartered in Stockholm, Sweden, with shares traded at NASDAQ Stockholm: XSTO:SINCH. Learn more at sinch.com .

Change in Tecnotree Corporation’s holding of treasury shares

The Board of Directors of Tecnotree Plc has on 13 June 2024 decided on a directed share issue for the purpose of recruitment, retention and incentive. In the share issue, a total of 7,760 Tecnotree shares have on 13 September 2024 been issued and conveyed without consideration to the employees of Tecnotree Plc and other key persons. The decision on the directed share issue is based on the authorization granted to the Board of Directors by the Annual General Meeting of Shareholders held on 15 April 2024. Following the transfers, Tecnotree Plc holds 1,092,467 treasury shares.

Gaming Innovation Group - Issue of new shares

Gaming Innovation Group Inc. (“GiG” or the “Company”) has today issued 119,400 new shares of its common stock in connection with exercise of options, whereof 61,600 shares at a share price of NOK 15.00 and 57,800 at a share price of NOK 22.00 per share.  The new shares are issued by the Board of Directors under the Company's 150,000,000 authorized shares, and the Company confirms that the new shares have been duly authorized by all necessary corporate actions and that the new shares have been fully paid and validly issued. The Company’s share capital has increased from USD 134,588,574 to USD 134,707,974, and the number of outstanding shares has increased from 134,588,574 to 134,707,974 (par value USD 1.00). In addition, a total of 1,139,600 options are outstanding as of today. For further information, please contact:Tore Formo, Group CFO, tore@gig.com, +47 91668678 About Gaming Innovation Group (GiG)Gaming Innovation Group is a leading iGaming technology company, providing solutions, products and services to iGaming Operators. Founded in 2012, Gaming Innovation Group’s vision is ‘To be the industry leading platform, sportsbook and media provider delivering world class solutions to our iGaming partners and their customers.  GiG’s mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under the ticker symbol GIGSEK. www.gig.com

HUMBLE’S SHARES HAVE BEEN APPROVED FOR ADMISSION TO TRADING ON NASDAQ STOCKHOLM

“Being listed on a regulated market means a quality stamp and marks an important step in Humble's continued journey. It is a testament to how we work with developing our growth and ownership strategy and with our corporate governance. The list change also creates better conditions for long-term value creation for our shareholders and enables more institutional investors to invest in the Company's shares.” – Simon Petrén, CEO Humble Group AB. Humble was listed on Nasdaq First North Growth Market in November 2014 under the company name at the time, Bayn Europe AB. The Listing is an important step in the Company’s continued development and has been an expressed ambition within the Company’s board of directors and management. The Listing entails a quality label by the Company’s improved maturity level. In addition, the Listing entails that the Company’s shares will become more attractive as means of payment and may facilitate in future acquisition discussions. Further, the Listing is assessed to better reflect the Company’s size from a capital market perspective and enable for more institutional investors to invest in the Company’s share. In light of the above, the board of directors of Humble has applied for admission to trading of the Company’s shares on Nasdaq Stockholm. Nasdaq Stockholm’s listing committee has resolved that Humble fulfils the requirements to be admitted to trading on Nasdaq Stockholm, provided that customary conditions are fulfilled, including that a prospectus is approved and registered by the Swedish Financial Supervisory Authority.   There is no offer or issuance of new shares in connection with the Listing and shareholders of Humble do not have to take any measures. The ticker for the shares (HUMBLE) and the ISIN-code (SE0006261046) will remain unchanged. For complete information regarding the Listing, please refer to the prospectus that is expected to be approved by the Swedish Financial Supervisory Authority and published (only in Swedish) on Humble’s webpage (www.humblegroup.se) on 23[rd] of September 2024. AdvisorRämsell Advokatbyrå AB is Humble’s legal advisor in connection with the Listing. For additional information, please contact:Simon Petrén, CEO, Humble Group ABEmail: simon.petren@humblegroup.sePhone: +46 (0)8 61 32 888 The information in this press release has been published by the above contact person, at the time specified by Humble Group's news distributor Cision at the time of publication of this press release. About HumbleHumble Group is a Swedish FMCG group, which delivers next-generation consumer products that are better for people and the planet. Humble’s business consists of the business segments Future Snacking, Quality Nutrition, Sustainable Care and Nordic Distribution, which have a profile within health and sustainability. The company strives to drive organic and structural growth through acquisitions and by utilizing synergies between the business entities. For more information visit www.humblegroup.se. Humble is listed on Nasdaq First North Growth Market, under the ticker HUMBLE. FNCA Sweden AB is Humble’s certified adviser.

Announcement regarding managers’ transactions in Wirtek A/S

Company Announcement no. 12/2024 13 September 2024 Wirtek A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in Wirtek A/S made by persons discharging managerial responsibilities and/or persons closely related with them. Name Shares owned Transaction Shares owned after transaction before transactionMichael 2.200.117 43.851 shares 2.156.266 sharesAaen shares(sale) Further information · Michael Aaen, CEO, Wirtek A/S, Phone: +45 2529 7575, E-mail: ir@wirtek.comNiels Jernes Vej 10, 9220 Aalborg, Denmark, www.wirtek.com · Kent Mousten Sørensen, Chairman, Wirtek A/S, Phone: +45 2125 9001 · Grant Thornton, Certified Advisor, Phone: +45 3311 0020 About Wirtek Wirtek A/S is a Danish IT consultancy company that provides software development, testing, and consultancy services to help clients worldwide. Wirtek specializes in Digitalization, Energy, Workforce & Facility Management, Wireless Communication & Automation, and Trade & E-commerce. At Wirtek, we prioritize building long-term client relationships, with some lasting over a decade. We believe that quality partnerships are just as important as software quality in achieving our client's goals. Established in 2001, we have offices in Denmark and Romania and have been listed on Nasdaq First North Copenhagen since 2006.  Ticker Code: WIRTEK (DK0060040913) 

Historic Recovery Followed by Ongoing Exceptional Recoveries at Lucara

VANCOUVER, B.C., September 15, 2024 /CNW/ - (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is very pleased to announce the recovery of an extraordinary 1,094 carat rough diamond from its 100% owned Karowe Mine in Botswana. This remarkable stone bears striking similarities to the 692 carat diamond announced in August 2023, which was polished by HB Antwerp and yielded polished diamonds that sold for in excess of USD13 million. Lucara confirms that this newly recovered 1,094 carat stone will also be polished by HB Antwerp, as part of the ongoing partnership between the two companies. The newly recovered 1,094 carat diamond, the sixth stone in excess of 1,000 carats recovered by Lucara, continues the Company’s track record of unearthing large, high-value stones from the EMPKS ore type in the South Lobe of the Karowe Mine. Its exceptional size and quality underscore the unique characteristics of the Karowe ore body and reinforce the Company's position as the leading producer of large, high-quality diamonds. William Lamb, President and CEO of Lucara, commented on the significance of this latest recovery: "The recovery of this exceptional 1,094 carat diamond is a testament to Karowe's remarkable potential and further validates our investment in the underground expansion project. These continued discoveries of large, high-value diamonds demonstrate the consistent quality of our resource and its ability to deliver substantial returns. As we progress with our underground development, we're increasingly confident in Karowe's capacity to produce these legendary diamonds well into the future, cementing our position in the high-end diamond market." The recovery of a second historic +1,000 carat diamond this year aligns with Lucara's underground expansion project which aims to extend the life of the Karowe Mine to beyond 2040 and has been designed to access the parts of the South Lobe at depth where the EMPKS ore type is prevalent. This news release has been reviewed and approved by Dr. Lauren Freeman, PhD. Pr. Sci. Nat., Vice-President, Mineral Resources of the Company and a "Qualified Person" for the purposes of National Instrument 43-101. On behalf of the Board, William Lamb President and Chief Executive Officer Follow Lucara Diamond on Facebook , Instagram  and LinkedIn  The information is information that Lucara is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, on September 15, 2024, at 8:00 p.m. Pacific Time. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS Certain of the statements made in this news release contain certain “forward-looking information” and “forward-looking statements” as defined in applicable securities laws. Generally, any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance and often (but not always) using forward-looking terminology such as “expects”, “is expected”, “anticipates”, “estimates”, “intends”, “potential”, or variations thereof or stating that certain actions, events, conditions or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, (or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information and statements are based on the opinions and estimates of management as of the date such statements are made, and by their nature involve assumptions, and are subject to several known and unknown or inherent risks and uncertainties, many of which are difficult to predict and are usually beyond the control of management. These risks and uncertainties and other factors may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward-looking statements and information. In particular, forward-looking information in this release and risks related thereto may pertain to general business and economic conditions, the project schedule and capital costs for the Karowe UGP, inaccurate geological assumptions of a mineralized area and its economic potential (including with respect to the size, grade and recoverability of mineral reserves and resources), the impact of the supply and demand for, and the price volatility of, rough and polished diamonds, the impact of the renewed HB Antwerp diamond sales agreement on the Company’s projected revenue and sales channels, cost and timing of the development of deposits and estimated future production, the Company’s ability to meet its obligations under the Rebase Amendments with its Lenders, changes in interest and foreign currency rates, expectations that the Karowe UGP will extend mine life, forecasts of additional revenues, future production activity and forecasts of revenue, costs of power and diesel, unanticipated operational difficulties (including failure of plant, equipment or processes to operate in accordance with specifications or expectations), cost escalations, unavailability of materials and equipment, acts of foreign governments or delays in the receipt of government approvals, industrial disturbances or other job actions, adverse weather conditions, and unanticipated events relating to health safety and environmental matters, the potential impacts of economic and geopolitical risks, and other risks and uncertainties describe under the heading “Risks and Uncertainties” in the Company’s most recent MD&A and Annual Information Form available at SEDAR+ at www.sedarplus.ca. The Company believes that the expectations reflected in this forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct. Readers and investors are thus cautioned not to place undue reliance on such statements. Forward-looking information and statements contained in this news release are made as of the date of this news release and accordingly are subject to change after such date. Except as required by law, the Company disclaims any obligation to revise any forward-looking information and statements to reflect events or circumstances after the date of such information and statements. All forward-looking information and statements contained or incorporated by reference in this news release are qualified by the foregoing cautionary statements. View PDF version 

CVC and Waldakt, acting through Ronneby UK Limited, increase their ownership of Resurs Holding AB (publ) to 86% and extend the acceptance period for the final time

This announcement is not an offer, whether directly or indirectly, in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document, which has been published on the Offer website (www.leading-specialty-finance.com). Shareholders in the United States should also refer to the section titled "Special notice to shareholders in the United States" at the end of this announcement. Press release 16 September 2024 On 17 June 2024, CVC[1] and Waldakt[2] (together the "Consortium"), acting through Ronneby UK Limited[3] (the "Bidder"), announced a recommended public offer to the shareholders of Resurs Holding AB (publ) ("Resurs") to tender all shares in Resurs to the Bidder at a price of SEK 23.50 in cash per share (the "Offer"). On 3 September 2024, the Bidder declared the Offer unconditional and announced that it would complete the Offer and that the Offer had been accepted to such extent that the Bidder would become the owner of 80 percent of the shares in Resurs. The Bidder also extended the acceptance period until 13 September 2024 to allow shareholders that had not yet accepted the Offer time to do so. During this extension of the acceptance period, the Offer was accepted by such extent that the Bidder will become the owner of approximately 86 percent of the shares in Resurs. The acceptance period for the Offer is now extended for the final time, up to and including 4 October 2024 to give remaining shareholders time to accept the Offer. For the avoidance of doubt, this means that there will be no further extension of the Offer beyond 4 October 2024, and that shareholders who have not tendered their shares by this date will not be able to tender their shares in the Offer. The last date to accept the Offer is accordingly on 4 October 2024. Please note that a nominee or bank through which shareholders in Resurs hold their shares can set an earlier date as the final date to accept the Offer. The Bidder cannot, pursuant to Nasdaq Stockholm’s rules regarding takeover bids on the stock market, increase the price in the Offer. SEK 23.50 per share is thus the highest price that will be offered by the Bidder in the Offer. There is no guarantee that shareholders after 4 October 2024 will be able to sell their shares in the market at SEK 23.50, nor that any buyer will be prepared to buy any shares at this price. Gustaf Martin-Löf, Partner, and Martin Iacoponi, Managing Director, CVC, comment: "We are pleased that the majority of the shareholders of Resurs, including essentially all larger shareholders as well as Resurs’ management team and the board, have either tendered or sold their shares. We are also grateful for the additional support received from the shareholders during the extension period in the last few weeks which means we now hold 86% of the shares. However, we recognise that it takes time for all shareholders to become fully informed about the Offer and complete their decision making process. We are therefore providing a final opportunity for shareholders to tender before we close the Offer. In parallel we look forward to commencing the multi-year transformation journey with the Company, which will require significant investments and impact Resurs’ financial results and potentially capability to return dividends. We are committed to pursuing the necessary initiatives, whether in a public or private environment, and are looking forward to supporting management in this critical phase to take Resurs to its long-term potential." Final opportunity to accept the Offer To provide the remaining shareholders in Resurs who have not yet tendered their shares time to accept the Offer, the acceptance period for the Offer will be extended for the last time, up to and including 4 October 2024 at 15.00 (CEST). For the avoidance of doubt, this means that there will be no further extension of the Offer beyond 4 October 2024, and that shareholders who have not yet tendered their shares by this date will not be able to tender their shares in the Offer. The last date to accept the Offer is accordingly on 4 October 2024. Shareholders in Resurs whose holdings are registered in the name of a nominee, i.e. a bank or other intermediary, wishing to accept the Offer, must do so in accordance with instructions received by such shareholder's nominee. Please note that the nominee can set an earlier date as the final date to accept the Offer. Settlement for shares tendered in the Offer during this final extension of the acceptance period is expected to be initiated on or 15 October 2024. Since the Offer is unconditional, shareholders who have accepted the Offer, or will accept the Offer, have no right to withdraw their acceptances. Shares tendered in the Offer The shares tendered in the Offer at the end of the initial acceptance period (which ended on 30 August 2024) amounted to in aggregate 101,361,152 shares in Resurs, corresponding to approximately 51 percent of the share capital and votes in Resurs. Together with the 57,885,556 shares in Resurs already held and controlled by Waldakt, corresponding to approximately 29 percent of the share capital and votes in Resurs, that has been contributed to the Bidder, the Bidder's shareholding in Resurs amounted to in aggregate 159,246,708 shares in Resurs, corresponding to approximately 80 percent of the share capital and votes in Resurs. The shares tendered in the Offer during the extended acceptance period (which ended on 13 September 2024) amount to in aggregate 5,569,196 shares in Resurs, corresponding to approximately 3 percent of the share capital and the voting rights in Resurs. In addition, the Bidder has acquired an additional 6,192,276 shares in Resurs outside the Offer, corresponding to approximately 3 percent of the share capital and the voting rights in Resurs, since the announcement of the outcome announcement press release on 3 September 2024. No acquisitions have been made at a price exceeding the price in the Offer. Accordingly, upon settlement for the shares that were tendered in the Offer during the extended acceptance period that ended on 13 September 2024, the total number of shares in Resurs held by the Bidder will amount to 171,008,180 shares, corresponding to approximately 86 percent of the share capital and the voting rights in Resurs. Settlement for shares tendered in the Offer during the extended acceptance period that ended on 13 September 2024 is expected to be initiated on or around 24 September 2024. Compulsory redemption and delisting If the Bidder, whether in connection with the Offer or otherwise, acquires shares representing more than 90 percent of the total number of shares in Resurs, the Bidder intends to commence compulsory redemption proceedings under the Swedish Companies Act (2005:551) (Sw. aktiebolagslagen (2005:551)) to acquire all remaining shares in Resurs and promote a delisting of Resurs' shares from Nasdaq Stockholm. Information about the Offer Information about the Offer is made available at www.leading-specialty-finance.com. For additional information, please contact: Adam Makkonen, Ronneby UK Limited+46 (0)703 166 375ronneby@fogelpartners.se Carsten Huwendiek, Managing Director -Global Head, Marketing & Communications,CVCchuwendiek@cvc.com Nick Board, Director of Communications,CVC+44(0) 7827 804061nboard@cvc.com  For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares. The information in this press release was submitted for publication by the Bidder in accordance with the Takeover Rules for Nasdaq Stockholm on 16 September 2024 at 07.30 (CEST).  Important information This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. The Offer is not being made, directly or indirectly, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction, and the Offer cannot be accepted by any such use or by such means, instrumentality or facility of, in or from, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. Accordingly, this press release or any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. The Offer, the information and documents contained in this press release are not being made and have not been approved by an "authorised person" for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the "FSMA"). The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA under article 62 (sale of a body corporate) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire shares in a body corporate and the object of the transaction may reasonably be regarded as being the acquisition of day to day control of the affairs of that body corporate. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of the Bidder and Resurs. Any such forward-looking statements speak only as of the date on which they are made and the Bidder has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Carnegie is acting for the Bidder and no one else in connection with the Offer and will not be responsible to anyone other than the Bidder for providing the protections afforded to clients of Carnegie, or for giving advice in connection with the Offer or any matter referred to herein. Special notice to shareholders in the United States The Offer described in this press release is made for the issued and outstanding shares of Resurs, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which are different from those of the United States. The shares of Resurs are not listed on a U.S. securities exchange. Resurs is not subject to periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the "U.S. Exchange Act") and is not required to file any reports with the U.S. Securities and Exchange Commission (the “SEC”). The Offer is made in the United States pursuant to Section 14(3) of the U.S. Exchange Act and Regulation 14E thereunder, subject to exemptions provided by Rule 14d-1(c) under the U.S. Exchange Act for a Tier 1 tender offer (“Tier I Exemption”), and otherwise in compliance with the disclosure and procedural requirements of Swedish law, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered) and waivers of conditions, which are different from legal requirements or customary practices in relation to U.S. domestic tender offers. The offeror’s ability to waive the conditions to the Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, are not the same under a tender offer governed by Swedish law as under a tender offer governed by U.S. law. Holders of the shares in Resurs domiciled in the United States (the "U.S. Holders") are encouraged to consult with their own advisors regarding the Offer. Resurs' financial statements and all financial information included herein, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to the financial statements or financial information of companies in the United States or other companies whose financial statements are prepared in accordance with U.S. generally accepted accounting principles. The Offer is made to the U.S. Holders on the same terms and conditions as those made to all other shareholders of Resurs to whom an offer is made. Any information documents, including the offer document, are being disseminated to U.S. Holders on a basis comparable to the method pursuant to which such documents are provided to Resurs' other shareholders. The Offer, which is subject to Swedish law, is being made to the U.S. Holders in accordance with the applicable U.S. securities laws, and applicable exemptions thereunder, in particular the Tier I Exemption. To the extent the Offer is subject to U.S. securities laws, those laws only apply to U.S. Holders and thus will not give rise to claims on the part of any other person. The U.S. Holders should consider that the price for the Offer is being paid in SEK and that no adjustment will be made based on any changes in the exchange rate. It may be difficult for Resurs' shareholders to enforce their rights and any claims they may have arising under the U.S. federal or U.S state securities laws in connection with the Offer, since Resurs and the Bidder are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. Resurs' shareholders may not be able to sue Resurs or the Bidder or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel Resurs or the Bidder and/or their respective affiliates to subject themselves to the jurisdiction or judgment of a U.S. court. To the extent permissible under applicable law and regulations, the Bidder and its affiliates or its brokers and its brokers' affiliates (acting as agents for the Bidder or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly purchase or arrange to purchase shares of Resurs outside the United States, or any securities that are convertible into, exchangeable for or exercisable for such shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices, and information about such purchases will be disclosed by means of a press release or other means reasonably calculated to inform U.S. Holders of such information. In addition, the financial advisors to the Bidder may also engage in ordinary course trading activities in securities of Resurs, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with the applicable law. Any information about such purchases will be announced in Swedish and in a non-binding English translation available to the U.S. Holders through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish or U.S. law, rules or regulations. The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult an independent professional adviser regarding the tax consequences of accepting the Offer. Neither the Bidder nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be responsible for any tax effects or liabilities resulting from acceptance of this Offer. NEITHER THE SEC NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, PASSED ANY COMMENTS UPON THE MERITS OR FAIRNESS OF THE OFFER, PASSED ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS PRESS RELEASE OR PASSED ANY COMMENT ON WHETHER THE CONTENT IN THIS PRESS RELEASE IS CORRECT OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. [1] "CVC" refers to CVC Advisers International S.à r.l. (acting through CVC Advisers International Svenska filial) and its affiliates from time to time, together with Clear Vision Capital Fund SICAV FIS S.A. and each of its subsidiaries from time to time. "CVC Funds" refers to funds or vehicles advised and/or managed by CVC. [2] "Waldakt" refers to Waldakt Aktiebolag, a Swedish private limited liability company with corporate registration number 556315-7253, domiciled in Gothenburg, Sweden. [3] "Ronneby UK Limited" refers to a newly formed English private limited company with company number 15750820, domiciled in London, United Kingdom. As per the date of this announcement, the Bidder is indirectly wholly-owned by CVC Funds, and will, upon completion of the Offer, become indirectly co-owned by the members of the Consortium.

Wihlborgs building new facility for NOTE Lund

NOTE Lund AB is a subsidiary to the listed company NOTE AB, a leading Northern European manufacturing partner with an international platform for manufacturing electronic-based products that require high technological expertise and flexibility. The Group has some 1,500 employees, 140 of whom work at NOTE Lund. The new facility will comprise offices, production and warehouses with the aim of being certified in accordance with Miljöbyggnad Guld. The building encompasses a total of 11,900 square metres, which will allow for additional tenants, and will become Wihlborgs’ second building in the area following Tomaten 1, which was constructed for the contract manufacturer Inpac. Hasslanda is a business district in Lund that has developed in conjunction with the creation of the new exit to the E22 motorway. The area is south of Gastelyckan and north of bordering Staffanstorp Municipality. The Stora Råby 32:22 property is located at the very south of the area and right by the exit to the E22 motorway. As a result of the project, Wihlborgs will acquire 17,200 square metres of land from the City of Lund. The investment, including the land acquisition, amounts to SEK 263 million. “Our factory in Lund has grown substantially over the past few years, and we’re looking forward to moving to a new fit-for-purpose factory that will support our operations’ continued expansion going forward,” says Henrik Andersson, CEO of NOTE Lund. “We are looking forward to developing a modern facility with high sustainability standards for NOTE, which is a well-established and important company here in Lund. The project also helps us to strengthen our presence in Hasslanda, which is an attractive neighbourhood, and there is a substantial shortage in the warehouse and production segment,” says Ulrika Hallengren, CEO of Wihlborgs. Wihlborgs Fastigheter AB (publ)

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On September 12, 2024, BlackRock's holding in Metso’s shares amounted to 33,873,803 shares or 4.08 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 7,777,438 shares, which corresponds to 0.93 percent of the total amount of Metso’s shares. As a result, BlackRock's total position amounted to 41,651,241 or 5.02 percent of Metso’s shares and votes. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting 4.08% 0.93% 5.02%situation on thedate onwhich thresholdwas crossed orreachedPosition of Below Below 5% shares Below 5% sharesprevious 5%notification shares A: Shares andvoting rightsClass/type of Number of % ofshares shares and shares and voting rights voting rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 33,873,803 4.08%SUBTOTAL A 33,873,803 4.08%B: FinancialInstrumentsaccording toSMA 9:6aType of Expiration Exercise/ Physical or Number of % of sharesfinancial date Conversion cash shares and votinginstrument Period settlement and rights voting rightsAmerican N/A N/A Physical 8,370 0.00%DepositaryReceipt(US5926721094)Securities N/A N/A Physical 7,128,381 0.85%LentCFD N/A N/A Cash 640,687 0.07% SUBTOTAL B 7,777,438 0.93% Metso Corporation     Distribution:  Nasdaq Helsinki Ltd Main media www.mogroup.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Autoliv Appoints Adriana Karaboutis to its Board of Directors

On September 13, 2024, the Autoliv Board of Directors appointed Ms. Adriana Karaboutis as an independent director to the Autoliv Board of Directors effective immediately. With the addition of Ms. Karaboutis, Autoliv has expanded its Board size from eleven to twelve directors. Ms. Karaboutis most recently served as Group Chief Information and Digital Officer of National Grid PLC, one of the world’s largest public utility companies, a position she held from 2017 to 2023. She previously served as Executive Vice President, Technology, Business Solutions and Corporate Affairs at Biogen Inc., a global biotechnology company, overseeing Business Solutions from 2014 to 2017 with incremental responsibility for Corporate Affairs from 2015 to 2017. Prior to that, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., a global technology company from March 2010 to September 2014. Ms. Karaboutis previously spent more than 20 years at General Motors Company and Ford Motor Company in various international leadership positions, including computer-integrated manufacturing, supply chain operations, and information technology. Ms. Karaboutis has served on the board of directors of Perrigo Company plc, since May 2017, Aon plc, since September 2022, and Savills plc, since March 2024, and previously served on the boards of directors of Aspen Technology, Inc., Advance Auto Parts, Inc., and Blue Cross Blue Shield of Massachusetts. She served as president of the Michigan Council of Women in Technology from 2008 to 2010 and was a board member of the Manufacturing Executive Leadership Forum from 2009 to 2014. Ms. Karaboutis also served on the Babson College advisory board for the Center for Women’s Entrepreneurial Leadership. “I am very pleased to welcome Adriana to the Autoliv Board of Directors,” said Jan Carlson, Chairman of the Board of Directors of Autoliv, Inc. “Adriana’s solid industry experience and public company leadership is a welcome addition to the Autoliv Board at a dynamic time for Autoliv and the automotive industry.” Ms. Karaboutis is appointed for a term expiring at the 2025 Annual General Meeting of Stockholders at which time the Board is expected to contract to eleven members with the retirement of Mr. Hasse Johansson. Inquiries:  Media: Gabriella Etemad,  Tel +46 (70) 612 64 24Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14 About Autoliv Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2023, our products saved  35,000 lives and reduced more than 450,000 injuries. Our 70,000 associates in 25 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2023 amounted to $10.5 billion. For more information go to www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

The exercise price for the warrants of series 2023/2024 TO2 in Cell Impact has been determined to SEK 0.17 and the subscription period starts today.

If all the warrants of series 2023/2024 TO2 are exercised, the Company will receive approximately SEK 22 million before issuing costs. In order for the warrants to not expire without value, the holder is required to actively subscribe for new shares no later than 30 September 2024 or sell the warrants no later than 25 September 2024. Please observe that certain nominees might close their application earlier than 30 September 2024. Complete terms and conditions for the warrants and the prospectus, approved by the Swedish Financial Supervisory Authority and published by the Company on 15 November 2023, is available at the Company's webpage, www.cellimpact.com. The prospectus is also available on the Swedish Financial Supervisory Authority’s webpage, www.fi.se. Summarized terms for the warrants of series 2023/2024 TO2: Subscription period: 16 – 30 September 2024 Last day of trading warrants of series 2023/2024 TO2: 25 September 2024 Issue volume: 128,905,776 warrants of series 2023/2024 TO2, which entitles to subscription of 128,905,776 shares. If all warrants are exercised, the Company will receive approximately SEK 22 million before issuing costs. Exercise price: SEK 0.17 per share. Dilution: Upon full exercise of the warrants of series 2023/2024 TO2, the number of shares may increase by up to 128,905,776 shares, from 591,450,032 to 720,355,808 and the share capital to increase by up to approximately SEK 14,921,636.69, from approximately SEK 68,463,980.24 to approximately SEK 83,385,616.93. Please note that warrants that are not exercised no later than 30 September 2024 or not sold no later than 25 September 2024, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. How warrants are exercisedNominee-registered warrants (Custody account):Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. Direct-registered warrants (Securities account):No issue account statement nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The application form including instructions for payment will be available at the Company’s webpage, www.cellimpact.com. OutcomeThe outcome of the exercise of warrants will be published via a press release on or around 1 October 2024. Shares that have been subscribed and paid for will be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Cell Impact. AdvisersCarnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner and Pareto Securities AB as Joint Bookrunner. Advokatfirman Vinge is a legal adviser to the Company and Baker McKenzie represents Sole Clobal Coordinator and Joint Bookrunners in connection with the rights issue. 

Compressor distributor in the Netherlands to become part of Atlas Copco Group

Perslucht Wilda, founded in 1979, provides portable air compressors, generators, light towers and small electric compressors and associated services. The company has 9 employees. “The acquisition of Perslucht Wilda provides an excellent opportunity to extend our direct network and presence with aftersales service in the Netherlands”, said Andrew Walker, Business Area President Power Technique. The purchase price is not disclosed. The acquisition is expected to close during the fourth quarter 2024. The company will become part of the service division within the Power Technique Business Area.

Chairman of the board of Redsense Medical AB resigns - Acting chairman of the board appointed

Redsense Medical AB (publ), a leader in innovations for safety and monitoring of the vein needle in dialysis treatment, announces that board chairman Eva Walde has chosen to leave her post due to personal reasons. The board has unanimously decided to appoint board member Susanne Olauson as acting board chairman until the next ordinary general meeting, when a permanent successor will be elected. The company thanks Eva Walde for her efforts during her time as chairman and wishes her every success in her future undertakings.

Commencement of subscription period in Curasight’s preferential rights issue

Ulrich Krasilnikoff, CEO, comments “We aim to keep the momentum so far this year in progressing our business and look forward to further developments in our pipeline as well as continuing our business development efforts. Radionuclide Ligand Therapy continues to be in focus as an important option within radiotherapy in cancer and the injection of capital via the warrants issued through this fund raise will enable us to fund operations into the second half of 2025, enabling us to continue to progress our pipeline and remain an active player in industry discussions, We look forward to an active second half of the year in the lead up to the exercise periods of series TO2 and TO3. We anticipate news flow from our pipeline from projects such as the phase II trial in prostate cancer, being run under the partnership agreement with Curium and acceptance of the Clinical Trial Application by EMA for uTREAT®, in a phase I/IIa trial in the first indication for treatment. We also expect to dose the first patient with uTREAT®, in this indication, providing proof-of-concept in relation to uTREAT®.” Motive and use of proceeds Curasight works within the field of radiopharmaceuticals, with the ambition of improving diagnosis and treatment for a more gentle and efficient cancer care. The Company has pioneered the novel uPAR Theranostics platform which uses a highly specific PET imaging ligand to target the uPAR receptor for improved diagnosis uTRACE® and treatment uTREAT®. uPAR is expressed in many types of human cancers and the expression levels of uPAR have been shown to be strongly associated with metastatic disease, i.e. cancer aggressiveness, and subsequent poor prognosis. Curasight’s clinical PET ligand uTRACE® has been successfully validated in more than 400 patients in several clinical PET imaging trials with uTRACE® in nine clinical phase II trials with promising results in indications such as brain, prostate, lung, head & neck, neuroendocrine, oral, and breast cancer. Using the team’s scientific understanding and clinical research results, Curasight is committed to developing its uTRACE® and uTREAT® platforms in parallel in a range of different cancers. The warrants issued through the Rights Issue are, together with the warrants issued through the recently executed directed issue of units, set to fund the Company’s R&D activities including maintaining the momentum of clinical trials being carried out under the partnership with Curium Inc. for uTRACE® in prostate cancer and activities to accelerate the pipeline. Anticipated timeline for Objectives Below is a selection of the Company's objectives for the years 2024-2027. 2024 · Q4 Last patient included part I – uTRACE® (Phase II, Prostate Cancer, Partnered project) · Q4 Preliminary efficacy data – uTRACE® (Phase II, Prostate Cancer, Partnered project) 2025 · H1 Acceptance of CTA by EMA – uTREAT® (Phase I/IIa, Therapeutic program, First indication) · H1 Last patient included Part II – uTRACE® (Phase II, Prostate Cancer, Partnered project) · H1 First patient dosed, part I – uTREAT® (Phase I/IIa, Therapeutic program, First indication) · H2 Topline results, Phase II – uTRACE® (Phase II, Prostate Cancer, Partnered project) · H2 Preliminary efficacy data – uTREAT® (Phase I/IIa, Therapeutic program, First indication) · H2 First patient included part II – uTREAT® (Phase I/IIa, Therapeutic program, First indication) Long term strategic Objectives 2026 · Acceptance of CTA by EMA and first patient included part I – uTREAT® (Phase I/IIa, Therapeutic program, Basket trial) · Last patient included part II - uTREAT® (Phase I/IIa, Therapeutic program, First indication) 2027 · Topline results, Phase I/IIa – uTREAT® (Phase I/IIa, Therapeutic program, First indication) · Last patient included part I and preliminary efficacy data – uTREAT® (Phase I/IIa, Therapeutic program, Basket trial) Rights Issue of units On 4 September 2024, the Board of Directors resolved on execution of a preferential rights issue of a total 1,216,907 units, consisting of a total of 2,433,814 warrants of series TO2 and 1,216,907 warrants of series TO3. The Board’s decision was made with support from the authorization from the Extraordinary General Meeting on 2 July 2024,   Those who were shareholders on the record date of 13 September 2024 has received one (1) unit right for each (1) share in Curasight. Seventeen (17) unit rights give the shareholder the right to subscribe for one (1) unit at a price of DKK 0.01 per unit. One (1) unit consists of two (2) warrants of series TO2 and one (1) warrant of series TO3. Those who are not shareholders in Curasight have not receive unit rights and will thus not be able to participate in the Rights Issue, unless they purchase unit rights in the market. Subscription of units must take place during the subscription period that starts today, 16 September 2024, and runs to and including 30 September 2024. Unit rights that are not used during the subscription period will lose their value. Trading in unit rights (TICKER: CURAS UR) takes place on Spotlight Stock Market until and including 26 September 2024. Trading in BTU (Paid Subscription Unit) takes place until after the Rights Issue has been registered at Erhvervsstyrelsen. Please be aware that some banks have a shorter deadline than 30 September 2024 in relation to handling your instructions. It is to be noted that the Rights Issue itself will not increase the number of shares or the share capital. Existing shareholders who choose not to participate in the Rights Issue will thus not experience a dilution effect after a fully subscribed Rights Issue. Warrants of series TO2 and series TO3 Warrants of series TO2 will have an exercise period that runs from and including 21 November 2024 until and including 5 December 2024. The exercise price for warrants of series TO2 will be set on the day before exercise period and will be based on the Volume Weighted Average Price in the Company’s share 20 days back, with a discount of 30 percent and be within the range DKK 11.50-15.55. Through the exercise of warrants of series TO2, Curasight can receive a maximum of approximately DKK 57.3 million. The warrants of series TO2 will be subject to trading at Spotlight Stock Market. If the Rights Issue is fully subscribed and all warrants of series TO2 issued in the Rights Issue and the directed issue are exercised the share capital will increase by DKK 184,190.70 to DKK 1,218,312.05 and the number of shares will increase by 3,683,814 to 24,366,241, resulting in a dilution of approximately 15.1 percent. Warrants of series TO3 will have an exercise period that runs from and including 4 June 2025 until and including 18 June 2025. The exercise price for warrants of series TO3 will be set on the day before exercise period and will be based on the Volume Weighted Average Price in the Company’s share 20 days back, with a discount of 30 percent and be within the range DKK 15.55-19.40. Through the exercise of warrants of series TO3, Curasight can receive a maximum of approximately DKK 35.7 million. The warrants of series TO3 will be subject to trading at Spotlight Stock Market. If all warrants of series TO3 issued in the Rights Issue and the directed issue are exercised, the share capital will increase by an additional DKK 92,095.35 to DKK 1,310,407.40 and the number of shares will increase by an additional 1,841,907 to 26,208,148, resulting in a dilution of approximately 7.0 percent. Timeline The timeline is illustrated below: · 16 September 2024 – Subscription period and trading in BTU commences · 26 September 2024 – Last day of trading in unit rights (CURAS UR) · 30 September 2024 – Subscription period ends · 3 October 2024 – Outcome of preferential rights issue is announced · Mid-October 2024 – Preferential rights issue is registered at Erhvervsstyrelsen and end of trading in BTU · Mid/late-October 2024 – Trading in warrants of series TO2 and series TO3 starts · 21 November 2024 – Start of the exercise period for warrants of series TO2 · 3 December 2024 – Last day of trading in warrants of series TO2 · 5 December 2024 – End of the exercise period for warrants of series TO2 · 4 June 2025 – Start of the exercise period for warrants of series TO3 · 16 June 2025 – Last day of trading in warrants of series TO3 · 18 June 2025 – End of the exercise period for warrants of series TO3 Prospectus, teaser and the possibility to subscribe for units Prospectus and teaser about the Rights Issue are available via the Company's (www.curasight.com), Sedermera Corporate Finance AB's (www.sedermera.se) and Nordic Issuing AB's (www.nordic-issuing.se). At the Company’s website, a detailed Q&A document describing the details of the Rights Issue is also available. Subscription of units in the Rights Issue is made through each shareholder’s bank and all shareholders interested in participating in the Rights Issue is advised to contact their bank to receive specific instructions on how to proceed. Advisors Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor. Nordic Issuing AB is the settlement agent.

Norse Atlantic Airways Celebrates Sold-Out Inaugural Flight from London Gatwick to Las Vegas

The new route operates three times a week, allowing travellers a convenient schedule to explore Las Vegas’s world-class entertainment, fine dining, and attractions. The flight is served by the airline’s state-of-the-art Boeing 787 Dreamliners, ensuring passengers enjoy a comfortable and relaxing journey. With fares starting from £299* return, including taxes, Norse Atlantic Airways remains committed to offering affordable long-haul travel experiences without compromising on comfort or service. “We are delighted to see such an incredible response to our new London to Las Vegas route. The fact that the inaugural flight was completely sold out underscores the strong demand for affordable, direct transatlantic travel. Las Vegas is a destination like no other, and we are excited to offer our passengers the opportunity to experience the magic of this iconic city combined with exceptional value,” said Bjorn Tore Larsen, Norse Atlantic Airways CEO and Founder. “Norse Atlantic Airways is an exciting addition to our airline carriers at Harry Reid International Airport,” said Rosemary Vassiliadis, Clark County Department of Aviation Director. “Domestic and international travel has been booming with more than 57.6 million passengers served in 2023, and the U.K. continues to be one of the top three international visitor markets to the destination. The addition of convenient flight options ensures more business and leisure travelers can enjoy the sports and entertainment capital of the world.” Steve Hill, CEO and President of the Las Vegas Convention and Visitors Authority, said: "Congratulations to Norse Atlantic Airways on their inaugural flight from London to Las Vegas. We are thrilled to welcome Norse and this new route, which strengthens our connection with the UK, our number one source of overseas visitation. This Norse Atlantic flight offers travelers a convenient and affordable way to experience the world-class entertainment, dining, and attractions that make Las Vegas a global destination.” As Norse Atlantic continues to expand its global footprint, the airline aims to connect key transatlantic destinations with affordable, high-quality air travel. The addition of Las Vegas to its network reinforces the airline’s goal of making travel more accessible and enjoyable for everyone. Norse Atlantic exclusively operates modern Boeing 787 Dreamliner aircraft. The cabin offers passengers a relaxed and comfortable travel experience with each seat including a personal, state-of-the-art entertainment experience. Our Norse Premium cabin offers an industry leading 43” seat pitch and 12” recline, allowing passengers to arrive at their destination feeling refreshed and ready to explore their destination. Norse Atlantic offers two cabin choices: Economy and Norse Premium. Passengers can choose from a simple range of fares, Light, Classic and Flextra, that reflect the way that they want to travel, and which options are important to them. Light fares represent Norse’s value option, while Flextra fares include the maximum baggage allowance, two meal services and increased ticket flexibility. All economy light bookings now also include a 10kg carry-on bag in addition to the personal under seat item, offering customers even greater value and convenience than before. The included carry-on bag policy only applies to bookings made from Monday 2nd September and directly on the flynorse.com website. For bookings made via third party different rules may apply. For more information on Norse Atlantic Airways and to book flights, visit www.flynorse.com. *£299 return fare is a promotional price currently available in the Norse Atlantic Airways sale and valid from 12[th] September 2024 for a limited period. Some periods may be subject to blackout restrictions. This promotion is subject to availability, it may not be available on every flight. This promotion is only available for bookings made on selected routes and does not apply to connecting flights.

Fortum provides expert services for the European Commission's Nuclear Decommissioning Assistance Programme

FORTUM CORPORATION PRESS RELEASE 16.9.2024 Fortum's Nuclear Services has signed a multi-year framework agreement with The Nuclear Decommissioning Assistance Programme (NDAP), which operates under the European Commission. Fortum’s role is to provide expert reviews and assessments related to the status and progress of European decommissioning programs funded by the EU, specifically the Ignalina (Lithuania), Kozloduy (Bulgaria), and Bohunice (Slovakia) decommissioning programs. The work will be carried out under specific assignments ordered by the European Commission within the framework agreement. The first assignments under the framework agreement are already in progress.   “This is a very important and interesting program, and we are pleased that the European Commission has chosen us for this task. We bring our extensive experience in decommissioning and waste management, combining the expertise of a service provider and a nuclear power plant owner. As a great example of our first-hand experience on execution of nuclear decommissioning projects, we recently completed dismantling of Finland’s first nuclear reactor, FiR1 research reactor,” comments Antti Ketolainen, Director, Decommissioning and Waste, Nuclear Services at Fortum. The Nuclear Decommissioning Assistance Programme (NDAP) is an initiative by the European Union to support the safe decommissioning of nuclear facilities. The program is part of the EU’s broader efforts to ensure nuclear safety and manage radioactive waste effectively . Fortum CorporationCommunications Further information:Antti Ketolainen, Director, Fortum, Decommissioning and Waste, Nuclear Services, +358407518956, antti.ketolainen@fortum.com Fortum Fortum is a Nordic energy company. Our purpose is to power a world where people, businesses and nature thrive together. We are one of the cleanest energy producers in Europe and our actions are guided by our ambitious environmental targets. We generate and deliver clean energy reliably and help industries to decarbonise their processes and grow. Our core operations in the Nordics comprise of efficient, CO2-free power generation as well as reliable supply of electricity and district heat to private and business customers. For our ~5 000 employees, we commit to be a safe, and inspiring workplace. Fortum's share is listed on Nasdaq Helsinki. fortum.com  Fortum’s Nuclear ServicesOur Nuclear Services has more than 40 years of experience in designing, licensing and operating nuclear facil­ities and supplying related services and technologies. Our expertise covers the whole life-cycle of nuclear power plants from new builds to decom­mis­sioning and final disposal of nuclear waste.

Recipharm’s investment enhances efficiency and speed for customers and patients

Recipharm, a leading global pharmaceutical contract development and manufacturing organisation (CDMO), today announces a significant investment in its Oral Solid Development and Pilot Scale Centre in Zwickau, Germany. The investment includes three new GMP Pilot Scale suites for blending, tableting and hard capsule filling, which will complement the existing GMP pilot scale capabilities in dry granulation and wet granulation and related tools for material characterisation and material science. The investment includes: · A pilot scale hard capsule filler with dual filling and mini tablet dosing capabilities · A Style One EVO Compression and Compaction Simulator, which complements the existing pilot scale dry granulation and tableting capabilities · A pilot scale tablet press. The new pilot scale centre for dry technologies will be GMP-ready by Q1 2025. This goes hand in hand with ReciPredict  – an innovative combination and systematic application of material sciences, statistical tools and simulation. ReciPredict promises to deliver unparalleled efficiency and reliability to the pharmaceutical industry, by streamlining the product development cycle, from initial formulation through to manufacturing. Dr. Uwe Hanenberg, PhD, Head of Product Implementation, commented: "With these advancements, we can now offer late-stage product development, clinical supply and commercial manufacturing from a single site. This integration makes it more efficient and cost-effective for our customers, providing them with access to top experts, while ensuring efficiencies in material consumption, including APIs. With our investment in ReciPredict as well as the GMP pilot scale for dry granulation and now the pilot scale for dry technologies, we have the tools and equipment at hand to support our customers with a faster clinic-to-market timeline for new drugs and de-risking manufacturing, ensuring greater certainty in meeting customer needs." With its new capabilities Recipharm in Zwickau is the ideal partner for API and excipient characterisation, product and process development, clinical Ph II and Ph III supply, small scale batch manufacturing, scale up and tech transfers, product optimisation and life cycle management. For more information or to schedule a discussion, please contact:Uwe Hanenberg (Uwe.Hanenberg@Recipharm.com) About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,200 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com Media contact:Guenaelle Holloway, Head of communicationsGuenaelle.Holloway@recipharm.com+44 7730 303 708

Västflyg to launche a new direct route from Stockholm Arlanda Airport to Trollhättan Vänersborg Airport starting October 2nd 2024

Already operating Bromma Airport from Trollhättan Värnersborg Airport, Västflyg will further expand and add another route serving the Swedish capital. Starting on October 2nd, they will operate Stockholm Arlanda Airport, further connection the western parts of Sweden with the capital, contributing to increased growth for business and offering a smooth transfer further out into the world. - I’m very happy that Västflyg chooses to further expand and add another of Swedavias Airports to their offer. And a new domestic route is of course extra welcome, says Elizabeth Axtelius, Director Aviation Business at Swedavia. A strong domestic flight is essential for people to be able to meet across the country and have smooth connections to the rest of the world, whether traveling to meet friends and family, discover new places or on business, she says. - We see that there is a strong demand to be able to travel from Trollhättan and further out into the world. Today, there are direct flights from Arlanda to many destinations that our immediate area cannot offer. This means that we are extra happy to be able to present Arlanda as a destination, which enables easier and faster travel for our customers, says Anna Petre, CEO of Västflyg. The new direct line between Stockholm Arlanda Airport and Trollhättan Vänersborg will be operated twice a week, on Wednesdays and Sundays. Further information about the program and range is available at www.vastflyg.se For further information, please contact Swedavia’s press service at +46 (0) 109 01 00 or press@swedavia.se About Västflyg Västflyg is a local airline run by five local entrepreneurs. Västflyg's vision is a sustainable flight from Trollhättan-Vänersborg airport to lift the region. Air travel significantly shortens the travel time between Trollhättan-Vänersborg and thus creates the conditions for viable companies, jobs and a sustainable society even far outside of Stockholm. Swedavia’s work for fossil-free aviationSwedavia has carried out ambitious climate work for many years. All ten of its airports achieved the goal of zero fossil carbon dioxide emissions from their own operations by year-end 2020. Swedavia also works actively to promote the switch to sustainable aviation fuel (SAF) and has the goal that five per cent of all fuel used for refueling at Swedish airports shall be fossil-free by 2025. Swedavia’s climate transition work and its pioneering work to operate climate-smart airports have won international awards, and in 2021 the trade organization Airports Council International (ACI) named Stockholm Arlanda Airport Eco-Innovation Airport of the Year. Swedavia offers all passengers flying from one of Swedavia’s airports the option to purchase SAF for all or part of their journey via flygreenfund.se/swedavia. Swedavia is a group that owns, operates and develops 10 airports throughout Sweden. Our role is to create the connectivity that Sweden needs to facilitate travel, business and meetings. Satisfied and safe travelers are the foundation of Swedavia's business. Swedavia is a world leader in the development of airports with the least possible climate impact. Since 2020, Swedavia's own airport operations have been fossil-free at all ten airports. The group's turnover in 2023 was approximately SEK 5.9 billion and approximately 2,600 employees.

BlueNord ASA - Minutes from Extraordinary General Meeting

Oslo, 16 September 2024: BlueNord ASA (the "Company") has today held an extraordinary general meeting ("EGM") as a digital meeting through the solution Lumi AGM.  All items on the agenda were resolved in accordance with the proposals. Following this, the Board of Directors of the Company consists of: -    Glen Ole Rødland (chair)-    Robert J. McGuire (board member)-    Marianne Lie (board member)-    Tone Kristin Omsted (board member)-    Peter Coleman (board member)-    Kristin Færøvik (board member)-    Joäo Saraiva e Silva (board member) Minutes from the EGM are attached to this notice and will be made available on the Company's website: www.bluenord.com. This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ***  Contact:Cathrine Torgersen, Chief Corporate Affairs OfficerPhone: +47 915 28 501Email: cathrine.torgersen@bluenord.com 

New CEO takes office today

Tarik Cengiz will work on developing existing partnerships in the company's current markets. He will also put a lot of focus on driving a geographic expansion and increased sales by addressing potential international partners such as distributors, agents or OEM partners. "I would like to warmly welcome Tarik to VibroSense, both I and the board look forward to working together with him when VibroSense now clearly focuses on distributors and new markets. The board and I would also like to thank Hans Wallin for all the time and care he put in to move the company forward during sometimes very tough times," says Håkan Petersson, chairman of the board of VibroSense Dynamics AB. "I look forward to starting to work actively on taking VibroSense to a new phase in the company's development and I am really excited and happy to take on my new assignment. I see a great need for what VibroSense offers the market and good opportunities to develop and expand the business. The goal is to create growth with good profitability," says Tarik Cengiz , CEO of VibroSense Dynamics. Contact Håkan Petersson, Chairman of the Board VibroSense Dynamics AB,Tel: +46 40 88 026 E-mail: info@vibrosense.com www.vibrosense.com "The new Gold Standard for reliabledetection of nerve damage" About VibroSense Dynamics AB ( pub ) VibroSense Dynamics AB ( publ ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers. Our vision is for the company's products to be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.

PHI announces significant order agreement from Altium for 20 HoloMonitor systems

"This order agreement from Altium is a testament to their strong confidence in the capability of HoloMonitor and its potential to meet market demands. Our collaboration with Altium has been influenced by an onboarding process and integration of new sales partners, which is starting to pay off as those systems will have a great contribution to our growth in the coming fiscal year", comments Patrik Eschricht, CEO of PHI. The order agreement for 20 HoloMonitor units follows the distribution agreement that PHI’ entered with Altium in November 2023. As PHI’s global distribution partner, Altium has utilized its wide network to develop HoloMonitor's market presence further.  Over the last year, Altium has subcontracted various resellers and opened up many new markets for PHI in countries such as Azerbaijan, Bosnia and Herzegovina, Croatia, Czechia, Denmark, Estonia, Finland, Iceland, Israel, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Spain, Sweden, Türkiye, among several other strategic markets. This large order agreement from Altium shows great confidence in the capabilities of HoloMonitor and is intended for resale to end customers. The final shipments from PHI to Altium will be made before the end of 2024. "Compared to Q3 and Q4 2023/24, during which Altium ordered 10 systems, this agreement is double the order size. The developing sales volumes are higher than we could have managed in-house ourselves, so we are very pleased with this first year of our distribution partnership", adds Patrik Eschricht, CEO of PHI.

Buyback of Class B shares in Essity during week 37, 2024

The share purchase is part of the SEK 3bn buyback program announced by Essity on June 17, 2024. The buyback program will extend from June 17, 2024, until the 2025 Annual General Meeting and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission’s Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity’s capital allocation. Class B shares in Essity were repurchased as follows: Date Aggregated daily Weighted average Total daily volume (no. of price per day transaction value shares): (SEK): (SEK):September 9, 2024 54,000 319.0152 17,226,821September 10, 2024 54,000 320.0826 17,284,460September 11, 2024 54,000 322.7391 17,427,911September 12, 2024 54,000 321.7781 17,376,017September 13, 2024 54,000 320.3011 17,296,259Total accumulated 270,000 320.7832 86,611,468during week 37, 2024Total accumulated 3,456,000 295.2896 1,020,520,926during the buybackprogram All purchases were conducted on Nasdaq Stockholm by Danske Bank on behalf of Essity. Following the above purchases, Essity’s holding of treasury shares amounted on September 13, 2024, to 3,456,000 Class B shares. The total number of shares in Essity amounted on the date of this press release to 702,342,489, of which 60,412,986 Class A shares and 641,929,503 Class B shares.  The full details concerning the completed transactions are appended to this press release.

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX). Visit Calliditas.com for further information.

Investment AB Latour (publ) issues bond loans

Today Investment AB Latour issued three bond loans of in total SEK 2,200 m, within the aggregate nominal amount of the existing MTN program. The first bond loan amounts to SEK 500 m with a tenor of 2 years and carries a floating interest rate of three months STIBOR + a margin of 0.40 per cent annually. The second bond loan amounts to SEK 650 m with a tenor of 4 years and carries a floating interest rate of three months STIBOR + a margin of 0.70 per cent annually. The third bond loan amounts to SEK 1,050 m with a tenor of 4 years and carries a fixed interest rate of 2.708 per cent annually. Handelsbanken, SEB and Nordea have arranged the issuance. Göteborg, September 16, 2024 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson, CEO For further information, please contact:Johan Hjertonsson, President and CEO Latour, +46 702 29 77 93Anders Mörck, CFO Latour, +46 706 46 52 11 Investment AB Latour is a mixed investment company consisting primarily of a wholly-owned industrial operations and an investment portfolio of listing holdings in which Latour is the principal owner or one of the principal owners. The investment portfolio consists of ten substantial holdings with a market value of about SEK 89 billion. The wholly-owned industrial operations have an annual turnover of about SEK 25 billion.

Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027). Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test’s performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of 85% and specificity of 98%, as reported in a 1 August 2024 press release. The sensitivity of the Immunovia test exceeded that of CA19-9, a commonly used biomarker for pancreatic cancer, by 20 percentage points. The conference is being hosted by the American Association for Cancer Research (AACR) in Boston, Massachusetts. This special conference brings together leading pancreatic cancer researchers, physicians, and patient advocates to share innovative approaches for diagnosing and treating pancreatic cancer. “We are grateful to have been selected by the AACR reviewers to present the model-development-study results at this inspiring conference of pancreatic cancer advances. Rigorous scientific review and dissemination of our data will be critical for driving adoption of our next-generation test following its launch next year,” said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia. For more information, please contact: Jeff Borcherding  CEO and President  jeff.borcherding@immunovia.com   +46 70 911 56 08  Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.  Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.  USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.  Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit  www.immunovia.com

Nitro Games Oyj: Nordisk Games has sold 6.5 million shares in Nitro Games to current shareholders and new investors

Members of the Board of Directors and management of Nitro Games have participated in the transaction with a total of approximately SEK 2.7 million. The block trade covered Nordisk Games' entire holding of shares in Nitro Games and, following the transaction, Nordisk Games will no longer remain a shareholder in the Company.

New understanding of the limits on nano-noise

Thanks to nanoscale devices as small as human cells, researchers can create groundbreaking material properties, leading to smaller, faster, and more energy-efficient electronics. However, to fully unlock the potential of nanotechnology, addressing noise is crucial. A research team at Chalmers University of Technology, in Sweden, has taken a significant step toward unraveling fundamental constraints on noise, paving the way for future nanoelectronics. Nanotechnology is rapidly advancing, capturing widespread interest across industries such as communications and energy production. At the nano level – equivalent to a millionth of a millimeter – particles adhere to quantum mechanical laws. By harnessing these properties, materials can be engineered to exhibit enhanced conductivity, magnetism, and energy efficiency. “Today, we witness the tangible impact of nanotechnology – nanoscale devices are ingredients to faster technologies and nanostructures make materials for power production more efficient,” says Janine Splettstösser, Professor of Applied Quantum Physics at Chalmers. Devices smaller than the human cell unlocking novel electronic and thermoelectric properties To manipulate charge and energy currents down to the single-electron level, researchers use so-called nanoscale devices, systems smaller than human cells. These nanoelectronic systems can act as “tiny engines” performing specific tasks, leveraging quantum mechanical properties.“At the nanoscale, devices can have entirely new and desirable properties. These devices, which are a hundred to ten thousand times smaller than a human cell, allow to design highly efficient energy conversion processes,” says Ludovico Tesser, PhD student in Applied Quantum Physics at Chalmers University of Technology. Navigating nano-noise: a crucial challenge However, noise poses a significant hurdle in advancing this nanotechnology research. This disruptive noise is created by electrical charge fluctuations and thermal effects within devices, hindering precise and reliable performance. Despite extensive efforts, researchers have yet to find out to which extent this noise can be eliminated without hindering energy conversion, and our understanding of its mechanisms remains limited. But now a research team at Chalmers has succeeded in taking an important step in the right direction. In their recent study, published as editor’s suggestion in Physical Review Letters , they investigated thermoelectric heat engines at the nanoscale. These specialised devices are designed to control and convert waste heat into electrical power. “All electronics emit heat and recently there has been a lot of effort to understand how, at the nano-level, this heat can be converted to useful energy.  Tiny thermoelectric heat engines take advantage of quantum mechanical properties and nonthermal effects and, like tiny power plants, can convert the heat into electrical power rather than letting it go to waste,” says Professor Splettstösser. Balancing noise and power in nanoscale heat engines However, nanoscale thermoelectric heat engines work better when subject to significant temperature differences. These temperature variations make the already challenging noise researchers are facing even trickier to study and understand. But now, the Chalmers researchers have managed to shed light on a critical trade-off between noise and power in thermoelectric heat engines. “We can prove that there is a fundamental constraint to the noise directly affecting the performance of the ‘engine’. For example, we can not only see that if you want the device to produce a lot of power, you need to tolerate higher noise levels, but also the exact amount of noise. It clarifies a trade-off relation, that is how much noise one must endure to extract a specific amount of power from these nanoscale engines. We hope that these findings can serve as a guideline in the area going forward to design nanoscale thermoelectric devices with high precision,” says Ludovico Tesser. More about the research: The study “Out-of-Equilibrium Fluctuation-Dissipation Bounds”  was published in Physical Review Letters. At the time of the study, all researchers were active at Chalmers University of Technology. The research project has been funded by the European Research Council (ERC) under the European Union’s Horizon Europe research and innovation programme, as well as by a Wallenberg Academy Fellowship. For more information, contact: Janine Splettstösser, Professor at Applied Quantum Physics at the Department of Microtechnology and Nanoscience at Chalmers University of Technology, janines@chalmers.se  +46 31 772 31 11 Ludovico Tesser, PhD student in Applied Quantum Physics at the Department of Microtechnology and Nanoscience at Chalmers University of Technology, tesser@chalmers.se Ludovico Tesser speaks English and Italian and Janine Splettstösser speaks English and German and they may be available for live and pre-recorded interviews. At Chalmers, we have podcasting studios and film equipment on site and can assist requests for TV, radio, or podcast interviews. Image caption: The image illustrates a tiny nanoscale heat engine connecting hot and cold sides. The temperature difference drives a current, generating power, but both current and power are noisy hindering precise and reliable performance. The Chalmers researchers have managed to demonstrate a trade-off relation between noise and power from these nanoscale engines, paving the way for future nanoscale thermoelectric devices with high precision. Image credit: Chalmers University of Technology | Carina Schultz

MPCC: Ex-dividend USD 0.10 today (Q2 2024)

From today, September 17, 2024, the shares of MPC Container Ships ASA (OSE: MPCC) will be traded ex-dividend USD 0.10 (NOK 1.0583).  This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

DBP International AB: transition of the SI053 clinical trials protocol to a new Clinical Trial Information System has been completed

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) is pleased to announce the successful transition of its clinical study "An open-label dose escalation study to estimate the maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs), and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC) in adult patients with newly diagnosed glioblastoma (GBM)," to a new Clinical Trial Information System (CTIS). Adoption to this on-line system will be mandatory by February 2025 and is implemented to streamline trial management across all involved member states and to ensure compliance to the Clinical Trials Regulation. "This is a significant formal step in preparing for the initiation of clinical trials for SI053”, comments Dr. Charlotta Grånäs Folkesson, CMO of DBP. More about CTIS: https://euclinicaltrials.eu/ More about clinical trials of SI053: https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-515128-35-00, https://clinicaltrials.gov/study/NCT04967690?term=Double%20Bond%20pharmaceutical&rank=5 More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o

Uniwater enters agreement to acquire Biowater Technology – expands geographical reach and specialist expertise in water treatment

Biowater Technology is an engineering and construction company specialized in wastewater treatment, based in Tonsberg, Norway.  With the acquisition of Biowater Technology, Uniwater expands its offering into new markets and adds cutting-edge solutions for water and wastewater treatment to the portfolio. – We are thrilled to welcome Biowater Technology to the Uniwater group. This acquisition aligns with our vision of leveraging specialized technologies and expertise to address water challenges in communities in a global context. Together, we are well-positioned to drive innovation and expand our offerings to a wider customer base, says Pål Warolin, CEO, Uniwater Group. Founded in 2007, Biowater Technology has a strong focus on innovation and product development, including next generation biofilm solutions for efficient wastewater treatment. Mainly operating in Norway and Sweden where they deliver turnkey solutions, the team also have reoccurring engineering projects and product sales globally in Brazil, Canada, Finland and Switzerland.  – We are delighted to join Uniwater, a like-minded future focused group with exciting ambitions. With strong new ownership, we are dedicated to developing a valuable organization in Norway that solves future treatment challenges. We look forward to opportunities within the Uniwater family whilst continuing to be a prominent process specialist, technology developer and contractor, says Ilya Mario Savva, CEO, Biowater Technology. The transaction is subject to customary regulatory approvals and is expected to close during the fourth quarter 2024. About Biowater TechnologyBiowater Technology is an engineering and construction company, that design and develop biological solutions for wastewater treatment. The company is led by CEO Ilya Mario Savva and has 45 employees. Learn more about Biowater Technology here: https://www.biowater.no/

Eevia receive sales order for 827 KSEK (73 KEUR)

Eevia received the sales order from a large international nutraceutical ingredients house, which markets ingredients on three different continents and multiple application areas.  The customer has a focus on sustainability and therefore products made in Finland close to the source is favored. The product is Feno-Myrtillus® 25 Organic and the value of the start order is 73 KEUR (827 KSEK). This is a repeat order. Eevia has this bilberry extract in stock and will ship half of the order immediately and the rest within weeks. Sales from inventory have a very positive impact on cash flow from operations. For further information, please contact: Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.comor investor@eeviahealth.com Telephone: +358400 22 5967 INFORMATION ABOUT EEVIA HEALTH PLC Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas. Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably. Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA . To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn@EeviaHealth.

MilDef wins Danish IT hardware order for new artillery system, worth 27.5 MSEK

MilDef has a long-term relationship with the purchasing organization DALO to which MilDef delivers tactical IT equipment, such as computers, monitors, network infrastructure and software. In addition to the actual ordering of uniquely developed hardware for e.g. artillery systems, MilDef's involvement in both ground and air defense systems has deepened over the years. “With a long history of serving the Nordic defence procurement agencies, MilDef is well positioned to play a key role in the modernization of increasingly interwoven defence systems in the Nordic region and NATO. We are now seeing the effects of increased collaboration and technology sharing across national borders, which fits MilDef's offering perfectly,” says Daniel Ljunggren, President and CEO of MilDef.The information was submitted for publication, through the agency of the contact persons set out below, at 07:59 CET on September, 17 2024. 

Autoliv appoints Fabien Dumont as Executive Vice President & Chief Technology Officer

Fabien Dumont previously served as Vice President Engineering in Autoliv China and has been with Autoliv since 1998. In leading the Autoliv China Engineering team, Fabien Dumont has played a vital role in developing innovations and technologies that support the fast-moving Chinese market. This includes leading the design and technological transformation of the steering wheel business in China. China is an increasingly important innovation and growth hub for the global automotive industry, where the technology development is intense, with faster timelines to bring new products to market and a growing level of innovations. “Fabien Dumont’s experience in both Operations and Engineering will be essential as we continue to bring the capabilities from the fast-moving China market and business to the rest of Autoliv. I am very pleased to welcome Fabien to the Executive Management Team, bringing valuable knowledge and perspectives,” said Mikael Bratt, President and CEO of Autoliv. Fabien Dumont will continue to be based in China and close to the fast-developing market. He succeeds Jordi Lombarte who continues as Senior Technical Advisor. Mikael Bratt continued, "I thank Jordi Lombarte for his valued contribution to Autoliv in a period of intense business transformation and I look forward to his continued contributions.” The change is effective immediately. Inquiries:  Media: Gabriella Etemad, Tel +46 (70) 612 64 24Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14 About Autoliv Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2023, our products saved 35,000 lives and reduced more than 450,000 injuries. Our 70,000 associates in 25 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2023 amounted to US $ 10.5 billion. For more information go to www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Weakened market conditions impact Dometic’s financial performance in the third quarter

The current macroeconomic situation and market conditions, including high interest rates, lower consumer spend and customer purchasing patterns, are having a negative impact on Group net sales. As a result, Group organic net sales for the third quarter are expected to decline by approximately 15% compared to the same period previous year, with an EBITA margin before items affecting comparability in the range of 8-9%. Supported by a continued robust operating cash flow, we expect the net debt to EBITDA leverage ratio to be approximately 3.1x, compared to 2.9x at the end of the second quarter 2024. "Long-term trends in the Mobile Living industry are strong. However the current macroeconomic situation, market conditions and customer purchasing patterns have a negative impact on the business in all sales channels, which is expected to remain throughout the year. Demand visibility has turned shorter than normal and the situation has worsened during the third quarter as customers are cautious building inventories as the low season approaches. In this challenging environment we continue to drive our strategic agenda and are strengthening the sales organizations in future growth areas, such as Outdoor Standalone Products and Mobile Power Solutions. We continue to invest in product innovation strategically, in particular in service intensive product areas, while continuing to reduce cost and increase efficiency. We are proactively adjusting capacity and we are today 1,600 fewer FTEs (full-time equivalents) than two years ago and will continue to take mitigating actions to remain agile and efficient.” says Juan Vargues, President and CEO of Dometic. Dometic's report for the third quarter will be published on 23 October, 2024. FOR FURTHER INFORMATION, PLEASE CONTACT: Rikard Tunedal, Head of Investor RelationsPhone: +46 73 056 97 35Email: rikard.tunedal@dometic.com This information is information that Dometic Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on September 17, 2024

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On September 13, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting Below Below 5% Below 5%situation on the 5%date onwhich thresholdwas crossed orreachedPosition of 4.08% 0.93% 5.02%previousnotification A: Shares and votingrightsClass/type of Number of % ofshares shares and shares and voting voting rights rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 Below 5% Below 5%SUBTOTAL A Below 5% Below 5%B: FinancialInstruments accordingto SMA 9:6aType of financial Expiration Exercise/ Physical or Number % of sharesinstrument date Conversion cash of and voting Period settlement shares rights and voting rightsAmerican Depositary N/A N/A Physical Below Below 5%Receipt 5%(US5926721094)Securities Lent N/A N/A Physical Below Below 5% 5% CFD N/A N/A Cash Below Below 5% 5% SUBTOTAL B Below Below 5% 5% Metso Corporation  Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Aker Horizons ASA: Lars P. Sørvaag Sperre appointed new CEO; Kristian Røkke proposed nominated as Chairman

“It is a pleasure to welcome Lars as Aker Horizons’ new CEO. His extensive track record with industrial development activities and capital markets, as well as having navigated complex situations in Norske Skog, will allow him to hit the ground running in steering the company through its next phase,” said Øyvind Eriksen, CEO of Aker ASA and current Chairman of Aker Horizons. “On behalf of the entire Board, I would like to thank Kristian for his leadership the last four years. His new role as Chairman of the Board will ensure continuity for the company going forward.” Lars P. S. Sperre will assume the role as CEO, effective 1[ ]October 2024. Mr. Sperre’s experience includes a 17-year career at Norske Skog, including as SVP Corporate Strategy and CEO. He holds a law degree from the University of Bergen. Aker will propose to the Nomination Committee of Aker Horizons that Kristian Røkke takes the position of Chairman of the Board of Aker Horizons (“the Board”). Further, Aker will propose that Øyvind Eriksen is named Deputy Chairman of the Board. The Board remains otherwise unchanged. The Nomination Committee has been informed of Aker's planned proposal and will discuss it at its earliest convenience. Aker Horizons will soon call for an Extraordinary General Meeting. "The energy transition continues to be both an enormous investment challenge and an unprecedented opportunity. Over the past four years, we have experienced firsthand the complexities of being a first mover in emerging markets and new technologies, while achieving progress in advancing the energy industry's path to Net Zero. I am confident these experiences will serve us well as the industry continues to evolve. I look forward to contributing to the next phase of this journey in my new role as Chairman," said Kristian Røkke. “Investments in renewables have faced headwinds the last few years, but opportunities ahead are considerable. I am honored and ready to carry the baton in Aker Horizons and look forward to joining the team,” said Lars P.S. Sperre. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Mats Ektvedt, Partner in Corporate Communications, on 17 September 2024 at 08:15 CEST. For further information, please contact: Mats Ektvedt, MediaTel: +47 41 42 33 28mats.ektvedt@corporatecommunications.no

Catena has issued green bonds maturing 2027 and 2029 and repurchased bonds maturing 2025

17 September 2024, 8.30 a.m. CEST The bond loans, in total of SEK 1 billion, are split between one loan at SEK 500 million maturing on 17 September 2027 at an interest rate of three months STIBOR +1.00 percent, and one loan at SEK 500 million maturing on 17 September 2029 at an interest rate of three months STIBOR +1.35 percent. In conjunction with the new bonds, Catena repurchased SEK 612 million of its outstanding June 2025 floating rate notes (SE0013104635) and SEK 272 million outstanding June 2025 fixed rate notes (SE0013104627). The excess proceeds of the issue will be used in accordance with Catena’s green framework. The new bonds will be listed on Nasdaq Stockholm. Nordea and SEB have acted as joint bookrunners on the transaction. For further information, please contactDavid Silvesjö, Chief Treasury Officer, Tel. + 46 730-70 22 22, david.silvesjo@catena.seJörgen Eriksson, CEO, Tel. + 46 730-70 22 42, jorgen.eriksson@catena.seFollow us: catena.se  / LinkedIn 

Safello enters into an agreement with TRUST to ensure compliance with the Travel Rule

Stockholm 17 September 2024 | Safello, the leading cryptocurrency exchange in the Nordics, has entered into an agreement with TRUST, a secure infrastructure to meet the requirements as the so-called "Travel Rule" expands to include cryptocurrency transactions. This step is a crucial part of Safello's efforts to ensure regulatory compliance and protect customer data and privacy. The Travel Rule stems from the Financial Action Task Force's (FATF) international standards and requires financial institutions to share certain information about the parties in a transaction when money is transferred to another financial institution. The aim is to increase the traceability of transactions to prevent money laundering and the financing of terrorism. Through the recently adopted EU regulation (EU) 2023/1113, the Travel Rule is expanded to include providers of crypto-asset services and crypto-assets starting from the turn of the year. By becoming part of the TRUST network, Safello is well-positioned to meet these new and stricter requirements. TRUST is a well-established membership network in both the US and Europe, developed in collaboration with several leading cryptocurrency exchanges such as Coinbase, Kraken, Gemini, BitGo, and Fidelity Digital. The platform offers a decentralized solution where each crypto service provider must verify address ownership and share information peer-to-peer, ensuring that all necessary information can be transferred securely while protecting customer data. "Entering into an agreement with TRUST is a natural step in our ongoing efforts to meet and exceed regulatory requirements, while ensuring the security of our customers' assets and privacy," says Emelie Moritz, CEO of Safello. ### For more information, please contactChristian Ploog, press@safello.com Certified AdviserAmudova AB is Safello’s certified adviser. Safello is the leading cryptocurrency exchange in the Nordics, with over 376,000 users. The company is empowering financial independence by making crypto accessible to everyone. Safello offers a secure way to buy, sell and store crypto in seamless transactions at industry-leading speeds. Operating in Sweden, Safello has been registered as a financial institution with Finansinspektionen (Swedish Financial Supervisory Authority) since 2013 and is listed at Nasdaq First North Growth Market since 2021. For more information visit www.safello.com.

Addtech acquires PGS Tec GmbH

Addtech Process Technology, a business area in the Addtech Group, has today signed an agreement to acquire 85 % of the shares outstanding in PGS Tec GmbH (”PGS”). PGS designs, assemble and install customised water and gas supply systems to pharmaceutical, industrial and laboratory customers. The offering covers the entire spectrum of pipeline infrastructure, including valves, instrumentation and automation as well as service and maintenance. PGS has 15 employees and a turnover of approximately EUR 7 million and is headquartered in Wolpertswende, Germany. PGS will become part of and complement our operations within the Process Control business unit and strengthen our position in the European market. Closing will takes place at the beginning of October. The acquisition is expected to have a marginally positive impact on Addtech's earnings per share during the current financial year. Stockholm, September 17, 2024 Addtech AB (publ)  For further information, please contactNiklas Stenberg, President of Addtech AB, +46 470 49 00Claus Nielsen, Business Area Manager, Process Technology, +45 20 75 75 30 Addtech is a technical solutions group that provides technological and economic value added in the link between manufacturers and customers. Addtech operates in selected niches in the market for advanced technology products and solutions. Its customers primarily operate in the manufacturing industry and infrastructure. Addtech has about 4,000 employees in more than 150 subsidiaries that operate under their own brands. The Group has annual sales of more than SEK 20 billion. Addtech is listed on Nasdaq Stockholm. The information was submitted for publication, through the agency of the contact persons set out above, at 17 September 2024, at 9.00 a.m (CEST).

Metso invests in digitalization; opens Digital Design and Development Studio in Poland

Metso is continuing its investments in digitalization by opening a Digital Design and Development Studio in Krakow, Poland, on September 17, 2024. Metso’s digital strategy builds on the company’s core competencies in equipment excellence, processing, and metallurgical and material expertise combined with technical and field services support and enriched with leading-edge digital capabilities. The studio plays an important role in the development and implementation of digital solutions to enable customer value creation and to meet the needs of the industry. “Opening of the Digital Design and Development Studio marks the next phase in our digital offering development journey. This new digital capabilities and knowledge hub centers around the competences related to software development, design, data, UX design and AI required to serve our customers’ increasing appetite for advanced digital solutions,” says Olivier Guyot, Senior Vice President for Minerals Digital at Metso. Today, Metso has approximately 50 digital experts working in the Krakow office and the number is expected to increase significantly within the next months. All in all, Metso has some 250 people working on its rich portfolio of digital solutions. Digital with a purpose “Digital is a critical enabler for new sources of value because it helps our clients to optimize throughput and recoveries, increase equipment uptime and availability, and enable productivity while improving the sustainability of their operations. Digital solutions can also be the answer to reducing the knowledge gap and labor shortage in the industry,” says Guyot. In digital development for minerals processing customers, Metso is focusing on three main impact areas: Equipment performance to provide digitally enhanced Life Cycle Services, remote condition monitoring and prescriptive maintenance; Process performance digital portfolio to optimize customers’ ore-to-metal operations for efficiency and sustainability; and Business enablement to enhance the customer experience and improve employees’ productivity within a data-driven, AI-augmented environment. Metso is developing several solutions across these three areas. The new talents in the Digital Design and Development Studio in Poland will contribute to these, working closely with the global team. Find out more about Metso’s digital solutions on our website . Learn more about job openings in Metso’s digital teams on our website. Metso at MINExpo 2024 Metso will highlight its industry-leading sustainable technology and pit-to-port aftermarket solutions, including digital solutions, at MINExpo INTERNATIONAL[®] 2024, in Las Vegas. You can find the complete list of topics and presentation schedule on our website . Further information: Olivier Guyot, Senior Vice President, Minerals Digital, Metso, tel. +33 674 083 906, email: olivier.guyot(at)metso.com Helena Marjaranta, Vice President, Communications and Brand, Metso, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. Metso.com, x.com/metsoofficial

SAS and BRA sign long-term partnership to strengthen domestic connectivity in Sweden

Under the terms of the wet lease agreement, BRA will operate several aircraft on behalf of SAS, providing capacity on key domestic routes in Sweden as well as feeding into the Copenhagen hub. The partnership will ensure SAS’s ability to meet domestic demand while optimizing operations and improving regional air services across the region, ensuring greater connectivity and more options for travelers. Expanding reach The wet lease partnership is an important step towards providing passengers across Sweden with reliable and efficient air travel options. BRA, known for its commitment to service excellence, will operate its fleet on behalf of SAS, allowing for seamless integration into SAS’ existing operations. Building from Arlanda Airport, this partnership strengthens Swedish infrastructure, connecting local communities to the world and fostering greater global accessibility and opportunities. SAS CEO, Anko van der Werff, commented: “This new partnership with BRA is a testament to our long-term commitment to Sweden. By integrating BRA's expertise and fleet, we are not only enhancing Swedish infrastructure but also positioning Arlanda as a stronger central hub for domestic and international travel. This collaboration will significantly improve connectivity, allowing us to offer more seamless and frequent services between major cities and regional destinations. As a result, Arlanda will become an even more vital gateway, supporting both business and leisure travelers with greater convenience while we maintain our focus on sustainability and operational efficiency. We are excited to work closely with BRA in the coming years to realize these ambitions." BRA Chairman, Per G. Braathen, added: "We are proud to enter into this partnership with SAS, Scandinavia’s leading airline. By leveraging our experience and modern fleet, we will be able to contribute to securing domestic air connectivity in Sweden, which is critical for economic growth and regional development. Together with SAS, we aim to provide the best possible travel experience for passengers across the country." A sustainable future for air travel Both SAS and BRA share a strong commitment to sustainability and reducing the environmental impact of air travel. This collaboration therefore not only strengthens domestic connectivity but also supports SAS ambition to be a driving force behind the critical transition to sustainable aviation together with other stakeholders and partners.

Munters and ZutaCore form strategic alliance for data center cooling innovation

Munters and ZutaCore, will integrate Munters SyCool systems with ZutaCore’s advanced 2-phase liquid cooling technology. The aim is to tackle the challenges of managing AI-generated heat more efficiently and sustainably. The result will be a system that optimizes performance, from chip level dissipation to all parts of the heat rejection cycle. It also eliminates the risks associated with potential water leakage. “Combining the advanced closed-loop systems of Munters and ZutaCore delivers an unmatched end-to-end solution, which is uniquely positioned to meet the demands of high-density, high-value environments,” said Stefan Aspman, President of business area Data Center Technologies at Munters. As demand for AI and data processing grows, the need for efficient cooling systems in data centers becomes increasingly important. Liquid cooling, in particular, is crucial for managing the intense heat from AI chips while maintaining sustainability. “ZutaCore and Munters are pioneering a blueprint for sustainable AI data center architecture. It addresses intense heat loads with distinct advantages through its waterless 2-phase solution, and leads to savings in both CAPEX and OPEX, challenging other cooling technologies available today, he continues.” “AI workloads require high GPU density and stable thermal environments to optimize performance. This is where 2-phase, direct-to-chip liquid cooling stands out from other solutions. It operates without water, optimizes space utilization, uses significantly less power, and enables heat recovery, making it the most efficient choice for AI data centers,” said Erez Freibach, co-founder and CEO at ZutaCore. Initially, the alliance will focus on working closely with customers early in the design phase to ensure seamless integration of the combined solution. Ultimately, this approach will optimize the delivery of a fully integrated, waterless cooling solution that sets a new standard for efficiency and sustainability in data center cooling. For more information:Line Dovärn, Director, Investor RelationsE-mail: line.dovarn@munters.com, Phone: +46 (0)73 048 844 Media:Eva Carlsson, Director External CommunicationsE-mail: eva.carlsson@munters.com, Phone: +46 (0)7088 33500

Electrolux Group appoints new Head of Investor Relations & Sustainability Reporting

Ann-Sofi Jönsson is currently Head of Investor Relations, Group Risk Management and Sustainability at Munters Group AB, and has previously held similar positions within Saab, ABB AG, Accenture AG and Siemens Building Technologies. She will report to Therese Friberg, Chief Financial Officer of Electrolux Group.

Genova announces the expiration time for the tender offer

Reference is made to Genova Property Group AB (publ)’s (the "Company” or "Genova”) announcement on 12 September 2024, according to which the Company, in connection with the contemplated transaction of new subordinated green capital securities with an expected issue amount of SEK 300 million (the “New Green Capital Securities”), invited the holders of the Company’s outstanding green capital securities with ISIN SE0015245519 (the "Outstanding Capital Securities”) to participate in a tender offer as further described in the tender information document dated 12 September 2024 (the “Tender Information Document”) subject to the terms and conditions set forth in the Tender Information Document (the “Tender Offer”) and that the Tender Offer amounts to not less than SEK 250 million. In accordance with the Tender Information Document, the Company hereby announces that the Tender Offer will expire today 17 September 2024, upon book close of the book building process for the New Green Capital Securities, unless the Tender Offer is extended, re-opened, withdrawn or terminated at the sole and absolute discretion of the Company. The settlement of the Tender Offer is expected to occur on 24 September 2024. The Tender Offer remains conditional upon the consummation of the issue of the New Green Capital Securities (as defined in the Tender Information Document). ABG Sundal Collier AB and Nordea Bank Abp have been mandated as dealer managers for the tender offer. Gernandt & Danielsson Advokatbyrå KB have been mandated as legal advisor. The tender information document is available on the following link: https://genova.se/investors/bonds/. For further information, please contact:CEO, Michael Moschewitz, mobile +46 (0)70-713 69 39, michael.moschewitz@genova.se About GenovaGenova Property Group AB (publ) is a modern property company with a personal touch that owns, manages and develops properties with focus on Greater Stockholm area and Uppsala Region. On 30 June 2024, the value of the company's property portfolio amounted to approximately SEK 9.5 billion with a lettable area of approximately 340,000 sqm and the company held approximately 9,344 building rights for residential units. Genova's share has been listed on Nasdaq Stockholm since 2020. Genova – Smålandsgatan 12 – SE-111 46 Stockholm – www.genova.se

Saab delivers British Army’s next generation artillery hunting radars

As of 22nd July 2024, five next generation Arthur systems, named TAIPAN by the British Army, have been delivered, accepted, and are now with 5th Regiment Royal Artillery.  Replacing MAMBA – last generation Arthur radar – TAIPAN offers the British Army rapid deployment and re-deployment, high operational mobility, and precise counter-battery operations, locating an increased number of targets at greater range with reduced electronic warfare signatures, leveraging Saab’s Digital Antenna technology. This ensures survivability, reliability and high availability. The Royal Artillery formally accepted TAIPAN as 5th Regiment’s Colours on June 28th at Larkhill Camp.  “We are immensely proud to support the British Army with our state-of-the-art TAIPAN systems. Our relationship with the Army and the Arthur system builds on years of experience extending back through service in Iraq and Afghanistan. The team at Saab looks forward to continuing our support for the UK as it become the first user of the new Arthur current generation and next generation systems,” said Andy Fraser, Group Managing Director, Saab UK. “Saab are our key partner for both MAMBA and now TAIPAN and what it as a company have and continue to deliver to our Armed Forces is hugely impressive. MAMBA has more than proved its worth and TAIPAN is a step change in capability.” said Lt Gen Sir Andrew Gregory KBE CB, Master Gunner St James’s Park.Future maintenance and additional work will be supported at Saab’s UK-based Centre of Radar Excellence in Fareham as part of Saab’s strategy for expanding its global industrial base outside of Sweden. Beyond the UK, Arthur is in-service with an additional 12 countries, including 6 NATO countries and South Korea. Contact Saab Press Centre+46 (0)734 180 018presscentre@saabgroup.com Saab is a leading defence and security company with an enduring mission, to help nations keep their people and society safe. Empowered by its 22,000 talented people, Saab constantly pushes the boundaries of technology to create a safer and more sustainable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations. 

Dicot Pharma provides an operational update

Dicot Pharma's rights issue in August was oversubscribed, and an over-allotment option was exercised, resulting in a total of approximately SEK 135 million before costs to the business. This gives the pharmaceutical company a strong financial position. As the company announced in June, results from animal studies within the framework of LIB-01's research program show that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes, and high blood pressure. Based on these promising results and the successful outcome of the rights issue, Dicot Pharma's board and management have conducted a strategic review, which now forms the foundation of the operational plan, where the primary focus will continue to be on the clinical development of the potency drug candidate LIB-01. Operational update: · A phase 2a trial is set to begin in the fourth quarter. The company remains on track with its previously communicated timeline regarding all preparations, and the clinical trial application was submitted in July 2024. The placebo-controlled trial, involving approximately 140 patients, aims to demonstrate a statistically significant effect of LIB-01 in improving erectile function in patients with erectile dysfunction. · The company advances certain R&D activities related to upcoming development phases, including tablet development, scaling up the manufacturing process, and preparations to open an Investigational New Drug Application (IND) in the USA, which is required for conducting clinical trials there. The company will also make other important preparations required for clinical phase 2b. · In addition to the development of the potency drug candidate LIB-01, the company´s strong financial position allows for the initiation of a preclinical development program in metabolic diseases. A comprehensive market analysis conducted by an external party on behalf of Dicot Pharma has been matched against the company´s own available results in metabolic diseases, which in total strongly justifies further research into a number of prioritized indications. · In the fourth quarter, the company intends to apply for listing on the Nasdaq First North Growth Market, as it is assessed to support Dicot Pharma's continued development, internationalization, and competitiveness. The listing will enable a broader and more international shareholder base and is anticipated to generate increased interest in the share from stakeholders and analysts. · In line with the business strategy for LIB-01, i.e., entering partnerships with larger pharmaceutical companies to finance and further develop the drug for the world market, the strong outcome of the rights issue puts Dicot Pharma in a favorable position. Efforts to engage with potential partners will now be intensified alongside the phase 2a study and will be carefully managed by the board and management to maximize shareholder value. "We are in a favorable position, both financially and in terms of study results. The board and management have high ambitions for Dicot Pharma, with an innovative mindset, determination, and shareholder value as our guiding principles. Developing the next generation of potency drugs remains our core business, and thanks to the outcome of the rights issue, we now have the capacity to expand and explore new indications. We are very excited about what lies ahead", comments CEO Elin Trampe. For further information, please contact: Elin Trampe, CEOPhone: +46 72 502 10 10E-mail: elin.trampe@dicotpharma.com About Dicot Pharma AB Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market. Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,500 shareholders. For more information, please visit www.dicotpharma.com.

Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4

The warrants of series TO 4 were issued to subscribers in Brain+’ rights issue of units in June 2024. The warrants are traded at Nasdaq First North Copenhagen, and each warrant gives the holder the right to subscribe for one (1) new share in Brain+ at a price of DKK 0.08. As earlier announced, the exercise price has been calculated as 70% of the volume weighted average trading price for the Company’s shares on Nasdaq First North Copenhagen in the period from 16 August 2024 to 12 September 2024, however with a lower limit of DKK 0.08. If all warrants are exercised/guaranteed, it will provide Brain+ with proceeds of DKK 5.2 million before transaction related costs. The total commitments received so far secure Brain+ approximately DKK 0.7 million in gross proceeds. Brain+ is in active dialogue with shareholders, holders of warrants of series TO 4 and other investor for acquiring further commitments to exercise and guarantor commitments. Overview of commitments from board and management in the ongoing Brain+ TO 4 warrant exercise [][]Name No. of warrants Exercise Guarantee Total committed to commitment commitment commitment exercise (DKK) (DKK) (DKK)Tim Jürgens, 625,000 50,000.00 50,000.00via JuePes CoolVentures UG,(chairman oftheboard)Johan Luthman, 1,615,491 129,239.28 80,000.00 209,239.28EVP of R&D,Lundbeck (boardmember)Anish Shindore, 1,250,000 100,000.00 100,000.00via GSD GroupSL, (boardmember)Kim Baden 1,687,500 135,000.00 135,000.00-Kristensen(ChiefExecutiveOfficer)[1]Hanne Vissing 2,391,570 191,325.60 191,326.60Leth (ChiefFinancialOfficer)[ 1]Simon Nielsen 372,150 29,772.00 29,772.00(Chief Strategy&InnovationOfficer)Total 7,941,711 635,337 80,000.00 715,337.88 [1]Part of commitment relates to subscription of new shares via pension depository. If such subscription is not possible for any reason, Hanne Vissing Leth and Kim Baden-Kristensen undertake to fulfill their commitments by providing a guarantee commitment. The total commitment shall in any case correspond to what is stated in the table under “Total commitment”. Holders of warrants of series TO 4 can be certain upon exercise of their warrants to get the amount of shares they have subscribed for. Investors, who have provided guarantee commitments, will have their commitments activated only to the extent that all warrants are not exercised. If guaranteed commitments are activated, Brain+ will make a directed share issue to the guarantors at a subscription price equal to the exercise price of the warrants. The total number of shares issued based on exercise of warrants and in a potential subsequent directed issue cannot exceed the total number of 65,496,978 outstanding warrants of series TO 4. If the total of guarantor commitments exceeds the number of warrants not subscribed for, there will be a pro-rata allocation of shares to guarantors in the directed issue. No compensation is payable for guarantee commitments from members of Brain+’ management and board. Holders of warrants of series TO 4, who do not wish to exercise their warrants to subscribe for new shares, should sell the warrants over the market no later than 25 September 2024. Please note that warrants of series TO 4 that are not exercised no later than 27 September 2024, or not sold no later than 25 September 2024, will expire without value. For warrants to not lose their value, the holder must actively subscribe for new shares or sell the warrants. The complete terms and conditions for the warrants of series TO 4 can be found in the company announcement issued by Brain+ on 7 May 2024. The company announcement, as well as additional informative documents are available at the Company’s website: https://www.brain-plus.com/2024-unit-rights-issue/.  Summarized terms for Brain+’s warrants of series TO 4 Exercise 16 - 27 September 2024period:Exercise DKK 0.08price:Last day 25 September 2024oftrading:Issue 65,496,978 warrants, which entitle to a maximum subscription ofvolume: 65,496,978 new Brain+ shares. If all warrants are exercised, the Company will receive approximately DKK 5.2 million in proceeds before transaction related costs.Dilution: Upon full exercise of warrants of series TO 4, the number of shares of nominal value DKK 0.08 each in Brain+ will increase by 65,496,978 from 171,501,141 shares to 236,998,119 shares, and the share capital will increase by DKK 5,239,758.24 from DKK 13,720,091.28 to DKK 18,959,849.52. If all warrants of series TO 4 are exercised, the dilution of the number of shares and votes in Brain+ will be approximately 27.6 percent. How warrants are exercised (Nominee-registered warrants) Subscription and payment for new shares by exercise of warrants shall be made in accordance with instructions from each nominee/custodian bank. Please contact your nominee/custodian bank directly for additional information and instructions. Outcome The outcome of the exercise of warrants of Series TO 4 will be published by Brain+ in a company announcement on or around 1 October 2024. Shares that have been subscribed and paid for will be delivered to the subscriber when registration of the capital increase has been completed with the Danish Business Authority. AdvisorsIn connection with the rights issue, Sedermera Corporate Finance AB act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent. For more information about the warrant exercise, please contact: Sedermera Corporate Finance ABPhone: +46 (0) 40 615 14 10E-mail: cf@sedermera.sewww.sedermera.se For more information about Brain+ and the warrant exercise, please contact: Kim Baden-Kristensen, CEO                               Hanne Vissing Leth, CFOPhone: +45 31 39 33 17                                     Phone: +45 53 88 99 02E-mail: kim@brain-plus.com                               E-mail: Hanne@brain-plus.com www.brain-plus.com Certified Adviser Keswick Global AGPhone: +43 1 740 408 045E-mail: info@keswickglobal.com (cf@sedermera.se) Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia by 2030.

Zeqmelit® Launched in Norway and Finland

AcuCort had previously communicated that the launch of Zeqmelit® in Norway and Finland would occur shortly after the product's launch in Sweden. Zeqmelit® was launched in Sweden on September 2, and as of September 15, the medication is available in pharmacies in Norway and Finland. – The launch of Zeqmelit® is progressing as planned, and we have received very positive feedback from both doctors and patients since the product was introduced to the market. Another important milestone has now been achieved with the international expansion brought by the launch in Norway and Finland. Doctors in three Nordic countries can now prescribe Zeqmelit®, and allergy patients can then collect the product at pharmacies, says AcuCort’s CEO, Jonas Jönmark. For further information: Jonas Jönmark, vd, AcuCort ABTel: +46 70 365 5400Email: jonas.jonmark@acucort.se About AcuCort AB (publ)AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

SAS opens route to Seattle

With Seattle added to the network, SAS will offer nonstop flights to 11 North American gateways, further enhancing its global connectivity from Copenhagen Airport, serving as a key international gateway to and from Scandinavia and Northern Europe. “We are excited to expand our North American network with Seattle. The route from Copenhagen will provide more travel options for our customers and strengthen the connection between Scandinavia and the Pacific Northwest, a region of growing economic importance with deep Scandinavian roots”, says Anko van der Werff, President & CEO of SAS. Seattle is one of the wealthiest cities in the U.S. and has maintained deep and proud connections with Scandinavia dating back to the early 1900s. These ties have been shaped by waves of Nordic immigrants who brought their culture, skills, and entrepreneurial spirit to the region, leaving a lasting impact on the city's identity and economy. “This new addition to our network further expands our global reach and underscores our commitment to providing travelers with more direct route options. Seattle has been a highly requested destination by our customers, and we are excited to respond to their needs by launching this route. Additionally, Seattle’s growing cargo operations make this expansion even more strategically valuable”, van der Werff continues. Copenhagen-Seattle will start operations on May 21. Schedules have been designed to maximize connectivity with the rest of the SAS Network, offering seamless one-stop access to and from 39 European cities via Copenhagen. Key destinations such as Berlin, Helsinki, Milan, and Zurich will be among the cities benefiting from this enhanced connectivity. Seattle-Tacoma International Airport (Sea-Tac) handled 50.9 million passengers in 2023 and passenger traffic at Sea-Tac is expected to continue growing. Seattle is one of several new routes that SAS will announce soon.

GiG publishes investor presentation regarding the proposed distribution of GiG Platform

On 4 September 2024, Gaming Innovation Group Inc. (“GiG”) convened a special meeting of shareholders to resolve on the spin-off of GiG Platform as an independent company (the “Spin Off”). Today, an investor presentation has been published with further information on the proposed distribution and the business of GiG Platform. The investor presentation offers a synopsis of GiG Platform, provides the rationale for the Spin Off, presents the management team, tracks GiG Platform’s progress & financial performance and showcases the strategy of the business. For additional information, please refer to the Plan of Separation appended to the notice to the Special Meeting of Shareholders on 23 September 2024, which is available on GiG’s website. The investor presentation will also be available at www.gig.com.  For further information, please contact:Richard Carter, CEO Platform & Sportsbook, richard.carter@gig.comPhil Richards, CFO Platform & Sportsbook, phil.richards@gig.com, +44 7789743288  About Gaming Innovation Group (GiG)Gaming Innovation Group is a leading iGaming technology company, providing solutions, products and services to iGaming Operators. Founded in 2012, Gaming Innovation Group’s vision is ‘To be the industry leading platform, sportsbook and media provider delivering world class solutions to our iGaming partners and their customers.  GiG’s mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under the ticker symbol GIGSEK. www.gig.com

Torrey Pines Investment and Innovestor’s Life Science Fund Launch Polku Therapeutics

Helsinki, Finland, August 29, 2024 -- Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Innovestor’s Life Science Fund, a Nordic-focused venture capital fund investing in early-stage biotech and digital health companies, together with Helsinki University Funds, announced the pre-seed funding and launch of Polku Therapeutics Oy. Polku Therapeutics, a Helsinki-based innovative startup, will focus on the development of novel drug treatments for neurodegenerative disorders. The experienced team of serial entrepreneurs and specialist investors have partnered with the University of Helsinki, the leading academic institution in Finland, to launch Polku Therapeutics. The biotech company’s technology is based on over a decade of research by Professor Timo Myöhänen and Senior Scientist Erik Wallén at the University of Helsinki to identify a disease-modifying therapy for Parkinson's Disease and Alzheimer’s Disease. Polku’s activities will be directed toward rapid identification of potential drug candidates and supported by the cutting-edge computer-aided drug design and the discovery and development expertise of Expert Systems accelerator. About Torrey Pines Investment Torrey Pines Investment LLC is a San Diego, CA, venture company. Since 2002 it has been focused on investing in early to development stage breakthrough medicines. Its therapeutic interest spans from oncology, inflammation, virology, cardiovascular and metabolic to neuro and other therapeutic areas. In 2019 Torrey Pines expanded its early asset-based investment program in partnership with major VC funds. It is supported and managed by a global hybrid AI and hub-and-spoke R&D infrastructure-based accelerator Expert Systems. The accelerator rationally creates and maintains nimble companies with breakthrough ab initio program design and rigorously progresses their assets towards development stages, successful partnering, M&A or public financing. About Innovestor Innovestor is a Finnish investment company focusing on venture capital and real estate. The firm currently manages six VC funds with total capital of over €250 million. Consisting of over 100 growth companies across multiple sectors of technology, life science and health, it represents one of the largest private venture-backed portfolios in the Nordics. Innovestorgroup.com Media Contact: Sebastian Soidinsalo, Director of Operations - sebastian@polku-therapeutics.com polku-therapeutics.com 

CS MEDICA Announces Approval of CANNASEN® Pain Patch in Malaysia and Trademark Registration in Thailand

CS MEDICA A/S, a Danish MedTech specializing in pain management, autoimmune diseases, and stress-related disorders, is pleased to announce a milestone in its Asian market expansion strategy. The Pain Patch has been officially approved as a general medical device (GMD) in Malaysia, marking it the second product authorized for sale in the country. In addition, CS MEDICA has successfully achieved trademark registration for CANNASEN® in Thailand, further solidifying its brand presence in the Asian market. About the CANNASEN® Pain Patch The CANNASEN® Pain Patch is an innovative treatment for managing joint and muscle pain. Applied externally to the affected area, the Pain Patch provides a cooling sensation and long-lasting pain relief. Ideal for alleviating muscle, neck, back, and shoulder pain, as well as treating sprains, sports injuries, and arthritis. Classified as a Class I medical device under Europe's Medical Device Regulation (MDR) 2017/745, the CANNASEN® Pain Patch is also approved for sale by the US FDA, AUS TGA, UK MHRA, Israel, and now, Malaysia. This approval underscores the product's safety and effectiveness, reinforcing CS MEDICA's commitment to providing high-quality treatments. Overcoming Regional Regulatory Challenges Malaysia serves as a strategic entry point for CS MEDICA due to its progressive regulatory environment, and the approval of the CANNASEN® Pain Patch in Malaysia marks a significant achievement, particularly given the stringent regulatory challenges associated with products containing CBD in Asia. While CBD, a non-psychoactive compound derived from cannabis, faces varying degrees of regulatory scrutiny in different countries, CS MEDICA has demonstrated compliance by proving no THC traceability, meeting standards of ppb (parts per billion). CEO Lone Henriksen comments, "The approval of the CANNASEN® Pain Patch is another essential step in our Asian expansion strategy. It supports our goal to introduce innovative healthcare solutions across the region, starting with Malaysia. " Trademark Approval in Thailand In addition to the product approval in Malaysia, CS MEDICA has achieved trademark registration for its CANNASEN® brand in Thailand. This strategic milestone will strengthen brand recognition and market positioning in Thailand and other Southeast Asian countries, paving the way for future product launches. Looking Ahead Following these successful approvals, CS MEDICA is positioned to leverage its growing momentum and expand its product portfolio across Asia. The insights gained from these regulatory achievements are critical to easing the pathway for future registrations in other key markets, such as China. With a strong foundation and a proven strategy, CS MEDICA is committed to providing innovative medical solutions that meet the diverse needs of patients worldwide. 

SKF initiates a separation of its Automotive business

Gothenburg, 17 September 2024: The Board of Directors of SKF has decided to initiate a separation of its Automotive business with the objective of a separate listing on Nasdaq Stockholm through a Lex Asea distribution to its shareholders. The intention is to list the Automotive business on Nasdaq Stockholm during first half of 2026. Given different business dynamics, end markets and success drivers for the Industrial and Automotive business segments, a separation will facilitate a clearer focus on distinct opportunities to enhance customer value, accelerate growth as well as improve efficiency and competitiveness. “Both businesses are global leaders in their respective fields and will through a clearer focus increase customer value and leverage on their strategies as standalone companies. The Board of Directors and Management therefore believe that long-term value can be created by splitting the Group into two separate companies, benefiting customers, employees and shareholders”, says Hans Stråberg, Chair of SKF Board of Directors. A separation would increase Automotive’s ability to adapt faster to transforming global automotive markets, by allowing it to make independent business decisions and investments. A more tailored, leaner Automotive business model will further strengthen its competitive advantage and capture additional profitable growth opportunities, while at the same time accelerating its profitability transformation. “When we launched our new business strategy in February 2022, we articulated a desire to create a more autonomous Automotive business to provide strategic flexibility. I also said that we need to take bold decisions to unlock additional long-term profitable growth opportunities. Initiating a separation of the Automotive business is one of those decisions,” says Rickard Gustafson, President and CEO. A more focused Industrial company will be even better equipped to develop and execute its strategy and allocation of resources. By connecting operations more towards its industrial customers’ needs, it will cater for accelerated growth, improved efficiency, increased responsiveness and enhanced end-user experiences. The SKF Group will strengthen its long-term position as a global industrial focused technology leader delivering customer value through high quality and sustainable solutions. It is the intention to separate SKF’s current Automotive business. As a reference for the full-year 2023, net sales for the Automotive segment amounted to SEK 30 billion with an adjusted operating margin of 5.6%. The corresponding figures for the Industrial segment were SEK 73 billion and 15.4%, respectively. The Board of Directors intends to present a proposal for the distribution and listing of the Automotive business at a shareholders meeting in 2026. If the shareholders and other stakeholders approve of such a proposal, AB SKF shareholders will receive shares in the Automotive business in proportion to their existing shareholding in AB SKF. The intention is then to list the Automotive business on Nasdaq Stockholm during the first half of 2026. The distribution of the Automotive business is foreseen to meet the requirements of Lex Asea, meaning that the receipt of the shares distributed should be exempt from Swedish tax. Further details will be provided in due course. A webcast for media and investors will be held on 17 September at 15:30 (CET). Access the webcast via the link or call in using the dial in details below: Link to webcast: https://www.investis-live.com/skf/66e2a1bc26e9bc1200f9b061/paretSweden: +46 (0)8 5051 0031UK / International: +44 (0)207 107 0613 Aktiebolaget SKF      (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 17 September 2024 at 12.00 CET. For further information, please contact:Press Relations: Carl Bjernstam, +46 31-337 2517; +46 722 201 893; carl.bjernstam@skf.comInvestor Relations: Sophie Arnius, +46 31-337 8072; +46 705 908 072; sophie.arnius@skf.com

Comment on the airlines SAS and BRA's announcement today

"This announcement means that domestic flights will be concentrated at Stockholm Arlanda Airport, which will create conditions for more efficent domestic air travel with better transfer possibilities in the long term. At the same time, Bromma Stockholm Airport will basically have no regular traffic, says Jonas Abrahamsson, Swedavia's President and CEO, and continues: "We will now adapt our operations at the airport based on the new traffic structure. This will be carried out in close dialogue with employees affected by the change. Bromma is an efficient and well-maintained airport that is appreciated by many passengers. But it is no secret that the capacity utilisation at Bromma has been too low for several years. Concentrating air traffic at Stockholm Arlanda is therefore a natural step. This changes the conditions for the operation of Bromma and raises policy questions regarding the airport's future.  For more information, contact Swedavia's press office at +46(0)10-109 01 00 or press@swedavia.se The Swedavia Group owns, operates and is developing 10 airports throughout Sweden. Our role is to create the connectivity Sweden needs to facilitate travel, business and meetings. Safe, satisfied passengers are the foundation of Swedavia’s business. Swedavia is a world leader in developing airports with the least possible environmental impact. Since 2020, Swedavia’s own airport operations have been fossil-free at all ten airports. In 2023, the group had sales of approximately SEK 5.9 billion and has approximately 2,600 employees.

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

The Phase III trial is a prospective, randomized, double blind, placebo controlled, multi-center clinical study, which has reached its primary efficacy endpoint and exhibited good safety. Additionally, the study found that at 6 months after the first treatment, the regression rate (RR) in the APL-1702 group was significantly higher than that in the placebo group (47.0% vs. 29.5%, p < 0.01). Subgroup analysis data also showed that in all HPV-negative, HPV16-positive, and HPV18/others-positive subgroups, the APL-1702 group demonstrated favorable rates of histological regression comparing to placebo (64.7% vs. 25.0%, 37% vs. 25.4%, 60.0% vs. 36%). At 6 months after first treatment, the improvement rate for the two groups were 54% and 36%, respectively (p < 0.01). Among them, 38% of the subjects had cervical tissue restored to normal tissue at 6 months in the APL-1702 group, while only 19% had restoration to normal tissue in the placebo group. In the APL-1702 group, 79.1% of subjects had no disease progression, compared to 67.4% in the placebo group (p = 0.0171). Read Asieris’ full media release here: https://asieris.com/asieris-unveils-results-for-the-first-time-at-2024-pdtpd-conference-the-efficacy-data-of-non-surgical-treatment-of-cervical-hsil-with-apl-1702-in-reducing-the-histological-grade-of-cervical-preca/ Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Cevira[®]Cevira[®] (APL-1702) is a photodynamic drug-device combination product in development. Based on the principles of photodynamic therapy, the Cevira product aims to use a photosensitizer in combination with light activation to produce a therapeutic effect as a non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding carcinoma in situ.Photocure developed Cevira through Phase I and Phase II trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019. In November 2020 Asieris initiated the phase III clinical trial for APL-1702 (Cevira) which achieved its primary endpoint in September 2023, Clinical trial number: NCT04484415 . The new drug application for APL-1702 was accepted by the National Medical Products Administration (NMPA) in May 2024. About Photocure ASAPhotocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com About AsierisAsieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.

Immedica appoints Daniel Camardo as President of Immedica North America

Stockholm, September 17, 2024 – Immedica Pharma AB announces today the appointment of Daniel Camardo as President of Immedica North America and member of the company’s executive team. Mr. Camardo has more than 25 years of industry leadership experience spanning from small emerging biotech to mid-size rare disease and large multi-national companies and has contributed to the successful launch of multiple blockbuster medicines (>$1B annual net sales) and more than 14 BLAs and NDAs across the therapeutic areas Oncology, Rheumatology, Immunology, Neurology, Dermatology, Urology, and Metabolic Diseases. Daniel Camardo will be responsible for the establishment of a commercial infrastructure for Immedica in the North America and the recruitment of a team. Anders Edvell, CEO of Immedica, commented: “Daniel is an experienced executive leader who has a passion for rare diseases and a deep understanding about building high performing teams and launching rare disease products in North America”. “Daniel’s extensive industry experience includes transforming single product start-ups into high-functioning multi-franchise organizations. His breadth of skills and experience combined with his respected leadership and team-building style will be valuable to Immedica as our company enters the next exciting phase of its evolution,” concluded Anders Edvell. Daniel Camardo, President Immedica North America, said: “I’m excited to join Immedica at this pivotal time and lead the development of a U.S. commercial organization. I look forward to working closely with our European colleagues and U.S. employees to develop Immedica into a global leader in rare disease”.  Prior to joining Immedica, Daniel was a strategic advisor at CLC Biopharma and CEO of Athersys, focusing on innovative cell therapies. He held key executive roles at Horizon Therapeutics, driving its transformation into a rare disease leader. He also led commercial growth at Clarus Therapeutics and Astellas Pharma. Daniel holds an MBA from Northwestern University and is a Board Member at CommunityHealth. About ImmedicaImmedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care. Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 120 people in Europe, the Middle East and the U.S. For more information visit www.immedica.com Immedica contact:Linda HolmströmHead of Communicationlinda.holmstrom@immedica.com+ 46 708 73 40 95

A RescueRunner system ordered for Redningsselskapet in Norway

Redningsselskapet in Norway is strengthening its fleet with an additional RescueRunner, which will be integrated into their newest vessel, RS 177, a 22-meter boat part of the Ulstein Class. The RescueRunner system is a highly flexible and efficient boat system that can operate in shallow and inaccessible waters where larger boats cannot reach. With its impressive buoyancy and stability, the RescueRunner becomes a perfect complement to integrate with the mothership. “We are very pleased that Redningsselskapet has chosen to order a new RescueRunner and use it on their latest addition to their extensive rescue fleet. We hope it will be of great use and look forward to continued close cooperation in the future,” says Lukas Brehm, Vice President at Safe at Sea. The RescueRunner system will be delivered in Q2 2025. The order value is approximately SEK 620,000.

Inger Rydin is appointed interim COO and takes office immediately

“Inger Rydin is a senior and experienced leader who knows Integrum well. She is warmly welcomed to the management team. I look forward to working with Inger to create a value-driven organization that primarily focuses on the growth opportunities in the US,” comments Scott Flora, CEO of Integrum. Inger Rydin served as acting COO at Integrum from 2021 to 2023. She built a career in various leading strategic and operational positions at Essity, Mölnlycke Healthcare and Coloplast. Inger has also been CEO of fast-growing owner-managed companies and has served on the boards of companies listed in Oslo and Stockholm. “Integrum is on an exciting commercial journey, and I’m happy to join and contribute with my global experience,” comments Inger Rydin, COO of Integrum.

Genova successfully issues new green capital securities and announces the result of the tender offer

Genova Property Group AB (publ) (the "Company” or "Genova”) has successfully issued perpetual green capital securities (the “New Green Capital Securities”) in an initial amount of SEK 300 million and announces the results of the tender offer (the “Tender Offer”) to the holders of Genova’s existing perpetual green capital securities with ISIN SE0015245519 with an outstanding amount of SEK 800 million (the “Outstanding Capital Securities”). The Tender Offer expired at 15:00 CEST on 17 September 2024. Outstanding Capital Securities in an aggregate amount of SEK 367.5 million have been validly tendered by investors out of which SEK 342.5 million valid tenders have been accepted by Genova. Valid tenders from investors who have subscribed for and been allocated New Green Capital Securities in an amount of SEK 250 million have been prioritised in acceptance by Genova (“Priority Tenders”). Valid tenders not being Priority Tenders have been accepted on a pro rata basis in accordance with the process described in the Tender Information Document with a proration factor of 75 percent. Following the completion of the Tender Offer the volume of the Outstanding Capital Securities excluding Genova's holdings will amount to SEK 296.5 million. Settlement for the New Green Capital Securities and for the Tender Offer is expected to occur on 24 September 2024. "Genova has over the last twelve months been active in the debt capital market and proactively refinanced all senior unsecured bonds. The work to ensure a well-balanced capital structure continues and we opt to tender a larger volume of outstanding capital securities than intended to improve earnings going forward. With this transaction, including previously repurchases of our outstanding capital securities, we are now in a good position to capture future attractive market opportunities", comments Michael Moschewitz, CEO of Genova. The Tender Offer was made on the terms and subject to the conditions set out in a tender information document dated 12 September 2024 (the “Tender Information Document”) The New Green Capital Securities were issued under a total framework of SEK 450 million, carries a floating interest rate of 3m Stibor + 550 basis points and has no fixed maturity date with a first call date four years after the first issue date. Genova intends to apply for admission to trading of the New Green Capital Securities on the sustainable bond list of Nasdaq Stockholm. The Tender Information Document is available on the following link: https://genova.se/investors/bonds/. ABG Sundal Collier AB and Nordea Bank Abp have acted as arrangers and joint bookrunners in respect of the issuance of the New Green Capital Securities and as dealer managers for the Tender Offer. Gernandt & Danielsson Advokatbyrå KB have acted as legal advisor. For further information, please contact: CEO, Michael Moschewitz, mobile +46 (0)70-713 69 39, michael.moschewitz@genova.se About Genova Genova Property Group AB (publ) is a modern property company with a personal touch that owns, manages and develops properties with focus on Greater Stockholm area and Uppsala Region. On 30 June 2024, the value of the company's property portfolio amounted to approximately SEK 9.5 billion with a lettable area of approximately 340,000 sqm and the company held approximately 9,344 building rights for residential units. Genova's share has been listed on Nasdaq Stockholm since 2020. Genova – Smålandsgatan 12 – SE-111 46 Stockholm – www.genova.se

SAS is building a global hub in Scandinavia

Today, SAS presents 15 new routes from Copenhagen, including a new long-haul route to Seattle. Adding several new direct flights from Copenhagen to popular European and Intercontinental destinations will support greater growth for both SAS and all of Scandinavia as a global hub. Copenhagen Hub Expansion The new routes introduced in the summer schedule are Krakow, Madrid, Budapest, Lyon, Valencia, Malta, Bucharest, Milan Linate, Seville, Turku, Billund, Kristiansand, Harstad/Narvik and Bodø. Furthermore, there will be a frequency increase on 15 of the existing routes, including key destinations such as Stockholm, Oslo, Prague, Berlin and Helsinki, solidifying Copenhagen's position as a global hub. With the recent entry into SkyTeam, SAS is focusing on global reach and will continue to develop Copenhagen as its main hub for international travel. Copenhagen’s attractive location in continental Europe allows for efficient same-day travel across Northern, Central, and Western Europe. The hub will also serve as a key transit point for long-haul travel, connecting Europe with North America and Asia. “Following new ownership and the successful completion of our restructuring, SAS is emerging as a competitive and financially strong airline. By enhancing Copenhagen as our main hub and expanding our network, we are boosting connectivity and driving economic growth not only in Denmark but across Scandinavia. As we focus on building a global hub in Scandinavia, Copenhagen will become a central gateway, bringing the region even closer together,” says SAS CEO Anko van der Werff. “For our passengers, this means more travel options, improved convenience, and a seamless experience across a growing number of destinations”, van der Werff continues. Enhanced Connectivity for Oslo and Stockholm SAS continues to offer robust services from Oslo and Stockholm. Oslo Gardemoen will maintain up to 125 daily departures to more than 60 destinations, focusing on regional and European travel. Additionally, starting in the summer of 2025, SAS will introduce a new seasonal route between Oslo and New York (JFK), enhancing transatlantic connectivity. Stockholm Arlanda, with more than 70 direct routes and 120 daily departures, will remain an important gateway for European and intercontinental travel, supported by SAS' newly announced partnership with Braathens Regional Airways AB (BRA) which will optimize regional air services. As SAS enhances connectivity and shares more developments later this year, the airline is positioned to be a driving force behind the critical transition to sustainable aviation together with other stakeholders and partners. Supporting the company’s sustainability goals, new routes will feature fuel-efficient, modern aircraft, reducing emissions while expanding the network.

La Française des Deux SA has obtained all necessary regulatory approvals for its offer on Kindred Group plc and brings forward the expiry of the acceptance period to 2 October

FDJ announces that it has obtained final approval from the French Competition Authority to complete the Offer. The definitive clearance of the acquisition of Kindred by the French Competition Authority was the last regulatory condition required for the completion of the Offer. This means that FDJ has obtained all necessary regulatory, governmental or similar clearances, approvals and decisions, and that this condition for FDJ’s completion of the Offer hereby has been satisfied. FDJ has decided to bring forward the expiry of the acceptance period of the Offer to 17.00 CEST on 2 October 2024 (from the initial date of 19 November 2024). Completion of the Offer remains subject to other conditions, notably it being accepted to such an extent that FDJ becomes the owner of more than 90 percent of the total number of Shares in Kindred (on a fully diluted basis)[1]: · To date, five shareholders (Corvex Management LP, Premier Investissement SAS, Eminence Capital, Nordea and Veralda), representing 26.72 percent of Kindred’s outstanding Swedish depository receipts (SDRs), have made an irrevocable commitment to accept the Offer. · In addition, FDJ acquired 1.11 percent of Kindred’s outstanding SDRs directly from Veralda in March. FDJ will announce the result of the Offer on or around 3 October 2024 at the close of the market. If the Offer is completed, settlement and delivery for Kindred shareholders who tender their SDRs will take place on or around 11 October 2024. Reminder of certain terms of the Offer and required reminder of certain U.S. regulatory requirements, including with regard to FDJ’s right to waive or reduce the acceptance level condition after the acceptance period ends As stated in the Offer Document, completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that FDJ becomes the owner of Shares representing more than 90 percent of the total number of Shares (on a fully diluted basis) (the “acceptance level condition”). FDJ has reserved the right to waive, in whole or in part, one or more of the conditions set out in the Offer Document (including, with respect to the acceptance level condition, to complete the Offer at a lower level of acceptance). The acceptance period expires on 2 October 2024. To satisfy U.S. regulatory requirements, FDJ is obligated to announce the possibility of any waiver or reduction of the acceptance level condition via a press release issued at least 5 business days prior to the end of the acceptance period (i.e., 25 September 2024). While as of today there has been no decision to reduce or waive the acceptance level condition, with the purpose of satisfying U.S. regulatory requirements, FDJ hereby reminds the shareholders of Kindred that it may (but is not obligated to) reduce the acceptance level condition after the expiration of the acceptance period on 2 October 2024, and complete the Offer at a lower level of acceptance. In the event of such a reduction, (i) FDJ may reduce the acceptance level condition from 90 percent to not lower than 50.01 percent of the total number of Shares and declare the Offer unconditional, (ii) FDJ would grant an additional acceptance period of at least 5 business days from announcement of the reduction of the acceptance level condition and (iii) shareholders who had previously tendered their Shares in the Offer, and shareholders who tender their Shares during the additional acceptance period, would not have withdrawal rights during the additional acceptance period. In compliance with U.S. regulatory requirements, FDJ informs the shareholders of Kindred that if they have already tendered their shares in the Offer, but their willingness to tender will be affected by a possible reduction of the acceptance level condition as described herein, they should withdraw their tenders immediately, but in any event, before the expiration of the acceptance period on 2 October 2024. To be valid, such withdrawal must have been received in writing by Handelsbanken Issue department (address: Handelsbanken Capital Markets, Offerings & Issue Services, SE-106 70 Stockholm, Sweden) not later than 17.00 CEST on the last day of the acceptance period on 2 October 2024. Shareholders of Kindred holding nominee-registered Shares wishing to withdraw acceptance shall do so in accordance with instructions from the nominee. A waiver of the applicable acceptance level threshold for the Offer, and a resulting shareholding in Kindred below 90 percent of the total number of Shares will prevent FDJ from immediately commencing squeeze-out under Kindred’s articles of association, as well as from delisting Kindred from Nasdaq Stockholm. This would mean that there would still be other shareholders in Kindred whose rights would be protected by minority protection and listing rules. Consequently, in such a scenario, FDJ may not be free to take all the measures it would otherwise have taken in order to integrate the two companies. In addition, in the event that the Shares remain listed, there would be costs associated with maintaining a listing of the Shares as well as securing compliance with various regulatory requirements. A waiver of the applicable acceptance level threshold for the Offer, and a resulting shareholding in Kindred below 90 percent of the total number of Shares would also create concentration of ownership of the Shares with FDJ, which may result in decreased liquidity and value of the Shares, and may make it more difficult for shareholders to dispose their Shares in a timely manner and/or at a favorable price. This announcement is not an indication of current or expected acceptance levels. Advisors FDJ has retained Goldman Sachs Bank Europe SE, Succursale de Paris, and Valens Partners SAS as financial advisors and Freshfields Bruckhaus Deringer LLP, Advokatfirman Vinge KB and Mayer Brown Selas as legal advisors in connection with the Offer. Further information For further information on the Offer, please visit:https://www.groupefdj.com/en/fdj-launches-a-tender-offer-for-kindred-to-create-a-european-gaming-champion/ The information was submitted for publication on 18 September 2024, 07:00 a.m. CEST. For enquiries, please contact: Investor Relations:Marc WillaumeTelephone: +33 (0)1 41 04 19 74Email: invest@lfdj.com Media RelationsSabine WacquesTelephone: +33 (0)1 41 10 33 82Email: servicedepresse@lfdj.com Important information This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail. This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law (the “Restricted Jurisdictions”). The release, publication or distribution of this press release in or into jurisdictions other than Sweden may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than Sweden should inform themselves about, and observe any applicable requirements. In particular, the ability of persons who are not resident in Sweden to accept the Offer may be affected by the laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Offer disclaim any responsibility or liability for the violation of such restrictions by any person. This announcement has been prepared for the purpose of complying with Swedish law, Nasdaq Stockholm’s Takeover rules (the “Takeover Rules”) and the Swedish Securities Council’s rulings regarding interpretation and application of the Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this press release had been prepared in accordance with the laws of jurisdictions other than Sweden. Unless otherwise determined by FDJ or required by Swedish law, the Takeover Rules and the Swedish Securities Council’s rulings regarding interpretation and application of the Takeover Rules, and permitted by applicable law and regulation, the Offer will not be made available, directly or indirectly, in, into or from a Restricted Jurisdiction or any other jurisdiction where to do so would violate the laws in that jurisdiction and no person may accept the Offer by any use, means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities. Accordingly, copies of this press release and any formal documentation relating to the Offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction. The availability of the Offer to shareholders of Kindred who are not resident in and citizens of Sweden may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Persons who are not resident in or citizens of Sweden should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. The Offer, the information and documents contained in this press release are not being made and have not been approved by an authorized person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the “FSMA”). Accordingly, the information and documents contained in this press release are not being distributed to, and must not be passed on to, the general public in the United Kingdom, unless an exemption applies. The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire day to day control of the affairs of a body corporate; or to acquire 50 percent or more of the voting shares in a body corporate, within article 62 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and other effects of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, “estimates”, “plans”, “will be” or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Actual results and developments may differ materially from those expressed in, or implied or projected by these forward-looking statements due to many factors, many of which are outside the control of FDJ. Forward-looking statements appear in a number of places throughout this announcement and the information incorporated by reference into this announcement and may include statements regarding the intentions, beliefs or current expectations of FDJ or Kindred concerning, amongst other things: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies, the expansion and growth of FDJ’s or Kindred’s business operations and potential synergies resulting from the Offer; and (iii) the effects of government regulation and industry changes on the business of FDJ or Kindred. Any forward-looking statements made herein speak only as of the date on which they are announced. Except as required by the Takeover Rules or applicable law or regulations, FDJ expressly disclaims any obligation or undertaking to publicly announce updates or revisions to any forward-looking statements contained in this announcement to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. The reader should, however, consult any additional disclosures that FDJ or Kindred have made or may make. Important notice to shareholders in the United States of America This announcement has not been submitted to or reviewed by the SEC or any U.S. state securities commission and neither the SEC nor any such U.S. state securities commission has approved or disapproved or determined whether this announcement is truthful or complete. Any representation to the contrary is a criminal offence in the U.S. The Offer is being made for the Shares in the Company, whose SDRs are listed on Nasdaq Stockholm, and is subject to the Takeover Rules, the Swedish Securities Council’s (Sw. Aktiemarknadsnämnden) rulings and statements on the interpretation and application of the Takeover Rules applicable to the Offer and the Swedish Takeover Act (Sw. lag (2006:451) om offentliga uppköpserbjudanden på aktiemarknaden) and Swedish disclosure and procedural requirements, which are different from those of the U.S. It is important for U.S. Shareholders to be aware that this announcement is subject to disclosure and takeover laws and regulations in Sweden that are different from those in the U.S. In addition, U.S. Shareholders should be aware that this announcement has been prepared in accordance with Swedish format and style, which differs from the U.S. format and style. In particular the financial information of the Company included or incorporated by reference herein has been prepared in accordance with generally accepted accounting principles in Sweden and International Financial Reporting Standards, as applicable, and thus may not be comparable to financial information of U.S. companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States. The Offer is being made in the U.S. in reliance on, and in compliance with, Section 14(e) of, and Regulation 14E under, the U.S. Exchange Act and the “Tier II” exemption provided by Rule 14d-1(d) under the U.S. Exchange Act and otherwise in accordance with the requirements of Swedish law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. Shareholders are urged to read this announcement, which is available via www.groupefdj.com/en/fdj-launches-a-tender-offer-for-kindred-to-create-a-european-gaming-champion/. U.S. Shareholders may also call the following number: +33 (0)1 41 04 19 74 or email invest@lfdj.com to request a copy of the offer document. To the extent permissible under applicable Swedish and U.S. securities laws, rules and regulations and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the offeror and its subsidiaries and affiliates or their respective nominees or brokers (acting as agents for the offeror) may from time to time after the date of this offer announcement, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase Shares or any securities that are convertible into, exchangeable for or exercisable for Shares from Shareholders who are willing to sell their Shares outside the Offer, including purchases in the open market at prevailing prices or in private transactions at negotiated prices. Any such purchases will be made outside the U.S. and will be made in accordance with applicable law, including that they will not be made at prices higher than the Offer Price or on terms more favourable than those offered pursuant to the Offer unless the Offer Price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. at the website www.groupefdj.com/en/fdj-launches-a-tender-offer-for-kindred-to-create-a-european-gaming-champion/ to the extent that such information is made public in accordance with the applicable laws and regulations of Sweden. In addition, the financial advisors to the Company and, to the extent permissible under applicable Sweden and U.S. securities laws, rules and regulations and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the financial advisors to the FDJ may also engage in ordinary course trading activities in securities of the Company, which may include purchases or arrangements to purchase such securities. It may be difficult for U.S. Shareholders to enforce their rights and any claim arising out of U.S. securities laws, since the offeror and the Company are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. Shareholders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or nonU.S. court for violations of U.S. securities laws. Further, it may be difficult to compel a nonU.S. company and its affiliates to subject themselves to a U.S. court’s judgment. The receipt of cash pursuant to the Offer by a U.S. Shareholder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each U.S. Shareholder of Shares is urged to consult his or her independent professional advisor immediately regarding the U.S. tax consequences of an acceptance of the Offer. Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer; (b) passed upon the merits or fairness of the Offer; or (c) passed upon the adequacy or accuracy of the disclosure in this offer announcement. Any representation to the contrary is a criminal offence in the U.S. Goldman Sachs Bank Europe SE, Succursale de Paris (“Goldman Sachs”), which is authorised and regulated by the European Central Bank and the Federal Financial Supervisory Authority (Die Bundesanstalt für Finanzdienstleistungsaufsicht) and Deutsche Bundesbank in Germany, and Valens Partners SAS (“Valens Partners”) are acting exclusively for FDJ and no-one else in connection with the matters referred to in this offer announcement and will not be responsible to anyone other than FDJ for providing the protections afforded to clients of Goldman Sachs and Valens Partners or for providing advice in connection with the matters referred to in this offer announcement. [1] Based on 215,823,068 shares, excluding treasury shares (14,303,068).

Skanska constructs new building for the University of North Texas in Texas, USA, for USD 87M, about SEK 920M

The project involves the construction of a new 10,300 square-meter (111,000-square-foot) multidisciplinary research and teaching building on the university's Denton campus. This state-of-the-art facility will fulfill a critical need for more modern facilities that support collaborative and interdisciplinary research on the campus. The new building will expand research space for areas such as biology, biomedical engineering, chemistry, physics, data science, and computer science and engineering while creating experiential learning opportunities for students. The building will be constructed with a cast-in-place structure and showcase a façade combining masonry, curtain walls, and metal panels. Work is beginning in September 2024 and is expected to reach completion in October 2026.

Eevia Health receives multiple sales orders for c. Ksek 635 (KEUR 56)

A total of 56 KEUR of sales orders came in from several customers. One order came from our distributor Breko, for Feno-Myrtillus 25 Organic and Feno-Myrtillus 5 Organic (Bilberry Extracts) and Fenoprolic Full Spectrum Extract (a pine bark extract) for the sum of KEUR 18.   Another repeat sales order is from a European nutraceutical brand owner headquartered in Sweden. The new order of KEUR 21 is an increase of an order of KEUR 51 that Eevia received in June. The volume will be delivered this week. Additionally, Eevia has received several smaller orders from Finnish customers for a total of KEUR 9 as well as a repeat order from a regular customer in Taiwan for KEUR 8. The products are Fenoprolic 70 Organic (Pine bark extract), Feno-Myrtillus 25 Organic (Bilberry extract), Feno-Vitis 5 (Lingonberry extract), and Bilberry Berry powder. All products are in stock and the orders are helpful for operational cash flow. For further information, please contact: Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.comor investor@eeviahealth.com Telephone: +358400 22 5967 INFORMATION ABOUT EEVIA HEALTH PLC Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas. Eevia Health is a manufacturer of 100% organically certified plant extracts.Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such asbilberry,lingonberry,chaga-mushroom,and pine bark, arewild-harvestedin a sustainable fashion. Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA . To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn@EeviaHealth.

Financial reporting days for Atlas Copco Group

2025April 29Q1 2025 result and Annual General MeetingSilent period starts March 30, 2025 July 18Q2 2025 resultSilent period starts June 18, 2025 October 23Q3 2025 resultSilent period starts September 23, 2025 2026January 27Preliminary 2025 reportQ4 2025 resultSilent period starts December 28, 2025

The Baltic Sea’s first green freight corridor has opened – Felix ketchup is now transported to Finland with 90 per cent fewer emissions

Felix ketchup, produced by the Orkla Group in Fågelmara, began to be shipped to Finland using green biofuel in July. The transport chain starts at the biggest ketchup factory in the Nordic region, with Scandic Trans lorries from Korsholm driving to Viking Line’s terminal in Stadsgården, Stockholm. The lorries then cross the Archipelago Sea on the climate-smart Viking Glory and Viking Grace and deliver their load to Orkla’s logistics centre in Turku. Thanks to the biofuel, carbon dioxide emissions along the 683 kilometre long transport chain are reduced by 90 per cent compared to fossil fuel. Scandic Trans refuels its lorries with biofuel produced from hydrotreated vegetable oil (HVO), while Viking Line buys liquefied biogas (LBG) made from organic waste from Gasum to cover fuel use during transport. “At Orkla’s companies, large volumes of food products are transported between the Nordic countries. The biogas project on this bustling route is one step in our sustainability journey. Our goal is to cut our greenhouse gas emissions in half by 2030 compared to 2016. Reducing our environmental impact is part of our day-to-day development work. So it was fantastic how easy it was for us as a cargo customer to make the switch to this green maritime corridor,” says Mauri Suuronen, Planning and Logistics Manager at Orkla Suomi. For each shipment, carbon dioxide emissions are reduced from 1,512 kilogrammes to 102 kilogrammes. That means an annual decrease in emissions of about 190 tonnes. “Lowering emissions has long been a key issue for road transport, so we have focused on introducing HVO biofuel. Now that it is also possible to use biofuel in the maritime part of the transport chain, the emissions reduction is revolutionary. And the most important thing is that biofuel can be used on a large scale, and the environmental impact can be reported for each transport mode. The transport sector’s reputation is not the best on environmental issues, so it is important to show that sustainable alternatives are available,” says Mikael Löfqvist, CEO of the transport company Scandic Trans. Viking Glory and Viking Grace currently operate mostly on liquefied natural gas (LNG), but they were built from the very start to run on the bio and synthetic fuels of the future. “We have invested a total of 450 million euros in our climate-smart vessels. As a result, we have now successfully launched scheduled freight service using biofuel in partnership with Orkla Suomi and Scandic Trans. This is a fantastic and important demonstration of the power of cooperation on sustainability measures – this requires supply and demand, and naturally a shared willingness to take climate-smart actions. This green freight corridor has attracted enormous interest across the Nordic region, and it is only a matter of time before more companies sign up,” says Harri Tamminen, Freight Director at Viking Line. For a year now, Viking Line has offered its passengers and conference customers the possibility of buying biogas equivalent to the amount used on their journey, thus reducing emissions from their travel by 90 per cent. This year, the company celebrated Baltic Sea Day by purchasing biofuel used on the Turku route for an entire week. For further information: Harri Tamminen, Freight Director, Viking Lineharri.tamminen@vikingline.com, tel. +358 40 848 1105 Mikael Löfqvist, CEO, Scandic Transmikael.lofqvist@scandictrans.fi, tel. +358 40 679 1011 Lotta Roitto, Communications Manager, Orkla Suomilotta.roitto@orkla.fi, tel. +358 40 747 0871 Johanna Boijer-Svahnström, Senior VP, Corporate Communications, Viking Linejohanna.boijer@vikingline.com, tel. +358 18 27 000

CS MEDICA A/S Announces Strategic Partnership with Scan MedPartners to Expand Reach into the US Market

CS MEDICA A/S, a Danish MedTech company specializing in pain management, autoimmune diseases, and stress-related disorders, is pleased to announce a new strategic partnership with Scan MedPartners, a US consultancy with a deep network and expertise in connecting Scandinavian medical technology companies with qualified high-value US partners in search of clinically proven, disruptive platform technologies, to improve outcomes for patients, providers and US payers. This collaboration represents a significant milestone in CS MEDICA's efforts to expand its presence in the United States, a core market for its innovative treatment portfolio. CS MEDICA A/S has identified the US market as a crucial growth opportunity for its FDA-registered treatments with bioactive CBD. These treatments are designed to serve as perfect complements to both prescription-based options and non-regulated CBD products. Through this strategic partnership, CS MEDICA A/S aims to bring its safe and effective treatments with pharmaceutical grade, patent pending bioactive CBD to a broader patient population within the US healthcare sector. Scan MedPartners will be pivotal in this expansion by leveraging its strong network of relationships with pharmaceutical and medical device industry portfolio decision-makers, specialty clinicians, hospital administrators, and associations across the US. With a deep understanding of the US healthcare landscape and a proven track record in securing high-value licensing agreements, Scan MedPartners will act as CS MEDICA's extended partner, ensuring that the company's treatments with bioactive CBD are recognized as valuable additions to the US market. "We are excited to partner with Scan MedPartners," said CEO Lone Henriksen, CS MEDICA. "Their extensive expertise and strategic connections in the US healthcare market will help us navigate this important market's complexities and drive the adoption of our treatments with bioactive CBD among patients and providers alike." Scan MedPartners assists primarily Scandinavian companies by connecting them with qualified US partners to validate their innovations in specialized therapeutic areas. By linking CS MEDICA A/S with qualified US partners and decision-makers, Scan MedPartners will facilitate the market positioning of its FDA-registered treatments with bioactive CBD and help secure distribution agreements with leading healthcare organizations. "We see tremendous potential in CS MEDICA A/S's regulated treatments with bioactive CBD across multiple therapeutics fields, highlighting pain management, arthritis, anti-hair loss, wound care and allergies, to the benefit of millions of US patients in need of better, more patient effective products. We are eager to support CS MEDICA A/S on their sales growth journey, helping them accelerate their US market entry via US commercial partners," said Arne Madsen, President, Scan MedPartners. "Our deep market insights and robust relationships with key stakeholders will ensure that CS MEDICA A/S's products gain the traction needed to succeed in this competitive environment."  As part of the partnership, Scan MedPartners will assume comprehensive responsibilities, including regulatory support and commercialization activities, ensuring a seamless market entry for CS MEDICA A/S into the US healthcare sector. 

Avida Finans acquires Santander’s Credit Card and Sales Financing Business

The acquired business includes approximately 450 000 private customers with a total outstanding performing loan volume of currently about 4 billion SEK.   “This is an exciting next chapter on Avida’s journey. Supported by our owners, we have set an ambitious strategy and invested heavily in our tech platform and services. We are now expanding our customer offering to include one of the markets leading businesses within credit cards and point-of-sale financing. This will significantly increase our reach and size. We look forward to welcoming all our new customers as well as the group of highly skilled colleagues that will join the Avida family,” says Tine Wollebekk, CEO of Avida.  "We consider that the sale is mutually beneficial and a good fit for both parties, enabling Santander to reallocate focus and resources to growth opportunities within its core business products, whilst enabling Avida to pursue its own growth agenda. We will ensure that customers are fully updated in order to ensure a smooth transfer, says Michael Hvidsten, CEO of Santander in the Nordics.  Following regulatory approvals, the transaction is expected to take effect from 31st December 2024. The acquisition will be financed through capital contributions from Avida’s owners and by raising debt. 

Earnings update for Q3 2024 due to challenging market conditions

Challenging market conditions, mainly consisting of slowdowns in end markets, are expected to have a negative impact on the financial outcome of Concentric AB (“Concentric” or the “Company”) in Q3 2024. As a result, Concentric publishes an earnings update and adopts an action plan to address the current market conditions.   Earnings update Weak demand in the Company’s end-markets in the sectors of agriculture, construction, truck and industrial applications have resulted in a negative development for the Company’s base business. The slowdown in the Company’s end-markets has resulted in reduced order volumes from key customers, which in turn has had a negative impact on the Company’s sales during Q3 2024. In addition, there has also been a slowdown in the Company’s electrification business. Concentric expects this level of demand from our customers to stabilise at these lower levels during Q4 2024 and going into 2025. During Q3 2024, Concentric estimates sales of approx. MSEK 780-820, underlying operating income of approx. MSEK 55-75 and an underlying operating margin of approx. 7-9 per cent. Action plan Concentric has adopted an action plan, which includes a capacity cost restructuring initiative. This restructuring comprises 65 employees and is expected to result in savings of approx. MSEK 56 on an annualised basis. A non-recurring restructuring provision of approx. MSEK 20 will also be accrued in Q3 2024. In addition, pricing measures are being taken to achieve better recovery margins. These actions are expected to impact the underlying operating margin positively by 1-2 per cent in Q4 2024. For further information, please contact Marcus Whitehouse, Tel: +44 121 445 6545 or E-mail: info@concentricab.com This information is information that Concentric AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:30 CEST on 18 September 2024.

DanCann Pharma A/S: Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme

As part of the ongoing monitoring of the Pilot Programme for medicinal cannabis, the Danish Medicines Agency has released a report on the reporting of suspected adverse reactions, cannabis end-products, and the consumption status for 2023. In 2023, the Danish Medicines Agency received a total of three reports of suspected adverse reactions related to cannabis end-products covered by the Pilot Programme. These reports involve non-serious suspected adverse reactions. The number of such reports per year has decreased by two-thirds in 2023 compared to 2022. At the same time, the consumption of medicinal cannabis products increased by approximately 72% in 2023, both in terms of the number of patients and the number of prescriptions issued for cannabis end-products under the medicinal cannabis Pilot Programme. No Safety Concerns Detected Based on the suspected adverse reaction reports received by the Danish Medicines Agency in 2023, no safety signals regarding cannabis end-products have been identified. The reports of suspected adverse reactions to cannabis end-products have not prompted the Danish Medicines Agency to implement any risk minimization measures during the period. For more information, please read the report from the Danish Medicines Agency, "Bivirkningsindberetninger om cannabisslutprodukter og forbrug under forsøgsordningen (pdf) ". About DanCann Pharma A/S DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm. For more information, visit: www.dancann.com For further information, please contact: Jeppe Krog Rasmussen, CEO E-mail: jkr@dancann.com Forward-looking-statement: Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Billerud appoints Doug Schwartz as President Billerud North America

Doug Schwartz has extensive experience in the U.S. forest and paper industry, including serving in key leadership roles at companies such as Sonoco Products Company (Sonoco), International Paper and Champion International Corporation. He most recently held the position of Vice President and General Manager, Rigid Paper Containers at Sonoco.  “I am very happy that Doug, with his proven track record, will now lead our North America operations, which are integral to Billerud’s business and growth strategy. Together with our competent American team, he will continue our commitment to serve our customers by delivering our core products—graphic paper, specialty papers, and pulp, as well as cartonboard and other packaging materials. At the same time, he will lead the team in identifying strategic product development initiatives to diversify and expand our product portfolio," says Ivar Vatne, Billerud CEO and President. “I am honored to have the opportunity to join Billerud North America as President. With an industry experience of more than three decades – and a strong team in place – I hope to bring new perspectives that build upon the strong foundation already established and capture new opportunities to achieve sustainable and profitable growth,” says Doug Schwartz, incoming President Billerud North America. For further information, please contact:Robert Pletzin, Director Global Media Relations, Billerud, +46 72516 86 06,robert.pletzin@billerud.com The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CEST, 18 September 2024.

Invitation to EQT’s first US capital markets event in New York on October 22, 2024

In the five years since EQT’s listing on Nasdaq Stockholm, EQT has quadrupled revenues and had a fivefold increase in its market cap to USD ~40 billion. At its capital markets event, EQT will reflect on its long term growth priorities, its distinctive value creation approach, and the future of private markets. The event will be hosted by EQT’s CEO Christian Sinding, representatives from EQT’s Executive Committee and EQT’s Partner group. Presentations and Q&A will begin at 10.00 am ET, and be followed by lunch, featuring remarks from EQT’s Founder & Chairperson, Conni Jonsson. The event will take place at The Times Square EDITION, and it is expected to conclude by 1.30 ET. Attendance is primarily intended for institutional shareholders, analysts, financial advisors, and media. Please register here . We look forward to welcoming you! Contact Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Metso expands presence in Western Canada with new service center to boost customer support in key mining hub

Metso continues to strengthen its footprint and proximity to customers by investing in a new service center in Prince George, British Columbia. British Columbia is one of the emerging mining regions in Canada and the new facility will support the growing needs of customers, primarily operating in copper and gold segments. “The new service center enhances our ability to deliver OEM-certified on-site inspections, turnkey service solutions, and off-site repairs. Strategically located near a key mining region, it enables faster repair times, shorter turnaround, and sustainability benefits by reducing transportation distances. We will also offer comprehensive field service support to better serve our customers”, says Justin Ayotte, Vice President, Sales and Service, Canada, Metso. The center will service a wide range of mining equipment from pit to port, including filters, flotation cells, grinding mills, crushers, screens, pumps, and apron feeders. With approximately EUR 6 million (8 MCAD) invested, Metso plans to begin construction after the land acquisition is finalized, with completion expected in the second half of 2025. The new center will create jobs to skilled personnel, including service engineers and technical experts.  Investing in service capabilities across North America In late 2023, Metso announced plans to enhance customer service capabilities in North America by expanding the Mesa Service center in Arizona. This expansion will increase the repair shop area by nearly 60%. Additionally, a state-of-the-art and fully equipped training center will be built on the same property to bridge the knowledge gap between people, equipment, and operational goals in the region. Both the service center expansion and the training center are expected to be completed during the fourth quarter of 2025.  Global network of service professionals and facilities Beyond North America, Metso continued to invest in its service footprint. In March 2024, Metso inaugurated its largest Service center globally in Karratha, Australia. The company also announced plans to expand its service center in Chile and construct a new service center in Peru.  Metso has an extensive service center network with over 3,000 field services professionals, technical support, and more than 40 service centers on six continents. The company has a service certification program and has been consistently investing in its people and service center network to enhance its customer service capabilities. Further information: Justin Ayotte, Vice President, Sales and Service, Canada, Metso, tel. +18198569536, email: justin.ayotte(at)metso.com Helena Marjaranta, Vice President, Communications and Brand, Metso Corporation, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

EQT to sell Open Systems, a Swiss leader in network and cyber security solutions, to Swiss Post

EQT is pleased to announce that the EQT Mid Market Europe fund (“EQT”), together with its co-shareholders, have agreed to sell Open Systems (“Company”) to Swiss Post. Headquartered in Zurich, Switzerland, Open Systems delivers network and cyber security capabilities in a single cloud-based platform known as Secure Access Service Edge (SASE). Open Systems’ innovative SASE Experience eliminates the complexity of secure global connectivity and network management, while providing seamless global 24x7 support. The Company plays a pivotal role in supporting customers globally in their network and cyber security transformation by offering a fully integrated, single-pane-of-glass cloud and software platform and supporting services. EQT acquired a majority stake in Open Systems in 2017. During EQT’s ownership, the Company almost doubled its sales and more than tripled its EBITDA, while making substantial investments into its technology platform and transforming from a network-focused managed security services provider to a leading SASE player with extensive cyber security capabilities. Open Systems also built a Managed Extended Detection and Response (MXDR) division, which was carved out in 2023 and now operates as a standalone company under the brand Ontinue, which will be retained by EQT. Organic growth was complemented by three strategic add-on acquisitions, including Sqooba, a Swiss provider of data science, AI, cloud, and cyber services founded by the current Open Systems CEO Daniel Neuhaus. As part of Swiss Post, Open Systems will continue its growth journey under the leadership of Daniel Neuhaus. With the acquisition, Swiss Post strengthens its role as provider of digital communication services by increasing its competences and know-how to support digitally connected businesses in Switzerland. Daniel Neuhaus, CEO of Open Systems: "I would like to thank EQT for their support over the years and their hands-on involvement in our development. Swiss Post’s investment is a validation of our long-term strategy to become a leading SASE software provider with the best customer experience. With Swiss Post, we have found a sustainable partner in Switzerland who shares our values and will support us in continuously delivering best-in-class technology and services to our customers while continuing to drive innovation." Philipp Woerner, Director within EQT Private Equity’s Advisory Team: “We have been continuously impressed by Open Systems’ track record of technological innovation in the network and cyber security space. Thanks to the dedication and commitment of the management team led by Daniel, Open Systems delivers attractive technology and services from Switzerland to its customers globally. We could not have imagined a better future home for Open Systems than Swiss Post to support continuing the strong development.” Nicole Burth, CEO of Swiss Post Communication Services, said: "Open Systems strongly complements our existing offerings in the area of cybersecurity. The Company is an excellent cultural fit and supports our strategy to bring cybersecurity to our Swiss customers. This makes the network and communication of businesses more efficient and secures it with the unique cloud security solutions Open Systems provides." The completion of this transaction is pending customary regulatory approvals and is anticipated to take place in Q4 2024. ContactEQT Press Office, press@eqtpartners.com

Höegh Evi: Change of company name has been formally registered

Concentric AB announces acquisition of GO Engineering

Concentric AB (“Concentric”) has reached an agreement (the “Acquisition”) to acquire 100% of G.O. ENGINEERING Gesellschaft zur Entwicklung von Hard- und Software GmbH and its associated entity ÖkoGW Verwaltungs- und Vermietungs GmbH & Co. KG (together “GO Engineering”). GO Engineering is a company specializing in high-quality electronics design and manufacturing based in Bühl, Germany. Summary of the Acquisition · Enhances Concentric’s electronics engineering capabilities. · Concentric will acquire GO Engineering for an enterprise value of MSEK 266 (MEUR 23.5), under a locked box mechanism per December 31, 2023. The enterprise value corresponds to a multiple of 9.8x LTM June 2024 adjusted EBITDA for GO Engineering. · Concentric will finance the Acquisition using cash reserves and existing debt facilities. · GO Engineering generated revenues of MSEK 332 (MEUR 29.3) and adjusted EBITDA of MSEK 27 (MEUR 2.4) for the rolling 12-month period that ended on June 30, 2024. · Both parties seek to complete the Acquisition on October 1, 2024, subject to any closing conditions being met. Concentric is delighted to announce the acquisition of GO Engineering, a renowned German company specializing in high-quality electronics design and manufacturing. This acquisition aligns with Concentric’s growth strategy and enhances its electronics engineering capabilities. Founded in 1990 and based in Bühl, Germany, GO Engineering brings extensive experience and expertise in electronics design and manufacturing across various industries, including commercial vehicles and industrial applications. This acquisition will strengthen Concentric’s electronic engineering capabilities, particularly in software and hardware development. Additionally, it will integrate printed circuit board assembly (PCBA) manufacturing — a crucial element in the electronics value chain — into the Concentric Group. Helmut Gerstner and Ralf Wörner, the current owners of GO Engineering, will remain involved in the business to ensure a smooth transition, with Gerstner providing support for a three-month period, while Wörner will contribute to the company’s operations on an ongoing basis. With the acquisition, we are excited to welcome more than 120 GO Engineering employees to the Concentric Group. The acquisition is anticipated to positively impact Concentric’s performance by boosting our electric sales and achieving medium-term cost efficiencies through in-house controller design and manufacturing. This will enhance our ability to respond to customer needs and leverage a unified electronic platform across our various brands and global operations. Martin Kunz, Concentric President & CEO, comments: “The integration of GO Engineering into Concentric will accelerate our electrification strategy and strengthen our position in both current and future markets for electric liquid cooling and thermal management products. After evaluating numerous potential partners in the electric motor and controller space, GO Engineering stood out for its innovative electric motor controllers. Additionally, their strong customer relationships and commitment to sustainability create synergies as we expand our product portfolio and enhance our in-house capabilities.” Helmut Gerstner and Ralf Wörner of GO Engineering, state: “We are excited to join forces with Concentric, a company that shares our dedication to innovation, quality, and sustainability. We believe Concentric’s global reach, resources and strong customer relations will provide a robust foundation for GO Engineering’s continued growth and success.” For additional information please contact Marcus Whitehouse (Concentric CFO) at Tel: +44 121 445 6545 or E-mail: info@concentricab.com

Exel Composites has won the bidding process in India for Vestas Wind Systems A/S for carbon planks for wind turbines

Exel Composites and its joint venture Kineco-Exel India (KECI) have won the bidding process in India for supplying pultruded carbon plank for wind turbine spar caps for Vestas Wind Systems A/S. The products will be manufactured with pultrusion in KECI’s new factory in Goa, India, optimized for serving wind power industry customers in India and globally. The parties have started the qualification process of the production facility according to Vestas’ specifications, after which KECI will be a qualified supplier of carbon flats for Vestas globally. Deliveries are estimated to begin in the last quarter of 2025. The agreement is an extension of an existing multi-year frame contract updated in 2023 and deepens the collaboration between the companies, which started over a decade ago. Headquartered in Aarhus, Denmark, Vestas is one of the largest and most prominent companies in the wind energy industry, designing, manufacturing, installing, and servicing wind energy projects worldwide. Spar caps, which utilize carbon planks, are essential structural components within wind turbine blades, providing the strength, stiffness, and load-bearing capacity needed to withstand the dynamic forces encountered during operation. As wind turbines continue to increase in size, carbon fiber composites will play a crucial role in meeting the demanding mechanical requirements needed for these advancements. “We are pleased to strengthen our partnership with our long-term customer Vestas and look forward to supporting them in their strategic initiatives in India and globally,” says Kathy Wang, EVP Industrial Solutions at Exel Composites. “It is a pleasure to work with the Exel team, we are looking forward to a fast development of the carbon plank business in India,” says Steven Zhu, Blade Procurement, Vestas APAC, China. Exel Composites and Kineco Exel India (KECI) offer wind turbine manufacturers a comprehensive range of glass fiber and carbon fiber composite components required for the manufacturing of modern on-shore and off-shore wind turbines. KECI was established in 2021 as a joint venture between Exel Composites and the Indian company Kineco Group. Additional Information: Lilli Riikonen, Head of Investor Relations investor@exelcomposites.com tel. +358 50 351 1128 About Exel Composites Exel Composites is one of the largest manufacturers of composite profiles and tubes made with pultrusion and pullwinding technologies and a pultrusion technology forerunner in the global composite market. Our forward-thinking composite solutions made with continuous manufacturing technologies serve customers in a wide range of industries around the world. You can find our products used in applications in diverse industrial sectors such as wind power, transportation and building and infrastructure. Our R&D expertise, collaborative approach and global footprint set us apart from our competition. Our composite solutions help customers save resources, reduce products' weight, improve performance and energy efficiency, and decrease total lifetime costs. We want to be the first choice for sustainable composite solutions globally. Headquartered in Finland, Exel Composites employs over 600 forward-thinking professionals around the world and is listed on Nasdaq Helsinki. To find out more about our offering and company please visit www.exelcomposites.com. About Kineco Group Kineco Group, founded in 1994, is India’s leading composites manufacturing company catering to highly demanding markets such as aerospace, mass transit and specialized industrial applications. Kineco Group has a strong legacy of innovation and employs over 750 people across its various manufacturing facilities in Goa India. More information is available at www.kinecogroup.com.

Nomination Committee appointed for AB Electrolux Annual General Meeting 2025

In accordance with decision by the Annual General Meeting, AB Electrolux Nomination Committee shall consist of five members. The Nomination Committee shall include members selected by each of the four largest shareholders in terms of voting rights that wish to participate in the committee, together with the Chairman of the AB Electrolux Board. The members of the Nomination Committee have now been appointed based on the ownership structure as of August 31, 2024. Christian Cederholm, Investor AB, is the Chairman of the committee. The other members are Marianne Nilsson, Swedbank Robur Funds, Anders Hansson, AMF Tjänstepension och Fonder, and Carina Silberg, Alecta. The committee will also include Torbjörn Lööf, Chairman of AB Electrolux. The Nomination Committee will prepare proposals for the Annual General Meeting in 2025 regarding Chairman of the Annual General Meeting, Board members, Chairman of the Board, remuneration for Board members, Auditor, Auditor’s fees and, to the extent deemed necessary, proposal regarding amendments of the current instruction for the Nomination Committee. The Annual General Meeting will be held on March 26, 2025, in Stockholm, Sweden. Shareholders who wish to submit proposals to the Nomination Committee should send an email to nominationcommittee@electrolux.com.

Duni Group plans a new warehouse hub in Germany

Duni Group wants to consolidate all storage, fulfillment of distribution and value-added services within one location in Germany. With current warehouse facilities in Bramsche/Osnabruck, the Group plans to establish a new warehouse hub in the close-by area of Meppen. The warehouse in Meppen is today an industrial site with good and suitable infrastructure. A new greenfield development will be established for a modern warehouse and distribution center designed to meet Duni Group’s requirements and fit for purpose. “The new warehouse in Meppen will be transformational to Duni Group’s logistics solution in Europe. The redesign of the warehouse will enhance competitiveness and scalability as well as contributing to our net zero target”, says Johan Crusefalk, Chief Logistics & Technology Officer. Part of the solution is to engage in a strategic cooperation with CEVA Logistics, which is a leading end-to-end logistics company spanning 170 countries and having a track-record of modernizing warehouse hubs in Europe and worldwide. CEVA Logistics will also facilitate distribution in and out of the new warehouse hub. Any restructuring costs and efficiency savings in relation to the new logistics solution will be accounted for in the Group’s financial reporting.  The site in Bramsche/Osnabruck will continue to be an important production hub for Duni Group and maintain the full-pallet outbound of all produced articles at the site. Personnel in production or production logistics will not be affected and for warehouse personnel, a dialogue with the local workers’ council has started. Approximately 220 people will be affected. Distribution in Meppen is intended to start in 2026.  For more information, please contact: Magnus Carlsson, EVP Finance/CFO, +46 40-10 62 00, magnus.carlsson@duni.com Katja Margell, IR and Communications Director, +46 76-819 83 26, katja.margell@duni.com  Duni Group is a market leader in sustainable dining and food packaging solutions for the restaurant market. The Group markets and sells its products under primarily the brands Duni, BioPak and Paper+Design, which are represented in more than 40 markets. Duni Group has around 2,400 employees in 23 countries, with headquarters in Malmö and production units in Sweden, Germany, Poland, Slovenia and Thailand. Duni Group is listed on NASDAQ Stockholm under the ticker “DUNI” and with ISIN code SE0000616716. Dunigroup.com